bristolmyers squibb company annual report hope experience inspire patients keep going breast cancer patient julia maasthe bristolmyers squibb mission companys mission extend enhance human life providing highestquality pharmaceutical related health care products pledgeto patients customers employees partners shareholders neighbors world serveto act belief priceless ingredient every product honor integrity maker cover breast cancer patient julia maas one morning found lump breast size marble yearold julia maas houston says diagnosed invasive ductal carcinoma following surgery radiation chemotherapy apparently cancer free nearly decade cancer recurred august time recommended therapies didnt work says maas desperate oncologist university texas md anderson cancer center suggested enter clinical trial bristolmyers squibb investigational compound called ixabepilone maas appears well since entering trial hope experience inspire patients keep going give saysbristolmyers squibb company annual report stockholders ver past years stayed tightly focused achieving nearterm goalsof launching new products advancing pipeline investing busi nesswhile also building toward longterm vision bristolmyers squibb weve made good progress toward goals know even required reason clear want health care leader futureto make differ ence generations come need build longterm growth strong financial performance company even strive every day realize mission extending enhancing human life achieve future growth leadership transforming company several important ways executing strategy sharpen focus areas significant medical need establish leadership innovative products renewing companys culturehow workto drive superior perform ance strongest possible commitment accountability ethical conduct interpreting mission broadly possible expanding access innovative therapies well building additional health care capacity parts world disease poverty taken toll bristolmyers squibb accomplished great deal areas specifically increased sales growth drivers including three newest medicineserbitux reyataz abilifyas well key inline therapies plavix avaproavalide advanced latestage pipeline launching one new drug us two europe moving three latestage compounds regulatory approval process boosted sales significantly health care businesses provide critical growth stability company strengthened compliance accounting financial reporting provided free discounted medicines million people need helped build critical communitybased health care infrastructure part companys larger initiative address hivaids pandemic southern west africa chairmans letter opportunities challenges prospects companys total net sales continuing operations increased percent overall performance helped growth new inline pharmaceutical products strength health care businesses impact weaker dollar earnings ahead plan consensus view investment community declined prior year largely due ongoing impact loss exclusivity several important pharmaceutical products us including monopril paraplatinand glucovance exclusivity losses remain challenge near term bristolmyers squibb indeed entire pharmaceutical industry next five years us patents expire across industry key products realized peter r dolanchairman chief executive officer billion total revenue industry also continues face steadily increasing costs associated research develop changing environmental factors affecting com ment time many governments pany sectorto find better ways build leader payors putting downward pressure drug ship growth future decided greatest prices urging companies concentrate opportunity lay focusing pharmaceutical busi finding new medicines provide meaningful rather ness specific disease areas significant unmet marginal benefits existing therapies need innovative medicines help people safety become even important focus serious illnesses attention areas cancer hivaids affective psy light realities came pretty chiatric disorders diabetes atherosclerosisthrombosis straightforward conclusion pharmaceutical compa hepatitis rheumatoid arthritis obesity alzheimers nies including bristolmyers squibb change disease solid organ transplant rejection fundamentally want continue thrive halfway fiveyear engines innovation improvement health shift pharmaceutical portfolio supports care successful growthoriented businesses strategy position us well vital company industry beand future still said although sales seen asan essential constructive vibrant part new existing products largely offset solution rapidly evolving health care decline sales products losing exclusivity needs challenges tomorrow earnings per share continue come pres bristolmyers squibb implementing transfor sure remainder transitional period mational strategy designed help us achieve goal including year next two years ago revisited pipeline projects prod several reasons generally uct portfolio business modelcarefully evaluating growth drivers carrying lower margins bristolmyers squibb company annual report products losing exclusivity well continue executing strategy investing significantly research development let provide details rd growth strongly believe investing progress executing strategy past pipeline opportunities right thing year plans long termeven negative impact thanks growth newer inline earnings short term products gains pipeline number expect picture turn around important licensing achievements grow beginning exposure exclusivity ing presenceor potentially meaningful presencein losses greatly reduced several years nearly disease areas mentioned earlier new products begin contributing meaningfully cancer erbitux treatment revenue earnings growth advanced refractory colorectal cancer scenario assumes continued exclusivity codeveloping comarketing imclone systems plavix antiplatelet medicine become incorporated since launch us leading product sales billion beginning erbitux helping focusing serious medical need primary patent plavixwhich confers exclu thousands people colorectal cancer hope sivity us currently chal benefit cancer patients well information lenged several generic drug companies believe becomes available clinical studies patent valid infringed imclone currently way plan initiate generics companies andtogether alliance oncology pipeline licensed two later partner sanofiaventiswe defending vigorously stage anticancer medicines vinflunine strategy focused primarily trans javlor pierre fabre mdicament france forming pharmaceutical business nonphar metastatic bladder cancer mdx maceutical health care businessesmead johnson medarex inc metastatic melanoma also nutritionals convatec medical imaginghave advanced two laterstage oncology compounds contributed greatly companys financial strength laboratories ixabepilone breast cancer stability also helping us fulfill srcabl kinase inhibitor chronic overriding mission myelogenous leukemia recently transi collectively businesses delivered yearover tioned phase ii registrational program year profit growth nearly percent granted fast track designation us food account approximately one quarter overall drug administration fda earnings percent net sales continue area psychiatric disorders abilify generate solid growth thanks innovation remains one successful new product market expansion continue introductions history us pharmaceuti important companys future cal industry codeveloping comarketing chairmans letter abilifywhich initially approved treatment rheumatoid arthritis fda granted priority schizophreniawith otsuka pharmaceutical review status baracludeand fast track designation company ltd two years market abatacept baracludealso submitted us abilify captured greater european regulatory authorities altogether percent share weekly new prescriptions promising compounds full development antipsychotics class total worldwide sales including four regulatory approval process bristolmyers squibb otsuka annualizing among compounds broader rate billion development portfolio gained important additional indi pipeline continues advance distin cation abilify us treat acute mania guish im especially proud productivity bipolar disorder recently received approval commitment rd organization nearly driving superior performance maintenance therapy certain patients two thirds companys compounds currently bipolar disorder also launched product full developmentincluding three four european union several key european mar regulatory reviewwere discovered kets abilify fastest uptake new laboratories inlicensing remains important atypical antipsychotic believe component strategy dramatic transforma beginning realize full potential impor tion favor rd capabilities tant treatment serious psychiatric disorders step building sustainable growth leadership hiv protease inhibitor reyataz continues future potentially even significant grow share well following launch percent exploratory develop us july nearly percent ment compounds come inhouse efforts weekly new prescriptions among protease inhibitors licensing also given strong impetus second prescribed therapy class building leadership disease areas focus launched reyatazin seven european mar currently collaborations kets uptake region vigorous approximately companies research already achieved greater percent institutions around world share france nearly percent share know invest keep rd uk germany engine primed running increased number disease areas pipeline overall rd expenditures percent billion also paving way potential future leadership significant portion growth going sup company planned advanced port latestage pipeline opportunities another major regulatory approval process three latestage area investment biologics capability compounds baracludeentecavir hepatitis b requires costly complex infrastructure muraglitazar diabetes abatacept biologicslargemolecule proteinsare becoming bristolmyers squibb company annual report important laboratories industry acade mia government apply new understanding richard l gelb disease processes increasingly targeted treatments erbitux companys first biologic product several investigational biologics richard l gelb joined bristolmyers pipeline including abatacept rheumatoid total revenues stood arthritis belatacept prevention solid organ million fortyfive transplant rejection mdx cancer years later company said vigorously pur eventually led ceo years sue pipeline product opportunities even chairman board margins come pressure result years total net sales ongoing exclusivity losses reason ive asked approaching billion entire organization reduceor minimum growth dick gelbs enduring legacygrowth companys size value also impact hold flatall spending nonpriority areas purpose led effort acquire mead johnson nutritionals several successful building right culture businesses also responsible building another important way transforming companys leadership position pharmaceutical products research great part engineering bristolmyers squibb build future growth merger bristolmyers company squibb leadership renewing strengthening corporationa combination created one company culture translates driving superior largest pharmaceutical companies world performance every part organization dick gelb became ceo prescription drugs accounted quarter company sales end also ensuring strongest possible commitment tenure pharmaceuticals medical devices accountability compliance ethical conduct accounted percent sales weve created important new structures role medicines companys portfolio processes areas human resources finance continued grow since contributions limited company compliance alone extended world large example link performance behavior work bristolmyers squibb foundation closely developed communicated example initiated known across organization set critical behaviors bristolmyers squibb freedom discoverunrestricted biomedical research grants awards program define conduct employees core bms date effort first largest kind cor behaviors include key attributes leadership porate america committed million communication alignment among others nostringsattached support expand frontiers essential factors attaining goals scientific understanding grants insti tutions countries personal level dick whats executives senior managers gelb generous often anonymous backer evaluated well demonstrate behav many worthy causes help individuals strengthen iors compensation tied part communities support civic institutions assessment complementing core behaviors everything dick gelb accom plished legacyof commitment advancing companys pledge standards business mission bristolmyers squibb extending impact conduct ethics commit employees growing contributions world largewill perform duties highest ethical standards remain everlasting model leaders everywhere continued strengthen financial controls accounting critical task year chairmans letter must essential constructive vibrant part solution health care challenges ensuring effectiveness internal control implementation medicare modernization financial reporting required section act help many senior citizens sarbanesoxley legislation im pleased say us better afford medicines recently assessed effectiveness outside us donated nearly million controls concluded engaged medicines products people need operating effectively required legislation also provided million direct assis independent registered public accounting firm tance million donated medicines issued report assessment appears products tsunami relief effort south asia annual report im especially proud people bristolmyers finally put additional significant resources squibb donated behind compliance activities past year funds tsunami relief contributions enlarged corporate compliance councilwhere matched dollar dollar bristolmyers issues policies thoroughly reviewed squibb foundation named compliance leaders several finally help build stronger healthier businesses also continued train personnel communities parts world devastated compliance awareness improved resources hivaids pandemic announced establish helpline employees anonymously ment two additional medical centers treat chil ask questions report concerns dren families hivaids southern africa funded million secure rx healthier future futureinitiative centerswhich sched believe become leader building uled open late modeled success healthier future company world ful bristolmyers squibbfunded pediatric clinic large define mission extending botswana opened today one enhancing human life broadest possible terms largest aids centers children world course mission includes vitally important date secure futurehas committed role discovering developing providing innova funding projects nine countries southern tive medicines serious diseases well quality west africa impact hivaids health care products help improve lives thats severe january opportunity visit commitment begins ends several secure futureprojects botswana help expand access pharmaceuticals swaziland south africa heartened taken lead role variety initiatives see firsthand difference initiative making us together rx discount card senior lives many women children well citizens recently together rx access communities individuals live card uninsured people years age still much work contributions patient assistance support secure futureof wide range programs provided approximately million innovative communitybased initiatives aim free medicines million people help develop sustainable health care capacity us looking forward part greatly needed fight aids bristolmyers squibb company annual report looking back looking ahead think dick james would proud closing want thank board directors company staying true values invaluable support counsel past ideals building accomplishments year well dedicated bristolmyers successes squibb employees around world tremen look ahead see plenty opportunity dous accomplishments commitment goals expand many achievements past building healthier future success im pleased welcome newest board year continuing execute strategy member james cornelius nonexecu build leadership growth addressing areas tive chairman guidant corporation significant unmet medical need working also want acknowledge outstanding hard foster company culture puts even contributions two extraordinary former colleagues greater emphasis strong performance driven sadly passed away strong values dedicating much effort richard l gelb chairman emeritus expanding access innovative medicines giant among business leaders every regard building health care infrastructure resources chairman chief executive officer year developing world thats tall order span dick built bristolmyers squibb power ambitious one know house scientific innovation financial strength successfuland leader yet within towering figure beat heart companieslike peoplehave great hopes truly compassionate committed man every future see report hope day lived mission values pledge good health universal bristolmyers squibb authored job turn hope reality people valued mentor dear friend everywhere thats measure success james b palmer md former chief thats live mission today well scientific officer president pharmaceutical future research institute brilliant scientist devoted life turning scientific knowledge lifesaving therapies brought james com pany respected greatly many recent pipeline achievements represent fruit vision peter r dolan chairman chief executive officer leadership company reflect remark march able ability inspire excellence part many colleagues pri unexpected death diminished us pharmaceutical pipeline pharmaceutical pipeline bristolmyers squibbresearchers dedicated throughout report call attention impor discovering developing innovative medicines tance ongoing clinical trials highlight responses address significant medical needs key disease areas individual clinical trial patients areas listed chart selected individual stories case studies hope results may emphasis future medicine patient unpredictable individual experimental study par needs match internal strengths ticipant personal accounts illustrate importance growth driversare among approved medicines participation clinical trials essential driving current future growth continuing development next generation medical innovation clinical development determine whether additional indi true test whether turn hope reality cations benefit patients registrationalcompounds patients whether document real clinical bene advanced investigational drugs submitted fit across significant number research participants regulatory agencies approval ability bring new products patients need find process submitted full developmentcompounds new uses current products dependent upon latestage clinical development hope demonstrating safety effectiveness favorable bene submit approval next two years compounds fitrisk relationship systematic testing patients exploratory developmentare preclinical early volunteer participate studies like clinical development compounds research programs scientific endeavor clinical testing novel drug compounds discoveryare earliest stages development complex timeconsuming resourceintensive process investigational compound research program rep guaranteed results described bristolmyers resented chart dot compounds squibb committed pursuing endeavor vigorously discussed special report hope beginning bringing new hope patients disease growth registrational full exploratory discovery area drivers development development affective psychiatric disorders alzheimers disease atherosclerosis thrombosis cancer diabetes hepatitis hivaids obesity rheumatoid arthritis solid organ transplant rejection inlicensed discovered bristolmyers squibb abatacept process submitted approval hope special report hopeis powerful idea faith belief future hope inspires people act transform dreams realities peoplesuch julia maas cover edie hudgins pictured patients featured pages followhope found investigational clinical trial otherslike scientists bristolmyers squibb employees hope promise delivering innovative products patients need special report youll learn develop new medi cines health care prod ucts expand access therapies create sustainable health care programs neediest among us thats bristolmyers squibb live mission extend enhance human lifeand keep beacon hope shining brightly kidney transplant patient edie hudgins edie hudgins conyers georgia apparent good health thats sudden autoimmune condition attacked kidneys sent emergency room left dialysis yearold daughter donated kidney shortly transplant operation hudgins enrolled clinical trial investigational immunosuppressive compound called belatacept prevent transplant rejection felt whatever could help someone else road would worth saysspecial report building hope medicines create growth drivers approvalsuccessful launch erbitux key erbitux cetuximab works growth new medicine represent fight cancer lies ability selectively target epider culmination years intense lab mal growth factor receptor found surface oratory clinical study often many human cancers including colon rectum new medicines beginning today novel monoclonal antibody used success continuing journey discovery fully appropriate patients metastatic colorectal cancer erbitux abilify plavix reyatazand hope key open door treating avaproavalide successfully solid tumors bristolmyers squibb partner launched productalready significant imclone systems incorporated implemented compre growing part companys hensive clinical development plan investigate utility portfolio yet weve hopefully erbitux nonsmall cell lung pancreatic begun tap potential benefits cers already submission planned head patients thats neck cancer new therapy head neck cancer bristolmyers squibb devel approved fda since oping medicines day im really pleased bristolmyers squibb imclone opportunity even morefor invested programs develop erbitux areas patients sometimes even unmet need says martin birkhofer md vice president families employees four growth drivers profiled erbitux global development champion bristolmyers section special report squibb reward comes offering hope future colon cancer patients working toward able make difference lives many patients cancer bipolar disorder patient chuck conein chuck coneinof deer park washington realized simply stressed brain felt like tv sets changing channels time conein says ended hospital diagnosed bipolar disorder years prescribed various medications one point medicated couldnt even drive recently doctor suggested abilify finally says conein feel im control life abilify mark altmeyer senior vice president treatment acute bipolar mania recently neuroscience marketing bristolmyers approved maintaining efficacy certain squibb knows full well much medicines patients bipolar disorder yet abilify like abilify aripiprazole help make difference unique pharmacology profile bristolmyers lives individuals still keeps letter squibb partner otsuka pharmaceutical co desk remind every day ltd exploring additional uses woman psychiatrist thanking studies suggest abilify may work differently prescribing abilify says years different conditions raising levels certain wasnt sure whether life worth living neurotransmitters low reducing lev tried lots medications none els high special type activ worked doctor prescribed abilify ity means abilify potentially play important letter says ive come shell role many diseases currently investigation abilify already benefited hundreds altmeyer understands possibilities thousands patients suffering well challenges worth says serious psychotic disorderschizophrenia holds letter hand abilify approved fda come work every day heart attack patient otello brighi never hadany health problems one morning says otello brighi ravenna italy day felt sudden pain chest arm diagnosed myocardial infarction brighi recovered november doctor recommended enter investigational clinical trial determine plavix could help prevent second heart attacks heart attack distant memory says brighi theres future even look upon hopebuilding hope special report reyataz reyatazatazanavir sulfate launched bristolmyers squibb june eighth drug class plavix trust plavix members protease inhibitors pis first pi family says brian gavin phd global ever approved oncedaily dosing medical affairs director plavix clopidogrel one year reyatazbecame secondmost bisulfate doctors prescribed plavix prescribed pi us reyatazis used uncle greataunt cardiovas us internationally combination therapy cular peripheral vascular disease plavix treatment hiv helps protect aunt uncle future vascular events heart attacks strokes im amazed mother suffered series many people tell strokes might candidate plavix grateful yet benefits plavix confers todayin reducing risk heart attack stroke appropriate patients following myocar fourpart clinical development pro dial infarction stroke acute coronary gram seeking expand utility reyataz syndrome peripheral arterial diseasethere patients hoped program still much learn provide additional information use several landmark clinical studies already reyatazfor new patients evaluate serve foundation understanding current lipid resistance profiles provide new uses plavix patients major formulations complete investigational studies ongoing seeking evaluate effec studies pediatric patients tiveness plavix patients risk wide oncedaily dosing minimal lipid effect spectrum lifethreatening thrombotic events established efficacy safety profiles altogether bristolmyers squibb partner important considerations patients living sanofiaventis mounted one largest hiv says ron cooper senior vice presi clinical trial programs ever developedtotaling dent us virology aids service organi patients worldwide zations patient groups physicians offices truly challenging rewarding im amazed many people approach experience work plavix says gavin tell grateful bristolmyers family would likely agree squibb hearing speak passionately positive impact including reyataz hiv combination therapy made lives makes feel absolutely proud special reportbuilding hope registrational soon anticipate growth muraglitazar dont tell cindy rubin md group driversthose medicines outlined director metabolic diseases global clinical research pages complemented diabetes serious health problem know firsthand four investigational compounds devastating diabetes says developed address additional internist treated many patients type diabetes many serious medical conditions type patients diabetes also medical diabetes mellitus hepatitis b virus conditions dyslipidemia cardiovascular diseases infection rheumatoid arthritis kidney eye major depressive disorder know firsthand damage often registrational com challenging devastating pounds already submitted regula keep blood tory approval process diabetes glucose good submitted threemuraglitazar abata control manage cept baracludewere discovered associated conditions complications bristolmyers squibb scientists diabetes growing worldwide health crisis fourth emsam selegiline transdermal million people suffer diabetes including system entered bristolmyers squibbs million americans many remain undiagnosed pipeline december following commercialization agreement unfortunately current treatments often fail achieve somerset pharmaceuticals inc good control disease many patients diabetes somerset received approvable approved muraglitazar would become first letter fda february new class investigational compounds called glitazars approved emsam would dual alphagamma ppar peroxisome proliferatoractivated first transdermal treatment major receptor activator designed improve glucose depressive disorder muraglitazar lipid abnormalities associated type diabetes abatacept baracludeare profiled based clinical findings date section patients says rubin believe muraglitazar potential help diabetic patients better control blood sugar levels april bristolmyers squibb entered global collaborative agreement merck co inc jointly develop market muraglitazar new drug application nda marketing approval muraglitazar submitted fda december rheumatoid arthritis patient mike hayward rheumatoid arthritisturned even simplest activitieslike unscrewing jars lifting packages walking stepsinto impossible feats yearold mike hayward philadelphia ached says couldnt even go ladder carpentry job stopped shooting pool friends however enrolling investigational clinical trial abatacept says hope achieve normalcy abatacept rheumatoid arthritis treat symptoms says michael body literally erodes away joints chronic corbo phd vice president abatacept progressive autoimmune abatacept designed global development disorder affects abatacept designed million people world actually target wide many treat symptoms critical step diagnosed autoimmune process stop working due disability suffer decrease clinical trials patients quality life reduced life span supported abatacepts development biologics advances made treatment license application process rheumatoid arthritis significant issues remain submitted fda marketing approval majority patients suffering disease fda granted abatacept fast track status abatacept investigational compound designation facilitates review drugs potential new class agents called selective may potentially address unmet medical needs costimulation modulators designed serious diseases hepatitis b patient donghui zhao donghui zhao lives beijing wife teenage son mother died liver cirrhosis tested positive hepatitis b virus hbv probably acquired birth says began feel extremely tired always look ing place rest sleep despite treatment serum hbv levels risen significantly entered investigational clinical trial baraclude since entering trial feel like healthy person says zhao believe science baraclude million people see many years work worldwide infected hepatitis b virus team put may begin pay hbv chronic hbv infection cause liver patients us japan cirrhosis liver cancer million people china enrolled baracludeclinical trial die annually baraclude exciting program september complications bristolmyers antiviral compound hbv ninth squibb submitted leading cause death worldwide nda fda baracludeas well market baraclude entecavir investigational nucleo ing authorization application european side analog blocks three stages hbv medicines agency fda granted baraclude replication process baracludeis exciting antivi priority review classification applied time ral compound says richard colonno phd vice submission drugs approved would president infectious diseases drug discovery significant improvement treatment recently opportunity jog disease compared marketed products baracludeclinical trial patient says colonno cross finish line baraclude meaningful experience says colonno hope help many people scientist meet baracludetreated patient around world address serious disease building hope special report development bristolmyers squibb today belatacept work richard wright phd compounds development motivated desire help patients every day include six advanced clinical think improving lives patients says development full development think mother friend mine underwent closely follow four heart transplant several years ago shes risk registrational compounds developing kidney dysfunction side effect pipeline moreadvanced investi immunosuppressant therapy im really looking forward gational compounds may ready able offer transplant patients potentially submitted regulatory agencies less toxic alternative marketing approval within next two us europe patients years investigational live transplanted organs receive may ultimately submit ted approved however every day think compounds represents possibility improving lives addressing significant medical need patients among full development four presented section belatacept new transplants year prevent rejection transplant prevention solid organ transplant recipients require lifelong therapy potent immuno rejection srcabl kinase inhibitor mdx ixabepilone suppressive drugs unfortunately longterm therapy treatment cancer additional full contribute high blood pressure high cholesterol development compounds edifoligide levels diabetes kidney toxicity whats transplant prevention vein graft failure patients risk death cardiovascular disease prema javlor vinflunine cancer ture graft loss bristolmyers squibb scientists engineered belatacept compounds discov ered developed block specific pathway tcell activation believed best minds biomedical science initiate transplant rejection exploring whether yet often hearts scien investigational approach reduce occurrence tists drive transplant rejection cause fewer side effects tradi best stories tional immunosuppressants says wright vice president global brand champion belatacept phase ii clinical trials involving kidney transplant patients treatment belatacept produced promising results excited results says wright confirmed phase iii trials believe belatacept potential become exciting new option kidney transplant patients chronic myelogenous leukemia patient cheryl iantorno march everything cheryl iantornos life came halt diagnosed chronic myelogenous leukemia didnt want believe fatal disease says iantorno irvine california august treatments failed october says bones ached sometimes incoher ent could barely get bed entered clinical trial bristolmyers squibbs investigational srcabl kinase inhibitor stand research see drug really works says iantorno hope srcabl kinase inhibitor chronic patients resistant agents myelogenous leukemia cml often fatal compound potential anticancer cancer bone marrow fortunately treat activity across many solid tumor types including ment evolved fervent prostate colorectal small recent years cell lung gastrointestinal wish availability imatinib cancers preclinical studies known us help patients multiple tumor types gleevec however well early clinical trial resistant existing agents results patients cml promising therapeutic options available nicaise hopes accelerated full development bristolmyers squibb scientists discov program confirm results january ered potential firstinclass compound fda granted srcabl kinase studied determine ability inhibit inhibitor fast track status src abl pathways cell mechanisms happen know yearold cml involved growth progression many patient undergone bonemarrow tumor types including cml says claude transplant needed frequent platelet transfu nicaise md vice president srcabl global sions says nicaise entered clinical trial development srcabl kinase inhibitor srcabl kinase inhibitor july potent vitro hope work fervent wish help patients building hope special report mdx melanoma cancer pigment producing cells skin remains among difficult forms cancer treat year ixabepilone david chuan lee md cases diagnosed world leads development team ixabepilone wide people die new investigational cancer drug cancer disease november bristolmyers squibb much remains done develop medarex inc new jersey biopharmaceuti effective treatments common cal company announced worldwide collabora cancers says lee know father tion develop commercialize potential diagnosed lung cancer passed new treatment melanoma called mdx away christmas mdx fully humanized antibody discovered bristolmyers squibb targets ctla molecule surface scientists ixabepilone may first new tcells responsible shutting driven immune response exploring whether mdx could help patients immune new hope ixabepilone system effectively fight tumors could bring bristolmyers squibb medarex conducting pivotal phase iii melanoma study class anticancer drugs known epothilones phase ii studies ongoing cancer designed avoid mechanisms types including renal cell prostate breast thought important drug resistance lee encouraged weve seen says may offer hope patients early clinical studies says rachel humphrey either dont respond stopped responding md vice president development treatments mdx look forward results phase ii clinical trials thou phase iii trial signifying unmet sand patients already received ixabepilone medical need promise novel therapies variety tumor types including breast compound received fast track review lung prostate pancreatic renal cancers status fda almost additional patients enrolled think mdx often phase iii trials metastatic breast cancer think patient treated year half member ixabepilone team ago says humphrey first driven possibility developing com small lump back second week pound may work treatments terrible pain fourth week stop working says lee son dead unfortunately failed lost dad cancer driven new respond available treatments wish hope ixabepilone could bring patients could given another option another cancer families chance mdx may represent option potential ray hope may someday able provide patients special reportbuilding hope discovery bristolmyers squibbs goal deliver discovery first steps long process drug steady stream innovative new med discovery find good therapeutic target prove icines patients need worldwide relevance fighting disease match target feeding stream source novel compound steps alone may take several years companys drug discovery engine new medicine may first arise mind scien lay foundation pipeline sus tist envisioning novel therapeutic approach also tainability says francis cuss md begin silicon synapses advanced drugdesigning frcp senior vice president drug computer synthesized automated high discovery focused three throughput chemical assembly line elementsimproving productivity multidisciplinary teams talented scientistsworking discovery process delivering leadingedge technologiesfirst design refine highquality drug candidates clinical compound discovered promising compound testing consistent basis enhancing subsequent development evaluated modified process called drug optimiza success rates tion work closely biologists chemists minimize molecules undesired effects maximize section special report desired effects says richard robertson phd senior offer brief overview com vice president drug safety pharmaceutical candidate panys approach discovery optimization result compound high three elements fueling product pipeline creates hope potency low potential toxicity future cuss team scrutinized every aspect drug discovery process eliminate redundancies improve quality quantity drug candidates half early drug candidates coming companys labs entered human testinga success rate average industry proportion early candidates entering clinic increased percent industry success rate risen percent good example companys approach oncology discovery program recently introduction new tech nologies combined advances genomics biochem istry generated explosive growth cancer research productivity resulting new generation highly targeted selective anticancer compounds development today new compounds emerging bristol myers squibbs discovery labs technical names describe specific cellular targets novel mechanisms action hiv researchers pinfang lin phd john kadow phd every good compoundrequires dedicated team discover develop biologist pinfang lin director hiv drug discovery john kadow direc tor virology chemistry working bristolmyers squibbs investigational hiv attachment inhibitor program multiple compounds already early clinical development compounds designed block hiv attaching cd receptor says kadow thus potentially helping prevent virus gaining foothold lin biologists profile compounds potency toxicity safety pharmacology viral resistance want help people suffering hivaids says lin find new hope entering range selective computer modeling sophisti orally active kinase golden era cated imaging genomics robotics inhibitors targeting drug discovery relies spec vegffgf receptor inhibitors trum hightech tools however technology experimental anticda agonist monoclonal part story says john houston phd antibody designed stimulate cancer vice president applied biotechnology patients immune system stop reverse tumor discovery biology final product always growth also early development nextgen depends human intuitionthe scientific eration androgen receptor antagonist designed insight innovation drive biologists target drugresistant prostate cancer chemists carl decicco phd vice president entering golden era discovery chemistry agrees enthusiasm position harvest fruits scientific excellence set us apart decades cancer research says cuss ability tackle challenges human disease oncology one disease areas scientists unrelenting focus medical apply approach result need efforts improving success rates proliferation compounds discovery delivered early pipeline believe exploratory development oncology best companys history says cuss also across companys disease areas bristolmyers squibb discovery poised see pharmaceutical pipeline deliver future patients everywhere special reportbuilding hope health care businesses bristolmyers squibb employees mead johnson nutritionals research around world dedicated gives us food thought nowhere discovering developing innovative evident mead johnson nutritionals throughout products provide real value history says stephen w golsby mead johnson presi offer significant benefits people dent mead johnson leader infant child need commitment nutrition take responsibility commitment embedded mission values seriously give infants children great start life runs throughout entire company lipilline nutritional products case point pharmaceutical business mead johnson introduced enfamil lipil first well related health care us infant formula including dha nutrient found products businesses breast milk important brain eye development section get glimpse scientists mead johnson took idea one businessesmead step fartheror perhaps one step back depending johnson nutritionals infant child point view knew babies prior birthand nutrition products bristolmyers squibb breastfed babies birthdepend mothers medical imaging cardiovascular imaging dha however intake dharich foods us rel products convatec ostomy atively low compared areas world therefore wound therapeutics perhaps get sense passion moti infants may receive adequate dha vates employees drives pregnancy address concern mead johnson make difference peoples lives launched expectalipil supplement providing mg dha pregnant nursing moms studies demonstrated better visual acuity better mental development infants fed enfamillipilwith iron versus formula without lipil says deborah diersen schade phd mead johnsons global regulatory scientific affairs addition breastfed infants whose mothers took dha supplement like expectalipilshowed improved cognitive performance five years age mead johnson researchers understand even one nutrient significant impact infants critical first year life whether youre breast feeding using infant formula says diersenschade know important time terms growth development helping baby reach greatest potential mother newborn tammy hawk tammy hawk chicagois one mom appreciates addition dha nutrient mead johnsons lipil line products important brain eye develop ment hawk pregnant connor four months old husband wanted give good head start life hawk works public relations firm serves mead johnson heard expectalipildha supplement soon launched took expectalipilto provide dha utero since birth feeding connor enfamillipil iron infant formula think every woman looking ways take best care baby says hawk pregnancy afterwardsspecial reportbuilding hope medical imaging innovators heart employees bristolmyers squibb convatec aquacel ag introduced medical imaging words com convatec first antimicrobial panys mission committed searching wound dressing incorporate innovative new ways see ever deeper human gelling properties hydrofibertechnology heart vasculature absorbs times weight innovation defines bring mis wound fluid eliminates need daily sion life behalf customers often painful dressing changes patients says cory zwerling medical imagings although simple concept creating technology took years hard work began proud says phil bowler mphil director forefront microbiology antiinfectives convatec deeside england first realized cardiovascular imaging true technical differentiation hydrofiberfrom fibrous dressings knew benefits president focus made us leaders unique properties would likely bring patients field cardiovascular imaging benefits hydrofibertechnology key continued success increasingly realized physicians decade cardiolitekit us worldwide says gary restani presi preparation technetium tcm sestamibi dent convatec researchers injectionthe successful radiopharma taking technology new level ceutical everhas provided physicians vital nextgeneration hydrofibertechnologyin information blood flow heart muscle next years new chemistry enable recently definityvial perflutren lipid convatec design develop gelling wound microsphere injectable suspension dressing products increased versatility helping physicians bring clarity unevaluable nextgeneration technology echocardiograms many patients doctors able finetune dressings medical imaging also working shape fit patient nature wound future cardiovascular imaging pipeline says michael j lydon phd vice president products could help create new standards convatec wound therapeutics care current programs include exploring technolo physical polymer chemist dave parsons gies assessing vulnerable plaquethe leading phd explains another potential benefit cause heart attackdeveloping highly selec wound dressing technology enables us make tive pharmacologic stress agent potential dressings look like traditional gauze dressings improve patient tolerability well advantages modern hydrofiber promising innovations product says help medical profes mission drives everything sionals transition traditional treatment business zwerling says proud modern wound care forefront cardiovascular imaging burn patient mark wilson industrial electricianmark wilson oklahoma city working electrical equipment may flash fire engulfed flame suddenly standing cloud smoke flesh hanging shins recalls wilson sustained severe burns arms legs face local burn center treated aquacel agantimicrobial wound dressing hydrofibertechnology without wilson would probably needed skin grafting extended hospi tal stay instead treated outpa tient basis returned work four months feel blessed didnt need multiple skin grafts says im glad able get home quicklyspecial report fostering hope expanding access health care hope precious commodity access bristolmyers squibb joined six thats working alone part pharmaceutical companies comprehensive ners bristolmyers squibb seeks lift prescription savings program ever offered pharmaceuti barriers treatment people whose cal industry together rxcard helped participating circumstances may prevent seniors qualified medicare recipients save purchasing medicines brandname prescription medicines us discount prescription us pharmacies congress passed programslike together rx seniors medicare prescription drug improvement modernization drug benefits act together rx plans assist cardholders end together rx access new drug benefit becomes available uninsured offer qualified together rxmember companies making individuals helping hand real difference people need says tom mckenna many thousands indigent patients vice president business processes thus far weve companys patient assistance enrolled million medicareeligible beneficiaries foundation oncologyvirology whove collectively saved millionan average access program provide medicines per prescription people cost partnership signed alone prescription assistance provides single resource allows patients together rx accessa savings program qualified navigate way better health uninsured people otherwise eligible outside us programs offer medicare introduced january significant discounts help make together rx access card gets individuals meaningful accessible two hiv medications savings brandname prescription medi cines products including bristolmyers section outline approach making hope squibb says mckenna accessible greatest need bristolmyers squibb patient assistance foundation incqualified patients living us prescription drug insurance get companys physician methodist minister g scott morris md mdiv g scott morris realizeda childhood dream founded church health center memphis tennessee patients uninsured get sick theyre stuck says morris give place turn morris encourages patients apply aid bristolmyers squibb patient assistance foundation able dispense medicines free charge disadvantaged people program tremendous help us says morris cant imagine caring decision company make help people genuinely need prescription medications without charge along bristolmyers squibbamericares program easy patients physicians oncologyvirology access program helped useone million plenty reasons reach indigent patients fill government programs grown year prescriptionsat since began chargefor company plenty pharmaceuticals valued dont cover everybody government pro million grams wholesale prices dont cover everybody says james prazak bristolmyers squibb participates rph vice president bristolmyers squibb partnership prescription assistance ppa patient assistance foundation program industry program helps lowincome helps people get full access medications says uninsured patients us get free nearly prazak lead productive lives free brandname medicines ppa already chance improve situations available several states expected patient assistance foundation available nationwide april idea special reportfostering hope contact information access programs united states together rx wwwtogetherrxcom together rx access wwwtogetherrxaccesscom bristolmyers squibb patient assistance foundation bristolmyers squibbamericares oncology virology oncologyvirology access program virology partnership prescription assistance wwwpparxorg convatec ostomy assistance program mead johnson helping hand program childs physician coordinates local specialty infant formulas mead johnson representative one central website tollfree num governments increase access sustainable ber people financial difficulties prevention care treatment hivaids go find assistance available bristolmyers squibb assists developing get says countries discounts percent randy alsman senior us prices job keep vice president hiv drugs videx giving people need strategic access didanosine zerit domestic stavudine says john reasons hang patient assistance mcgoldrick bristol hope initiatives eligible myers squibb executive patients need include vice president general free convatec ostomy products discounted counsel thus far developing free products mead johnson nutritionals countries participated subsaharan infants requiring specialty formulas african countries committed prices outside us united profit company nationsindustry accelerating access initiative goal initiatives bristolmyers squibb reached help help fulfill mission extend enhance people developing countries stricken human life says alsman end hivaids beginning company day programs job keep worked six pharmaceutical com giving people need reasons hang panies well united nations agencies hope special report creating hope better health sustainable programs children bristolmyers squibb seeks create hope consider hivaids africa even sustainable solutionsto responsi steady drumbeat negative news devastation ble neighbor citizenacross many hivaids brought african continent says fronts many people need mark kline md director baylor international part effort company paying pediatric aids initiative turning corner special attention children baylor partner bristolmyers squibb children represent future creating groundbreaking hivaids treatment programs hope eternal children children think time hope optimism also vulnerable among us children families affected hivaids kline every year million children adds infrastructure human capacity built developing countries die care treat hivinfected children families fifth birthday southern africa partnership companys secure percent deaths among children futureprogram local governments klines group less five years old caused opened clinical center botswana first anywhere hivaids latin america africa devoted exclusively treating hivinfected caribbean year children families training health care professionals children less five years old succumb pediatric aids conducting clinical research preventable treatable illnesses children underrepresented long us obesity childrenespecially among minoritieshas reached epidemic kline says yet centers first months operation proportions growing percentage botswana tested children youths diabetes type children treatment likely largest disease almost exclusively diag concentration hivinfected children treated nosed adults overweight world thrilled bristolmyers critical risk factor development squibb agreed take highly successful model yet hopeeven may fund two additional centers swaziland lesotho appeared lost special reportcreating hope latin america bristolmyers squibb addressing issue obesity children creating new measures hope least able inner cities highrisk communities speak grant catholic obesity crisis africanamerican medical mission board cmmb working community says canada hoping partnership pan american health come set best practices get chil organization seek implement strategy dren eat healthy foods get exercise reducing childhood mortality improving regularly influence parents family community practices home man think meals agement common illnesses clinical bristolmyers squibbs backyard skills health workers project utilizes mercer county new jersey innovative part network faith nership robert health based organizations wood johnson reach several hope university hospital million people five hamilton building hope everything central american groundbreaking caribbean countries obesity type says rabia mathai phd cmmb senior diabetes screening programs supported vice president programs bristolmyers bristolmyers squibb foundation com squibb foundation trailblazer interna panys local contributions program says hospital tional health first pharmaceutical president ceo christy stephenson company come forward join hands past two years certified diabetes educa partnershipto leverage faithbased network tors worked school nurses screen provide health care part world children local schools via noninvasive ministries health means measures identify kids high risk type provide total health care percent diabetes refer programs health care vulnerable populations provided prevent onset serious disease faithbased organizations like many second phase partnership areas fabric communities bristolmyers squibb bristolmyers squibb formed critical mass platforms foundation funding program would enable created people coming parents children join shapedown sometimes early intervention education special week course focuses provided today offer hope tomor healthier eating also lifestyle behavioral row helping avoid future health epidemics changes even issues selfesteem new yorks central harlem geoffrey cant treat child stephenson says canada president harlem childrens zone family affair generosity communitybased organization begun foresight bristolmyers squibb working children families able move families program threeyear bristolmyers squibb four programsand foundation grant create model program many others mexico vietnam thailand secure future bristolmyers squibbs groundbreaking secure futureinitiative taking forceful stand rising tide hivaids pandemic especially among children pandemics vulnerable victims southern africa percent deaths children five caused hivaidsshapedown program past two years jason marcus west windsor new jersey enjoyed benefited participating unique familycentered weight management program called shapedown includes fitness components nutrition education offered locally robert wood johnson university hospital hamilton rwjuhh says mother jill program raised jasons awareness healthy eating need stay healthy something together helping children stay fit healthy life involve entire family thanks grant bristolmyers squibb foundation rwjuhh shape program made widely available eastern europeall supported adopted part bristolmyers squibbs foundation working wide range part sustainability goals focus ners focused children children outside company children addition throughout world bristolmyers employees based new jersey connecticut squibb employees part give benefiting four innovative onsite childrens children hope healthier safer environ development centers ment instance puerto rico employees proverb stephenson adds work area schoolchildren environmental says health hope education including energy water conserva hope everything bristolmyers squibb tion st nazaire france local fueling hope sustainable schoolchildren learningthrough company programs focus making right deci sponsored programabout river otter local sions today health children endangered species facility employees children generations come financial review managements discussion analysis consolidated financial statements notes consolidated financial statements reports management report independent registered public accounting firm controls procedures fiveyear financial summary managements discussion analysis financial condition results operations executive summary ments period ended december prior periods march company discussion matters see restatement previously issued bristolmyers squibb company bms company bristolmyers financial statements sec consent order squibb worldwide pharmaceutical related health care products com help ensure circumstances led need financial restate pany whose mission extend enhance human life company ment recur company taken steps enhance effectiveness engaged discovery development licensing manufacturing marketing disclosure controls procedures including internal control finan distribution sale pharmaceuticals health care related products cial reporting completing restatement company continued company employs approximately people identify implement actions improve effectiveness disclosure company reported annual global sales continuing opera controls procedures internal controls financial reporting tions billion sales increased prior year level due actions contributed significantly company identifying additional errors favorable impact foreign exchange rate fluctuations us sales remained relating prior periods reflected restatement accordingly constant billion increased sales key brands newer products company restated consolidated financial statements correct offset exclusivity losses older brands international sales errors years company continues strengthen increased billion including favorable foreign exchange disclosure controls procedures surrounding internal controls financial impact two product lines achieved sales billion reporting specifically respect section sarbanesoxley act plavix pravacholplavix sales grew including favorable foreign actions include establishment policies procedures exchange impact billion pravacholsales decreased includ enhance compliance focus risk management ing favorable foreign exchange impact billion additional product lines achieved million annual sales including business environment product lines million annual sales pharmaceutical industry company conducts business annual sales excess million highly competitive subject numerous government regulations sales fourth quarter company signed definitive agreement companys products affected significantly many competitive fac sell oncology therapeutics network otn business distributor phar tors including product efficacy safety price costeffectiveness marketing maceutical products officebased oncologists january effectiveness product labeling quality control quality assurance man company announced intends divest us canadian consumer ufacturing operating research development new products suc medicines businesses cessfully compete business health care industry company must support mission extend enhance human life developing demonstrate products offer medical benefits also cost highestquality products company invested billion research advantages currently new products introduced company development growth expects increase spendingon must compete products therapeutic category already drug development accelerate development latestage pipeline market company manufactures branded products subject research development dedicated pharmaceutical products including mile higher prices generic products generic competition one stone payments inlicensing development programs billion companys biggest challenges globally percentage pharmaceutical sales compared pharmaceutical industry majority innovative products com august company announced entered settlement mercial value usually realized period product united states securities exchange commission sec concluding market exclusivity product loses exclusivity longer protected secs investigation regarding wholesaler inventory accounting matters patent subject new competing products form generic settlement reached consent order brands upon exclusivity loss product company lose major company currently operating secs investigation arose portion products sales short period time companys announcement april company experienced sub us internationally health care industry subject stantial buildup wholesaler inventories us pharmaceuticals business various governmentimposed regulations authorize prices price con several years primarily buildup prima trols could impact companys sales us congress rily due sales incentives offered company well companys state legislatures considered number proposals subsequent restatement restatement consolidated financial state enacted laws could effect major changes health care system either bristolmyers squibb company annual reportnationally state level driven part budget concerns medicaid investmentsbehind new product launches redeploying marketing access reimbursement restrictions implemented states promotional spending older products newer products proposed many others example december medicare company submitted two new drug applications ndas prescription drug improvement modernization act mma enacted us food drug administration fda regulatory approval including provide outpatient prescription drug coverage senior citizens united baracludeentecavir hepatitis b muraglitazar type diabetes states company predict potential impact legislation rolling biologics license application bla abatacept potential treat business however could negative impact ment rheumatoid arthritis also expected completed early companys us pharmaceutical business greater federal involvement successful launch investigational compounds enhance budget constraints may increase likelihood pricing pressures controls companys strategy transition product portfolio cover ten future many markets outside united states company operates disease areas discussed environments governmentmandated costcontainment programs internal growth vital companys future success company european countries except united kingdom germany provide continually evaluating pursuing external possibilities alliances market pricing new medicines pricing freedom limited united collaborative agreements company notable record executing kingdom operation profit control plan germany opera successful licensing arrangements supplement pipeline many tion reference price system companies also face significant delays mar arrangements led fruitful codevelopment copromotion ket access new products two years elapse new comarketing agreements company expects continue complement medicines become available national markets pipeline additional licensed products another component growth managed care organizations mcos us played companys strategy includes entry biologics business requires large role competition surrounds health care industry mcos increased investments manufacturing facilities thirdparty manufacturing seek reduce health care expenditures participants making volume arrangements meet future commercial demand expected generated purchases entering longterm contracts negotiate discounts new product launches addition company continues maintain various pharmaceutical providers market potential created collaborations major biotechnology research institutions enhance large pool participants marketing prescription drugs mcos life cycle companys product portfolio beyond initial approvalcom become important part companys strategy companies compete mercialization offering combination therapy product extensions inclusion mco formulary company generally success another major aspect companys strategy relates busi ful major products included ness specifically marketing sales approaches specialists playing pharmaceutical production processes complex highly regulated even greater role decisions related patient treatment care particularly vary widely product product shifting adding manufacturing capacity ten critical disease areas company focusing efforts lengthy process requiring significant capital expenditures regula reason company recasting business model focus specialists tory approvals biologics manufacturing involves complex processes well primary care physicians involved treating traditional pharmaceutical operations although company patients select disease areas order achieve strategic objec capacity manufacture biologics clinical trials commercial tives company also plans moderate selling general administrative launch current capacity manufacture larger commercial volumes spending next several years customer model noted products limited well elimination organizational inefficiencies company maintained competitive position market strives uphold position dependent success discovering results operations developing innovative products serve unmet medical needs following discussion companys results continuing operations excludes results related otn business segregated strategy continuing operations reflected discontinued operations company implementing new strategy discover develop periods presented see discontinued operations innovative medicines address significant unmet medical needs ten change critical disease areas areas affective psychiatric disorders alzheimersdementia atherosclerosisthrombosis diabetes hepatitis dollars millions hivaids obesity oncology rheumatoid arthritis related diseases solid organ transplant company continuously strives create better net sales treatments patients building high quality drug discovery develop earnings ment pipeline continuing operations since company undergone transition pharmaceutical minority interest product portfolio older product lines including glucophage franchise income taxes monopriltaxoland paraplatin experienced exclusivity loss net sales successful launches newer products including abilify treatment provision psychiatric disorders reyatazfor human immunodeficiency virus hiv income taxes erbitux cancer portfolio refocused growth brands effective tax rate fall within ten critical disease areas targeting specialists highvalue earnings primary care physicians sales products within ten disease areas continuing operations increasing steadily expected comprise half pharma net sales ceutical product sales end company making significant change excess bristolmyers squibb company annual reportnet sales invoices wholesaler records deferred revenue gross invoice sales price net sales continuing operations increased billion classifies inventory held wholesalers consignment inventory due favorable impact foreign exchange rate fluctuations us net companys cost inventory company recognizes revenue sales remained constant billion compared net gross net sales adjustments discussed involve growth prescription demand key brands including plavix avaproavalide significant estimates judgments risks rewards ownership sustiva new product introductions including abilify reyatazand transferred customer later inventory erbitux offset lower sales products result exclusivity losses sold wholesalers customers firstin firstout fifo basis formonopril paraplatinand glucophage franchise us net sales increased companys aggregate cost pharmaceutical products billion international net sales increased accounted using consignment model accordingly reflected billion billion excluding favorable consignment inventory companys consolidated balance sheet foreign exchange international net sales increased billion significant december deferred revenue related excluding favorable foreign exchange growth sales pri inventory pharmaceutical products accounted using consign marily attributable increased sales plavix avaproavalide launch ment model fully worked december deferred revenue reyatazand abilify europe offset decline pravachol net recorded gross invoice sales price approximately million sales continuing operations increased billion including december approximately million million million favorable impact foreign exchange rate fluctuations deferred revenue recognized respectively composition net increase sales follows corresponding effect earnings continuing operations minority interest income taxes increase million million million respectively volume company recognizes revenue gross sales basis deducts vari selling prices net ous sales adjustments arrive net sales reported consolidated foreign exchange statement earnings adjustments referred grosstonet sales increase sales adjustments described critical accounting policies following table summarizes companys grosstonet sales adjustments general companys business seasonal information us significant category pharmaceuticals prescriber demand reference made table within business segments pharmaceuticals section sets dollars millions forth comparison changes net sales estimated total prescription growth retail mail order customers certain companys gross sales primary care pharmaceutical products grosstonet sales adjustments company operates three reportable segmentspharmaceuticals prime vendor chargebacks nutritionals healthcare company signed definitive women infants children wic rebates agreement sell otn previously presented separate segment managed health care rebates results operations otn presented part companys contract discounts results discontinued operations accordance statement financial medicaid rebates accounting standards sfas accounting impairment cash discounts disposal longlived assetsaccordingly otn results operations prior sales returns periods reclassified discontinued operations conform cur adjustments rent year presentations percent companys sales segment total grosstonet sales adjustments follows net sales change increases prime vendor chargebacks medicaid rebates primarily due shift sales products higher dollars millions discounts prime vendor medicaid programs decreases sales pharmaceuticals returns primarily attributable higher sales returns resulting net sales discontinued products product conversions overall increase gross nutritionals tonet sales adjustments primarily due sales growth net sales increases managed care rebates principally due shift sales healthcare products higher discounts partially offset decrease wic rebates net sales due decline state wic contracts total company recognizes revenue sales substantially risks rewards ownership transferred customer generally occurs date shipment substantially risks rewards ownership transfer company uses consignment model recog nize revenue model company recognize revenue upon shipment product rather upon shipment product company bristolmyers squibb company annual reportthe following table sets forth activities ending balances significant category grosstonet sales adjustments managed women healthcare prime infants rebates vendor children charge wic contract medicaid cash sales dollars millions backs rebates discounts rebates discounts returns adjustments total balance december provision related sales made current period provision related sales made prior periods returns payments impact foreign currency translation balance december provision related sales made current period provision related sales made prior periods returns payments impact foreign currency translation balance december company recorded charges million medicaid rebates related sales made prior periods charges include million rebate claims prior years certain states primarily relation medicaid utilization oncology products previously reported company revisions resulting availability additional information addition company recorded million adjustments result lowerthan expected rebates foreign governments significant revisions made estimates grosstonet sales adjustments pharmaceuticals composition net increase pharmaceutical sales follows key pharmaceutical products sales representing total pharmaceutical sales respectively follows analysis change change foreign total change volume price exchange dollars millions vs vs cardiovascular plavix worldwide pharmaceuticals sales increased million pravachol due favorable foreign exchange impact domestic sales remained avaproavalide constant million compared million domestic sales monopril negatively affected increased competition pravachol exclusivity coumadin losses paraplatinand glucophage franchise offset increased sales virology plavix newer products including abilify reyatazand erbitux sustiva international sales increased million decrease reyataz excluding favorable foreign exchange impact primarily due generic videxvidex ec competition pravacholand taxol partially offset launches zerit abilify reyatazand continued growth plavix avaproavalide infectious diseases worldwide pharmaceuticals sales increased mil cefzil lion excluding favorable foreign exchange impact domestic sales tequin increased million primarily due increased sales oncology plavix pravachol abilify glucovance paraplatinand partly due taxol impact sales workdown nonconsignment wholesaler paraplatin inventory launch reyatazin july partially offset decreased erbitux sales glucophage ir taxolprimarily due generic competition affective psychiatric international sales increased million including disorders favorable foreign exchange impact primarily due increased sales abilify total revenue pravachol taxol plavix avaproavalide analgesic products europe metabolics partially offset price declines principally germany italy glucovance glucophage ir glucophage xr change excess bristolmyers squibb company annual reportsales plavix platelet aggregation inhibitor sold company sales sustiva nonnucleoside reverse transcriptase inhibitor treat primarily us increased including favorable foreign ment hiv increased including favorable foreign exchange exchange impact million primarily due impact million prior year primarily due increased strong prescription growth us market sales demand higher prices us sales increased million million increase including favorable foreign total us prescription growth increased exchange impact million primarily due strong pre international sales sustivaincreased including favorable scription growth us plavix cardiovascular product eign exchange impact million driven increased sales launched alliance company sanofiaventis spain uk france italy sustivasales increased sanofi market exclusivity plavix expected expire us million million primarily due workdown eu statements exclusivity subject adverse us wholesaler inventory third quarter market exclusivity pro determination may occur respect plavix patent litigation tection sustivais expected expire us countries additional information plavix patent litigation see note legal eu company others market sustivain japan proceedings contingencies sales reyataz protease inhibitor treatment hiv sales pravachol hmg coa reductase inhibitor decreased launched us third quarter europe second including favorable foreign exchange impact million quarter million compared million domestic sales decreased million total us pre reyatazhas achieved weekly new prescription share us protease scription demand decreased international sales decreased includ inhibitors market approximately market exclusivity reyatazis ing favorable foreign exchange impact million due expected expire us countries eu japan exclusivity loss select european markets including germany uk sales pravacholincreased million sales videxvidex ec antiretroviral agent used treatment hiv million primarily due wholesaler workdown inventory us increased decreased excluding favorable foreign exchange continued growth europe particularly france uk impact million videxvidex ec sales increased italy market exclusivity protection pravacholis expected expire april million million due increased sales europe us market exclusivity eu expired excep partially offset sales declines us company licensing tion france sweden expiration occur august arrangement us government videxvidex ec march respectively italy expiration occur terms became nonexclusive us governments method use january patent expires us includes earned pediatric exten sion japan countries eu sales avaproavalide angiotensin ii receptor blockers treatment license company nonexclusive allowed another com hypertension increased including favorable foreign exchange pany obtain license us government receive approval impact million driven increased sales europe marketing respect videxvidex ec company patents cover strong us prescription growth approximately sales increased ing reduced mass formulation videxvidex ec expire including favorable foreign exchange impact million us eu japan however patents apply type million primarily due strong us prescription growth reduced mass formulation specified patent reduced mass price increases avaproavalide cardiovascular products launched mulations may exist currently issued patent covering videx alliance company sanofi market exclusivity ec formulation avaproavalide known eu aprovelkarvea expected expire us countries eu avaproavalide sales zeritan antiretroviral agent used treatment hiv decreased currently marketed japan including favorable foreign exchange impact million primarily result continued decrease demand due potential sales monopril second generation angiotensin converting enzyme adverse side effects zeritsales decreased including favorable ace inhibitor treatment hypertension decreased including foreign exchange impact million million favorable foreign exchange impact million due impact primarily result decreased demand due potential adverse side market exclusivity loss sales million increase effects market exclusivity protection zeritis expected expire including favorable foreign exchange impact million us countries eu japan resulting introduction branded generic product new government contract market exclusivity protection monoprilexpired sales cefzil antibiotic treatment mild moderately severe us expired expected expire bacterial infections decreased including favorable foreign countries eu monoprilis currently marketed japan exchange impact million primarily due decreased domestic demand partially offset higher international sales cefzilsales sales coumadin oral anticoagulant used predominately patients increased million million market atrial fibrillation deep venous thrombosispulmonary embolism exclusivity expected expire us decreased million compared sales due eu expired japan increased generic competition sales increased million million market exclusivity coumadinexpired us bristolmyers squibb company annual reporttequin antibiotic used treatment respiratory tract infections us may extended pending patent sales million decrease compared sales term extension granted company also right copromote sales increased million million tequin abilify several european countries united kingdom france seasonal product sales increasing flu season sales germany spain act exclusive distributor product fluctuations due strong flu season rest european union eu market exclusivity protection weak flu season basic us patent expires however abilify expected expire eu may extended expected patent eligible statutory patent term exten pending supplemental protection certificates granted sion companys right market abilify expires november us puerto rico countries eu company sales taxol companys leading anticancer agent exclusive right market abilify june additional informa million compared million sales taxol tion revenue recognition abilify see note alliances almost exclusively international increased decreased exclud investments ing favorable foreign exchange primarily result generic competition europe generic competition taxolin majority major european glucophage franchise sales decreased million com markets began second quarter increased second pared increase million million half taxolsales increased decreased exclud decrease sales primarily resulted increased generic ing favorable foreign exchange million million competition glucophage ir oral medication treatment non primarily due generic competition us partially offset strong insulin dependent type diabetes experienced sales decrease sales japan france market exclusivity protection taxolexpired million sales decreased million mil us eu expected expire lion glucovance oral combination drug glucophage xr japan extended release tablets sales million mil lion respectively compared sales million sales paraplatin anticancer agent decreased including million respectively sales million million favorable foreign exchange impact million due generic competi respectively market exclusivity protection expired march tion us began mid increased entry mul glucophage ir october glucophage xr january tiple generic competitors fourth quarter domestic sales paraplatin glucovance company others market decreased million paraplatinsales increased products eu japan significant foreign exchange impact million mil lion primarily due introduction new formulation instances basic exclusivity loss date indicated expi paraplatinin price increases market exclusivity protection ration date patent claims active ingredient drug paraplatinexpired october us eu method using drug approved indication instances japan basic exclusivity loss date indicated expiration date data exclusivity period situations data exclusivity without patent protec erbitux injection used combination irinotecan treatment tion competitor could seek regulatory approval submitting clinical patients epidermal growth factor receptor egfrexpressing trial data obtain marketing approval company assesses market metastatic colorectal cancer refractory irinotecanbased exclusivity period products casebycase basis length chemotherapy single agent treatment patients market exclusivity companys products difficult predict egfrexpressing metastatic colorectal cancer intolerant certainty complex interaction patent regulatory irinotecanbased chemotherapy approved fda february forms exclusivity factors assurance particu sales erbitux sold almost exclusively us lar product enjoy market exclusivity full period time million year ended december patent relating company currently anticipates combination therapy erbitux expires companys right following table sets forth comparison reported net sales changes market erbitux north america japan expires september estimated total us prescription growth retail mail order company others market erbitux countries customers certain companys us pharmaceutical prescription prod eu ucts estimated prescription growth amounts based thirdparty data provided ims health supplier market research pharmaceutical total revenue abilify primarily domestic alliance revenue industry significant portion companys domestic pharmaceutical companys share net sales copromotion countries otsuka sales made wholesalers changes reported net sales differ pharmaceutical co ltd otsuka million compared prescription growth change net sales may reflect underlying million million respectively due contin prescriber demand ued growth prescription demand since launch schizophrenia agent introduced united states november december achieved weekly new prescription share us antipsychotic market european commission granted marketing authorization abilify june total revenue reached million since public sales commenced june september fda approved abilify treatment acute bipolar mania us market exclusivity protection abilify expected expire bristolmyers squibb company annual report continue monitor paraplatinsales intention working whole change change change change change change saler inventories less one month hand us ustotal us us total us ustotal company maintains inventory management agreements imas net sales prescriptions net sales prescriptions net sales prescriptions b b b us wholesalers account nearly total gross sales us pharmaceutical products current terms imas plavix wholesalers provide company information respect inventory lev pravachol els product hand amount outmovement products avaproavalide inventory information received wholesalers product record monopril keeping process excludes inventory held intermediaries coumadin sell retailers hospitals company determines amount sustiva outmovement product period one month using videxvidex ec recent prior four weeks outmovement product provided zerit wholesalers company also determines months hand estimates cefzil using factors historical sales made wholesalers third glucovance party market research data related prescription trends patient demand glucophage xr nutritionals excess composition net increase nutritionals sales follows reflects change net sales dollar terms including change average selling prices wholesaler buying patterns b reflects change total prescriptions unit terms based thirdparty data analysis change total change volume price foreign exchange following table sets forth companys key pharmaceutical products sold companys us pharmaceuticals business amount vs us pharmaceuticals businesss net sales applicable product vs year ended december estimated number months hand applicable product us wholesaler distribution channel key nutritionals product lines sales representing december total nutritionals sales respectively follows dollars millions net sales months hand change plavix dollars millions pravachol avaproavalide infant formulas abilify toddlerchildrens paraplatin nutritionals sustiva glucophage franchise worldwide nutritionals sales decreased million reyataz excluding impact adult nutritionals business divested coumadin first quarter worldwide sales increased million tequin million zerit international sales excluding impact adult nutritionals business videxvidex ec increased primarily due increased sales infant formula childrens monopril nutritionals products increase international sales primarily due increase enfagrow toddler childrens nutritionals product company determines months hand estimates dividing increase enfamil companys largestselling infant formula including estimated amount product wholesaler distribution channel favorable foreign exchange impact domestic sales excluding impact estimated amount outmovement product period four adult nutritionals business increased million weeks calculated described factors may influence million primarily due increased sales enfamil companys estimates include generic competition seasonality products nutritionals sales million increase including wholesaler purchases light increases wholesale list prices new product unfavorable impact foreign exchange international sales launches new warehouse openings wholesalers new customer stock increased including unfavorable foreign exchange impact ings wholesalers million million domestic sales increased paraplatinlost exclusivity october demand since decreased million million worldwide infant formula sales significantly resulting estimated months hand greater one increased million primarily due increased sales month value paraplatininventory one month hand december enfamil international sales enfamilincreased million approximately million company plans million domestic sales enfamilincreased million million worldwide toddler chil drens nutritionals sales increased including unfavorable foreign bristolmyers squibb company annual reportexchange impact million million result geographic areas increase sales enfagrow primarily throughout pacific region least companys products available countries million world largest markets united states france japan spain germany italy canada uk companys sales geographic areas healthcare follows healthcare segment includes convatec medical imaging change business consumer medicines united states japan com position net increase healthcare sales follows dollars millions analysis change total change volume price foreign exchange united states total vs europe middle east vs africa total healthcare sales business key products years western ended december follows hemisphere change total pacific total dollars millions total convatec ostomy sales united states remained constant growth pre wound therapeutics scription demand key brands including plavix avaproavalide sustiva medical imaging newer products including abilify reyatazand erbitux offset lower cardiolite sales products result exclusivity losses monopril paraplatin consumer medicines glucophage franchise sales united states increased primarily due increased sales plavix pravachol abilify glucovance increase convatec sales due increase paraplatin sales increases partially offset continued volume increase due foreign exchange partially offset impact generic competition united states glucophage ir decrease changes selling prices increase taxoland result loss exclusivity label change indicating result increased worldwide sales wound therapeutics products potential serious side effect serzone increased including favorable foreign exchange impact sales europe middle east africa increased decreased million ostomy sales flat excluding increase due excluding impact foreign exchange result sales decline foreign exchange impact increase convatec sales pravacholdue exclusivity loss select markets including germany due increase worldwide sales ostomy products uk taxol generic competition majority major million strong growth worldwide wound therapeutics products european markets began second quarter decrease increased million foreign exchange contributed sales sales mostly offset increased sales plavix germany spain increase avaproavalide italy spain sustivain majority major markets sales increased including increase foreign increase medical imaging sales due increase exchange result sales growth pravacholin france taxolin france volume increase changes selling prices increase due germany spain italy analgesics france plavix germany spain foreign exchange increase medical imaging sales avaproavalide italy sustivain spain primarily driven increased sales ofcardiolite increase sales western hemisphere countries increased including partially due change timing revenue recognition result increase foreign exchange primarily due increased sales plavix new distribution agreements entered january avaproavalide canada sales increased including decrease foreign exchange primarily due increased sales plavix consumer medicines sales remained flat million compared canada declined million sales increase pacific region sales increased including increase foreign us primarily driven higher sales excedrin offset exchange result increased sales taxoland paraplatinin decreased sales japan primarily due lower sales bufferinand japan plavix avaproavalide australia sales increased overthecounter medicines sales decline part due including increase foreign exchange result increased distributors reducing us inventory levels desirable levels sales taxolin japan increased sales enfagrowthroughout region bristolmyers squibb company annual reportexpenses expenses increased million million change primarily due increased sales support abilify avapro avalide higher pension costs higher charges related system infrastruc ture higher insurance premiums unfavorable foreign exchange impact dollars millions principally related euro cost products sold net sales advertising product promotion expenditures remained constant marketing selling billion compared increased investments abilify reyataz administrative plavix offset lower spending inline nonexclusive products net sales advertising promotion expenses increased million advertising million primarily result promotional support product promotion abilify reyatazlaunches plavix us additional sup net sales port inline products unfavorable foreign exchange impact europe research development companys investment research development totaled mil net sales lion increase increase acquired inprocess percentage sales compared research increase research development development expenses primarily due higher spending new devel net sales opment projects including investments latestage development including provision restructuring muraglitazar dual ppar agonist diabetes abatacept potential items net treatment rheumatoid arthritis baracludefor hepatitis b invest net sales ments area biologics partially offset mercks share codevelop litigation charges net ment costs related muraglitazar research development costs also net sales included million consisting primarily upfront milestone payments equity net income million charges related upfront payments licensing affiliates agreements million accelerated depreciation research net sales facilities research development spending dedicated expense net pharmaceutical products increased pharmaceuticals sales net sales compared decreased compared total expenses net increase reflects companys strategic focus ten critical disease net sales areasaffective psychiatric disorders alzheimersdementia atherosclero sisthrombosis diabetes hepatitis hivaids obesity oncology rheumatoid change excess arthritis related diseases solid organ transplant company cost products sold percentage sales increased last two focusing research development activities fully realize years compared value research development pipeline new priorities include increase primarily due increase accelerated depreciation rebalancing drug discovery development increase support million million million increase product liability reserves companys full latestage development pipeline closing unnecessary unfavorable impact us pharmaceutical sales mix due facilities also include devoting greater resources ensuring success impact generic competition us glucophage franchise ful nearterm product launches increasing companys efforts paraplatinand launch lower margin erbitux partially offset sales inlicensing opportunities growth abilify reyataz plavix cost products sold also included million commercial litigation expense million product million charge acquired inprocess research devel liability insurance recovery cost products sold included opment related purchase acordis specialty fibres acordis million accelerated depreciation assets manufacturing facilities ukbased company expected strengthen companys leader north america expected closed end million ship position wound therapeutics charges related acquired charge asset impairment restructuring expenses cost prod inprocess research development million primarily related ucts sold included million reversal prior period reserves milestone payments imclone systems incorporated imclone inventory writeoffs related canceled actions erbitux million milestone payment imclone million expensed acquired inprocess research development first marketing selling administrative expenses percentage sales quarter remaining million recorded additional marketing equity investment eliminate income statement effect portion selling administrative expenses increased million milestone payment company economic claim primarily due increased sales marketing support newer ownership interest imclone products including additional sales representatives supporting abilify addition increase also related costs associated compli restructuring programs implemented downsize realign ance sarbanesoxley act unfavorable foreign exchange streamline operations order increase productivity reduce operating driven strengthening euro marketing selling administrative expenses rationalize companys manufacturing network research bristolmyers squibb company annual reportfacilities sales marketing organizations actions primarily related busparand taxolsettlements additional informa restructuring program expected complete actions tion litigation see note legal proceedings contingencies restructuring programs substantially completed actions restructuring programs completed equity net income affiliates million compared december result actions company expects million million respectively equity net future annual benefit earnings continuing operations minority income affiliates principally related companys joint venture interest income taxes approximately million million sanofi investment imclone increases equity million programs respectively net income affiliates primarily reflect higher net income sanofi additional information restructuring see note restructuring joint venture additional information equity net income affiliates items see note alliances investments litigation charges net settlement income million expenses net income million million mil compared million million mil lion respectively expenses include net inter lion consisted million related private litigation govern est expense foreign exchange gains losses income thirdparty mental investigations related wholesaler inventory issues accounting contract manufacturing royalty income gains losses disposal matters million related platinollitigation settlement mil property plant equipment favorability primarily due lion related pharmaceutical pricing sales practices higher income thirdparty contract manufacturing lower net interest company established reserves liabilities total amount mil expense lower net foreign exchange losses decrease expenses lion comprised million relation wholesaler inventory issues primarily due net gains interest rate swaps certain accounting matters million relation pharmaceu tical pricing sales marketing practices addition company years ended december company recorded charges million litigation matters recognized recorded several items affected comparability results periods income million million income consists primarily mil presented herein set forth following table discussion lion income patent defense cost reimbursement million litiga items see note alliances investments note restructuring tion settlement income million settlement antitrust items note acquisitions divestitures note litigation involving vitamin manufacturers charges million discontinued operations year ended december provision acquired litigation cost process gain restructuring settlement products research research sale expense expense dollars millions sold development development business items net income net total litigation matters private litigation governmental investigations product liability pharmaceutical pricing sales litigation b commercial litigation antitrust litigation product liability insurance recovery gain sale adult nutritionals business accelerated depreciation downsizing streamlining worldwide operations upfront milestone payments acordis iprd writeoff income taxes items deferred taxes anticipation repatriation foreign earnings tax adjustments reduction net earnings continuing operations relates wholesaler inventory accounting matters consisting million reserves recorded fourth quarter million disclosed company second quarter amounts incremental million recorded last year bringing total reserve million b incremental million reserve recorded company last year bringing total reserve million bristolmyers squibb company annual reportyear ended december provision litigation cost restructuring settlement products research expense dollars millions sold development items net income total litigation matters private litigation governmental investigations product liability pharmaceutical pricing sales litigation litigation settlement income upfront payments licensing agreements accelerated depreciation asset impairment charges termination benefits exit costs relocation retention change estimates income taxes items reduction net earnings continuing operations year ended december provision acquired litigation cost process restructuring settlement products research research expense asset expense dollars millions sold development development items net income impairment income total litigation matters antitrust litigation commercial litigation litigation sale product rights termination benefits exit costs acquired inprocess research development asset impairment charge income taxes items settlement prior year tax matters reduction net earnings continuing operations bristolmyers squibb company annual reportearnings operating loss tax credit carryforwards foreign net operating loss tax earnings credit carryforwards charitable contribution carryforwards company continuing operations currently believes state net deferred tax assets state net operating minority interest loss tax credit carryforwards foreign net operating loss tax credit income taxes change carryforwards charitable contribution carryforwards valuation allowances provided likely realized dollars millions future pharmaceuticals pharmaceuticals nutritionals earnings minority interest income taxes million healthcare decreased million primarily driven gross margin erosion total segments due generic competition product mix additional sales representatives corporateother supporting abilify increased spending research development higher total nonclinical grants litigation settlement income partially offset higher sales earnings minority interest income taxes earnings continuing operations minority interest million increase primarily due increased income taxes decreased million million sales partially offset increased advertising product spending new contributing decrease increases costs products sold existing inline products result change product mix products losing exclusivity increased investment research development income expenses nutritionals affected comparability results discussed partially offset earnings minority interest income taxes increased million higher international sales net earnings continuing operations decreased million increase primarily due increased million million basic earn global infant formula sales price increase infant formula line favorable ings per share continuing operations decreased manufacturing variances tight operating expense management diluted earnings per share continuing operations earnings minority interest income taxes nutritionals segment decreased increased million result increased sales enfamil earnings continuing operations minority interest income taxes increased million million healthcare increase primarily result increased sales charges million earnings minority interest income taxes healthcare recorded litigation settlements asset impairments writeoffs segment increased million million primarily inprocess research development increase partially offset due sales growth convatec medical imaging businesses addi increased investment advertising promotion marketing selling tion favorable pricing product mix earnings minority administrative expenses earnings continuing operations increased interest income taxes segment decreased million million million basic primarily result unfavorable product mix inventory writeoffs diluted earnings per share continuing operations increased excedrinquicktabs consumer medicines business respectively respectively effective income tax rate earnings continuing operations discontinued operations minority interest income taxes compared december company committed plan sell otn higher effective tax rate attributable pri entered definitive sale agreement one equity partners llc otn marily million charge estimated deferred taxes taken fourth formerly reported distinct operating segment transaction quarter anticipation repatriating approximately billion special expected completed first half sale price equal dividends companys nonus subsidiaries pursuant american million plus certain price adjustments based otns excess current jobs creation act ajca increase estimates contingent tax assets current liabilities closing date sale result pretax matters compared charge related establishment gain million subject certain price adjustments post valuation allowance certain charitable contribution carryforwards closing matters gain sale otn recognized closing increase partially offset favorable resolution certain tax date discussions otn see note discontinued operations refund claims increased foreign tax credits effect certain lit following amounts related otn business segregated igation reserves nondeductible companys estimate tax continuing operations reflected discontinued operations cost related dividend repatriation december based periods presented tax laws effect estimate may revised result additional guidance clarifying language may issued congress andor department treasury changes companys factual assump tions may occur increase effective tax rate effective tax rate primarily due decrease effective tax rate benefit operations ireland puerto rico switzerland treatment provi sions certain litigation reserves nondeductible increase esti mates contingent tax matters compared company recorded valuation allowances certain state net deferred tax assets state net bristolmyers squibb company annual reportdollars millions authorization application baracludeto european medicines evaluation agency net sales august fda approved companys supplemental new drug earnings income taxes net earnings discontinued operations application snda include new longterm virologic clinical data bms study prescribing information related sustivaefavirenz net earnings discontinued operations million reflected new data demonstrate longterm durability virologic response people statement earnings primarily reflects reduction million living hiv naive protease inhibitors lamivudine tc tax contingency reserve related spinoff zimmer holdings inc nonnucleoside reverse transcriptase inhibitors nnrti three years treatment combination regimen containing sustiva developments july fda approved companys snda include new scien january company announced intends divest us tific data dosing package insert labeling related reyataz canadian consumer medicines business companys primary con snda reyatazlabeling includes data indicating combination hiv sumer medicine brands us canada excedrin keri choiceand treatments containing reyatazritonavir kaletra lopinavirritonavir abbott comtrex year ended december sales consumer medicines laboratories inc similar primary efficacy outcome measurement brands us canada totaled approximately million timeaveraged difference change baseline hiv rna level hiv companys consumer medicines businesses japan asia pacific latin infected patients previously taking antihiv medicines america europe middle east africa included divestiture june company otsuka announced european december company provided update rolling commission granted marketing authorization abilify antipsychotic med bla abatacept submitted provisions fdas continuous ication treatment schizophrenia otsuka pharmaceutical europe ltd marketing application pilot abatacept investigational biologic drug otsukas european holding company holds marketing authorization treatment rheumatoid arthritis development program granted abilify europe company otsuka currently copromote abilify fast track status fda complete nonclinical clinical sections united kingdom germany also copromote france spain bla already submitted fda remaining section addition company also exclusive right sell abilify number expected submitted early year countries europe us fda approved abilify treat december company somerset pharmaceuticals inc ment acute bipolar mania september december somerset joint venture mylan laboratories inc watson company otsuka received approval fda oral solution pharmaceuticals inc entered agreement commercialization mulation abilify oral solution became available us pharmacies distribution somersets emsam selegiline transdermal system investiga february tional monoamine oxidase inhibitor administered transdermal patch may company entered worldwide codevelopment acute maintenance treatment patients major depressive disorder cocommercialization agreement solvay pharmaceuticals solvay code somerset received approvable letter fda emsam february velop copromote investigational compound slv currently approved fda emsam would first transdermal treat phase development potential use treating obesity ment major depressive disorder metabolic disorders company may also elect develop market two december company corgentech inc announced topline additional investigational compounds selected solvays pool eligible results first two phase clinical trials edifoligide ef decoy compounds company paid solvay upfront milestone payment trial involving patients undergoing peripheral artery vein grafts primary million july expensed research development secondary endpoints failed show benefit edifoligidetreated group milestone payments expected made upon successful compared placebo group defined rate vein graft failure outcome certain development regulatory stages months following surgery edifoligide investigational product pre april company entered collaboration agreement vent vein graft failure coronary peripheral arteries merck worldwide codevelopment copromotion muraglitazar december company gilead sciences inc gilead entered companys dual ppar peroxisome proliferator activated receptor agonist cur joint venture develop commercialize fixeddose combination rently phase iii clinical development use treating type diabetes companys sustivaand gileads truvada emtricitabine tenofovir nda muraglitazar submitted fda december us reg disoproxil fumarate united states approved new product would ulatory approval terms agreement company received first complete highly active antiretroviral therapy haart treatment million upfront payment may received additional regimen hiv available fixeddose combination taken daily million milestone payment january filing nda november company medarex inc medarex entered company entitled receive million additional payments upon worldwide collaboration develop commercialize mdx fully human achievement certain regulatory milestones company merck antibody investigational product targeting ctla receptor mdx jointly develop clinical marketing strategy muraglitazar share developed medarex currently phase iii clinical development equally future development commercialization costs copromote treatment metastatic melanoma collaboration agreement became effec product physicians global basis merck receive payments tive january time company made cash payment based net sales levels million medarex expensed research development april company pierre fabre mdicament sa pierre additional million equity investment medarex fabre entered agreement develop commercialize javlor september company completed submission nda vinflunine novel investigational anticancer agent javlor currently fda baraclude investigational antiviral agent development phase iii clinical trials europe treatment bladder nonsmall treatment chronic hepatitis b addition fda granted company cell lung cancer phase ii clinical trials breast ovarian cancer priority review baraclude company also submitted marketing terms agreement company received exclusive license bristolmyers squibb company annual reportjavlor united states canada japan korea select southeast asian repatriated united states company determines earnings markets pierre fabre responsible development marketing remitted foreseeable future additional tax provisions would javlor countries including europe agreement required due complexities tax laws assumptions would company made expensed upfront milestone payments million made practicable estimate amounts income taxes potential additional million milestone payments would provided time ajca president bush signed law october pro april company announced completion acquisition vides temporary percent dividendsreceived deduction certain cash acordis million acordis privately held company based uk distributions earnings foreign subsidiaries deduction would result licenses patent rights supplies materials convatec wound federal tax rate approximately repatriated earnings assum therapeutics line acquired business incorporated part ing marginal federal tax rate earnings qualify companys convatec division acquisition enable convatec deduction repatriated earnings must reinvested united states pur strengthen position field wound care management continue suant domestic reinvestment plan approved companys chief execu provide new treatment options patients acute chronic wound care tive officer subsequently board directors january needs see note acquisitions divestitures department treasury issued guidelines permitted investments march company announced medical imaging business plan company expects meet requirements criteria qualify entered agreement kereos inc kereos development deduction however several provisions ajca require clarifica commercialization novel molecular imaging agents terms tion may addressed coming months treasury congress agreement companies work together develop molecular imaging companys estimate tax cost related repatriation december agents cardiovascular diseases cancer using kereos core technology based tax laws effect extent tax laws medical imaging obtained exclusive worldwide rights develop com guidance changes estimate revised companys estimate may mercialize select cardiovascular molecular imaging agents magnetic reso also revised result changes companys factual assump nance imaging mri kereos obtained exclusive worldwide rights use tions may occur family medical imaging targeting molecules kereos core technology cash cash equivalents december primarily consisted us develop commercialize molecular cancer imaging agents targeted dollar denominated bank deposits original maturity three months therapeutics including ki kereos lead candidate early mri detection less marketable securities december primarily consisted us tumors dollar denominated floating rate instruments aaaaaa credit rating february fda approved bla erbitux anticancer due nature instruments company considers reasonable agent company developing partnership imclone erbitux expect fair market values significantly impacted injection use combination irinotecan treatment patients change interest rates liquidated cash short notice egfrexpressing metastatic colorectal cancer refractory average interest yield cash cash equivalents irinotecanbased chemotherapy use single agent treatment december respectively interest yields marketable patients egfrexpressing metastatic colorectal cancer intoler securities averaged respectively ant irinotecanbased chemotherapy accordance agreement longterm debt december denominated primarily us company paid imclone million march milestone payment dollars also included japanese yen debt million longterm debt approval erbitux fda fda also approved imclones remained constant billion december majority chemistry manufacturing controls supplemental bla licensure companys debt fixed rate company however entered bb manufacturing facility erbitux june fixed floating interest rate swaps billion longterm debt interest expense net interest swap gains million million financial position liquidity capital resources million respectively increase interest expense cash cash equivalents marketable securities totaled approximately primarily due increased shortterm borrowings billion december compared billion december higher interest rates decrease driven company continues maintain high level working capital net gains interest rate swaps us commercial paper outstanding billion december increasing billion december billion average interest rate december company expects cash generated us us commercial paper outstanding december operations together borrowings capital markets sufficiently average interest rate years ended december cover cash needs working capital capital expenditures milestone payments international shortterm borrowings respectively dividends paid united states cash cash equivalents marketable current installments longterm debt respectively securities conversion workingcapital items borrowings december company replaced prior billion revolving credit expected fund nearterm operations facilities new billion fiveyear revolving credit facility syndicate december company approximately billion lenders extendable anniversary date consent undistributed earnings foreign subsidiaries company accrued provi lenders availability facility subject companys ability sion million estimated deferred taxes fourth quarter time borrowing meet certain conditions including financial covenant expected paid anticipation repatriating approxi net debt capital exceed facility contain mately billion undistributed earnings pursuant ajca material adverse change representation companys business condition taxes provided balance undistributed earnings approxi borrowing december company ratio consoli mately billion company invested expects invest dated net debt consolidated capital compliance undistributed earnings permanently offshore future earnings covenant since inception facility changes public credit ratings affect availability credit facility borrowings bristolmyers squibb company annual reportstanding revolving credit facilities december proceeds received issuance convertible debt company also unused shortterm lines credit foreign banks cash provided operations borrowings primarily used million million december respectively past three years pay dividends billion company also april moodys investors service moodys lowered companys invested billion past three years capital expansion improve longterm credit rating aa march affirmed prime plant efficiency maintain superior research facilities shortterm credit rating company july standard poors sp company repurchase common lowered longterm credit rating company aa aa affirmed stock company repurchased million shares common stock cost shortterm rating march sp placed longterm short million bringing total shares acquired since share term ratings company watch negative implications august repurchase programs inception million shares share repurchase sp downgraded shortterm credit rating company program authorizes company purchase common stock time time longterm credit rating company moodys sps long open market private transactions market conditions permit term credit rating remains negative outlook program intended reduce increase shares outstanding following discussion working capital cash flow activities option exercises obtain shares general corporate purposes dividends declared per common share dollars millions december company declared quarterly dividend working capital per common share indicated dividend full year cash flow per share dividend decisions made quarterly basis board operating activities directors investing activities companys financial condition liquidity could affected obliga financing activities tions make milestone onetime payments outcome pending litigation investigations including challenge plavix increase working capital million primarily due patent information see note alliances investments increased receivables resulting higher sales higher foreign note legal proceedings contingencies holding taxes expected refunded higher inventories resulting new product introductions higher demand existing key brands partially offset higher accounts payable due higher purchasing activities contractual obligations higher accrued expenses rebates returns mainly due increases payments due period companys contractual obligations royalties higher unrealized losses derivatives medicaid rebates december follows obligations expiring period net cash provided operating activities billion bil later dollars millions total years lion billion decrease net cash provided operating activities mainly attributable lower earnings shortterm higher usage working capital significant changes operating borrowings longterm debt assets liabilities million increase operating leases inventory primarily due introduction new products including purchase obligations reyatazand erbitux higher demand key brands including plavix standby letters avaproavalide sustiva million decrease deferred revenue credit consigned inventory due workdown consignment inventory liabilities million decrease accounts payable accrued total expenses including advertising promotion deferred revenue abilify longterm debt obligations included shortterm borrowings companys milestone payments increase primarily due consolidated balance sheet december balances represent income tax payments related gain arising sale standing nominal longterm debt values contractual obligations table excludes clairol business increase earnings higher rate decrease deferred interest payment obligations revenue consigned inventory due workdown consignment addition company committed make potential inventory higher accounts payable accrued expenses partially offset future milestone payments thirdparties part inlicensing develop reduction accounts receivable increased litigation settlement payments ment programs payments agreements generally become due payable upon achievement certain developmental regulatory andor net cash used investing activities billion compared commercial milestones achievement milestones nei billion billion decrease net cash used ther probable reasonably estimable contingencies investing activities mainly attributable million cash proceeds recorded companys consolidated balance sheet sale companys adult nutritionals business lower purchases discussion contractual obligations reference made note marketable securities million lower capital spending partially shortterm borrowings longterm debt note financial instruments offset milestone payment million imclone million pay note leases note pension postretirement benefit plans ment acordis acquisition increased purchases trademarks patents licenses restatement previously issued financial statements previously disclosed company experienced substantial buildup net cash used financing activities billion billion wholesaler inventories us pharmaceuticals business decrease mainly attribut buildup primarily due sales incentives offered company able increase shortterm borrowings partially offset wholesalers incentives generally offered toward end bristolmyers squibb company annual reportquarter order incentivize wholesalers purchase products amount sec consent order sufficient meet companys quarterly sales projections established previously disclosed august company entered final companys senior management april company disclosed settlement sec concluding investigation concerning certain whole substantial buildup developed subsequently undertook plan work saler inventory accounting matters settlement reached orderly fashion wholesaler inventory levels reducing consent copy attached exhibit companys quar amount sales made company wholesalers relative amount terly report form q period ended september sales made wholesalers customers thereby reducing inventories consent company agreed without admitting denying liability companys products held wholesalers violate certain provisions securities laws company also agreed october based review consideration previously establish million fund class shareholders distributed disclosed buildup wholesaler inventories companys us pharmaceu courts supervision million fund included million ticals business incentives offered certain wholesalers advice civil penalty distributed certain company shareholders plan pricewaterhousecoopers llp pwc independent registered public distribution established sec accounting firm company determined required restate terms consent company agreed subject certain sales earnings correct errors timing revenue recognition certain defined exceptions limit sales products sold direct customers sales made two largest wholesalers us pharmaceuticals busi including wholesalers distributors hospitals retail outlets pharmacies ness company determined sales accounted government purchasers based expected demand amounts consignment model based part relationship exceed approximately one month inventory hand without making amount nature incentives offered wholesalers amount timely public disclosure change practice company estab inventory held wholesalers lished companywide policy limit sales direct customers purpose following determination company also determined would complying consent policy includes adoption various pro correct historical accounting policies conform accounting us cedures monitor limit sales direct customers accordance generally accepted accounting principles gaap known errors made terms consent procedures include governance process escalate application gaap previously recorded appropriate management levels potential questions concerns regarding case company believed amount error material compliance policy timely resolution questions concerns companys consolidated financial statements addition part restate addition compliance policy monitored regular basis ment process company investigated accounting practices areas company maintains inventory management agreements imas involved significant judgment determined restate additional items us pharmaceutical wholesalers account nearly respect company concluded errors made application total gross sales us pharmaceuticals products current terms gaap including revisions inappropriate accounting imas wholesalers provide company information march company completed restatement financial state inventory levels product hand amount outmovement prod ments items restated financial statements three years ucts information received wholesalers product ended december restatement recordkeeping process excludes inventory held intermediaries completing restatement company continued identify sell retailers hospitals company determines implement actions improve effectiveness disclosure controls movement product period onemonth using recent procedures internal controls financial reporting connection prior four weeks outmovement product provided whole effort company substantially strengthened organization salers company also determines months hand estimates us personnel senior financial control functions ii adopted pharmaceuticals business using factors historical sales made rigorous policies procedures respect balance sheet review wholesalers thirdparty market research data related prescrip process iii focused internal audit function financial reporting controls tion trends patient demand iv engaged consultant assist evaluation documentation cer contrast companys pharmaceuticals business outside tain financial reporting disclosure processes throughout company united states nutritionals healthcare business units around particular respect designing standard operating procedures imple world company significantly direct customers limited information menting tools ensure disclosure issues effectively identified man direct customer product level inventory corresponding outmovement aged controlled globally v engaged consultant assist information reliability thirdparty demand information avail companys personnel conduct comprehensive detailed review cer able varies widely accordingly company relies variety methods tain companys tax reporting accounting particular respect estimate direct customer product level inventory calculate months developing effective processes establishing monitoring deferred hand business units company expects complete analysis income taxes valuation allowances companys annual effective tax direct customer inventory levels businesses first quarter rate addition request companys audit committee inde provide additional disclosure information respect direct cus pendent registered public accounting firm performed extensive proce tomer inventory levels company continue enhance meth dures respect companys interim financial information ods estimate direct customer product level inventory months hand based auditors assessment companys risk profile business units taking account complexities described expanded scope amount fieldwork performed certain areas company continue disclose key pharmaceutical connection audit company actions contributed products sold us pharmaceutical business amount net sales significantly company identifying additional errors relating prior peri ods reflected restatement march company cor rected errors restating financial statements two years ended december bristolmyers squibb company annual reportand estimated number months hand us wholesaler distribu december fasb issued final staff position fsp tion channel end immediately preceding quarter application sfas accounting income taxes tax end applicable quarter quarterly annual reports forms q deduction qualified production activities provided american jobs k business units company expects disclose creation act effect adoption fsp mate quarterly basis key product level inventories information required rial companys consolidated financial statements see note estimate months hand direct customer distribution nonus accounting policiesincome taxes pharmaceuticals business available prior time company december fasb issued fas exchanges nonmonetary required file quarterly reports form q accordingly company assets provisions statement effective nonmonetary asset expects disclose information website approximately days exchanges occurring fiscal periods beginning june provi end quarter addition foregoing quarterly disclosure sions statement applied prospectively eliminates company include foregoing information business units exception fair value measurement nonmonetary exchanges similar quarter annual report productive assets paragraph b apb opinion accounting company believes abovedescribed procedures provide reason nonmonetary transactions replaces exception exchanges able basis ensure compliance consent order provides sufficient commercial substance adoption accounting pro information comply disclosure requirements nouncement expected material effect consolidated finan company agreed consent certain measures cial statements implemented implement including establishing formal review november fasb issued sfas inventory costsan certification process annual quarterly reports filed sec amendment arb chapter standard requires abnormal b establishing business risk disclosure group c retaining outside amounts idle facility related expenses recognized current period consultant comprehensively study help reengineer companys charges also requires allocation fixed production overheads accounting financial reporting processes publicly disclosing sales costs conversion based normal capacity production facilities incentives offered direct customers purpose inducing sfas effective inventory costs incurred fiscal years begin purchase products excess expected demand e ensuring ning june company evaluating impact state companys budget process gives appropriate weight inputs come ment financial position results operations bottom top come top bottom june fasb issued fsp accounting disclosure adequately documenting process requirements related medicare prescription drug improvement company also agreed consent retain independent adviser modernization act medicare act medicare act introduces date companys year ended filed prescription drug benefit medicare well federal subsidy spon sec consent defines certain powers responsibilities sors retiree health care benefit plans provide benefit least independent adviser consent includes process independent adviser actuarially equivalent medicare part fsp requires effects make recommendations regarding companys compliance applicable new law accounted sfas employers accounting federal securities laws corporate obligations company agreed postretirement benefits pensions company adopted fsp consent adopt independent advisers recommendations regarding compli third quarter retroactive january ance applicable federal securities laws corporate obligations reduction net periodic benefit cost benefits million settlement resolve ongoing investigation sec based remeasurement accumulated postretirement benefit obli activities certain current former members companys manage gation january effect adoption fsp ment connection wholesaler inventory issues accounting material companys consolidated financial statements see note matters investigation ongoing addition investigation us pension postretirement benefit plans attorneys office district new jersey concerning inventory march emerging issues task force eitf reached consensus accounting matters covered companys settlement sec con issue participating securities twoclass method tinuing company continuing cooperate investigations fas requires use twoclass method computing earn ings per share enterprises participating securities multiple recently issued accounting standards classes common stock consensus effective fiscal periods begin december financial accounting standards board fasb ning march adoption eitf affect issued revised sfas sfas rsharebased payment companys consolidated financial statements standard eliminates ability account sharebased compensation trans december fasb revised interpretation consolidation actions using intrinsic valuebased method accounting principles variable interest entitiesfin fin requires variable interest entity board opinion apb accounting stock issued employees consolidated company company subject majority risk requires instead transactions accounted using fairvalue loss variable interest entitys activities entitled receive majority based method sfas r effective financial statements issued entitys residual returns fin also requires disclosures vari first interim period beginning june currently company able interest entities company required consolidate discloses pro forma net income related pro forma income per share significant variable interest consolidation requirements fin information accordance sfas accounting stockbased revised apply immediately variable interest entities created january compensation sfas accounting stockbased compensation existing entities first fiscal year interim period ending costs transition disclosure company evaluating impact march certain disclosure requirements apply finan statement could material impact results operations cial statements issued january regardless variable interest entity established accounting pronouncement material effect consolidated financial statements bristolmyers squibb company annual reportcritical accounting policies discussions revenue recognition see note accounting policies company prepares financial statements conformity account revenue recognition sales rebate return accruals note ing principles generally accepted united states preparation finan consignment cial statements conformity gaap requires use estimates assumptions affect reported amounts assets liabilities including grosstonet sales adjustments disclosure contingent assets contingent liabilities date company following significant categories grosstonet sales financial statements reported amounts revenue expenses adjustments impact companys three reportable segments prime reporting period companys critical accounting policies vendor chargebacks wic rebates managed health care rebates important companys financial condition results contract discounts medicaid rebates cash discounts sales returns operations require difficult subjective complex judgments adjustments involve significant estimates judgments part management application often result need require company use information external sources company make estimates effect matters inherently uncertain accounts grosstonet sales adjustments accordance eitf uncertainty factors surrounding estimates judgments issue accounting consideration given vendor customer used preparation consolidated financial statements actual results including reseller vendors products sfas revenue may vary estimates recognition right return exists sfas applicable see net company believes following discussion represents critical sales section reconciliations companys gross sales net sales accounting policies management companys independent registered significant category grosstonet sales adjustments public accounting firm discussed companys critical accounting poli cies audit committee board directors prime vendor chargebacks companys us businesses participate prime vendor programs revenue recognition government entities significant us department company recognizes revenue accordance sab defense us department veterans affairs parties revenue recognition financial statements amended sab whereby pricing products extended wholesaler list price par revenue recognition companys accounting policy revenue recogni ticipating entities entities purchase products wholesalers tion substantial impact reported results relies certain esti lower prime vendor price wholesalers charge difference mates require difficult subjective complex judgments part acquisition cost lower prime vendor price back management company recognizes revenue sales substantially company company accounts prime vendor chargebacks reduc risks rewards ownership transferred customer ing accounts receivable amount equal companys estimate generally occurs date shipment exceptions described chargeback claims attributable sale company determines esti previous years certain transactions companys us mate prime vendor chargebacks primarily based historical experi pharmaceuticals wholesalers accounted using consignment ence regarding prime vendor chargebacks current contract prices model case sales made wholesalers result incentives prime vendor programs company considers prime vendor excess wholesalers ordinary course business inventory level payments levels inventory distribution channel companys time understanding agreement course dealing con claim processing time lag adjusts reduction accounts receivable sistent business practice company would extend incentives based periodically throughout quarter reflect actual experience levels excess inventory connection future purchases time incentives would cover substantially vary directly wic rebates wholesalers cost carrying inventory excess wholesalers ordinary companys us nutritionals business participates competitive bid course business inventory level substantially risks rewards ding basis nutrition programs sponsored states tribal governments ership transfer upon shipment accordingly sales commonwealth puerto rico territory guam women infants accounted using consignment model determination children wic programs company reimburses sales wholesaler meet foregoing criteria involves evaluation vari entities difference wholesaler list price contract price ety factors number complex judgments consignment eligible products company accounts wic rebates establishing model company recognize revenue upon shipment product accrual amount equal companys estimate wic rebate rather upon shipment product company invoiced wholesaler claims attributable sale company determines estimate recorded deferred revenue gross invoice sales price classified inven wic rebate accrual primarily based historical experience regarding wic tory held wholesalers consignment inventory companys cost rebates current contract prices wic programs company inventory company recognized revenue net gross net considers levels inventory distribution channel new wic contracts sales adjustments discussed involve significant estimates terminated wic contracts changes existing wic contracts wic par judgments consignment inventory longer subject ticipations adjusts accrual periodically throughout quarter incentive arrangements described later inven reflect actual experience tory sold wholesalers customers fifo basis case new products product introduction managed health care rebates contract discounts extension existing line product company determines company offers rebates discounts managed health care organi products similar therapeutic category company zations us globally contract counterparties hos reliably estimate expected returns new product company pitals group purchasing organizations company accounts defers recognition revenue right return longer exists managed health care rebates contract discounts establishing company developed sufficient historical experience estimate sales returns accrual amount equal companys estimate managed health bristolmyers squibb company annual reportcare rebates contract discounts attributable sale adjusts sales return accrual taking account historical experience company determines estimate managed health care rebates companys returned goods policy shelf life companys prod contract discounts accrual primarily based historical experience ucts ranges average approximately months situ regarding rebates discounts current contract prices ations company aware products distribution channel company considers sales performance products subject managed nearing expiration date company analyzes situation health care rebates contract discounts levels inventory analysis indicates sales returns larger expected distribution channel adjusts accrual periodically throughout company adjusts sales return accrual taking account historical quarter reflect actual experience experience companys returned goods policy levels inventory distribution channel medicaid rebates event product recall product discontinuance company companys us businesses participate state governmentmanaged considers reasons impact actions adjusts sales medicaid programs well certain qualifying federal state return accrual appropriate taking account historical experience lev government programs whereby discounts rebates provided partic els inventory distribution channel product discontinuances ipating state local government entities discounts rebates provided estimates continuing demand latter programs included companys medicaid although company considers price changes competitive products rebate accrual considered medicaid rebates purposes introductions generic products introductions competitive new discussion company accounts medicaid rebates establishing products company generally believe factors impact accrual amount equal companys estimate medicaid rebate sales returns based historical experience companys returned claims attributable sale company determines estimate goods policy medicaid rebates accrual primarily based historical experience regarding returns new products significantly difficult company medicaid rebates well expansion prospective basis par assess company determines estimate sales return accrual pri ticipation nonmandatory aspects qualifying federal state marily based historical sales returns experience similar products government programs legal interpretations applicable laws related within line product within medicaid qualifying federal state government programs similar therapeutic category limited circumstances new prod new information regarding changes medicaid programs regulations uct extension existing line product company guidelines would impact amount rebates company historical experience products similar therapeutic category considers outstanding medicaid claims medicaid payments levels company reliably estimate expected returns new inventory distribution channel adjusts accrual periodically product company defers recognition revenue right return throughout quarter reflect actual experience longer exists company developed sufficient historical experience estimate sales returns company also considers shelf cash discounts life new products determines whether believes adjustment us certain countries company offers cash discounts sales return accrual appropriate shelf life connection new generally approximately sales price incentive prompt products tends shorter shelf life established products payment company accounts cash discounts reducing accounts company may still developing optimal manufacturing receivable full amount discounts company considers pay process new product would lengthen shelf life amount ment performance adjusts accrual reflect actual experience launch quantities may manufactured advance launch date ensure sufficient supply exists satisfy market demand sales returns cases company assesses reduced shelf life together levels company accounts sales returns accordance sfas inventory distribution channel projected demand determines establishing accrual amount equal companys estimate whether believes adjustment sales return accrual appropriate sales recorded related products expected returned provision sales returns million adjustments million million respectively respectively addition significant grosstonet sales adjustments described gross sales company makes grosstonet sales adjustments example returns established products company determines estimate company offers sales discounts significantly nonus businesses sales return accrual primarily based historical experience regarding also offers consumer coupons rebates significantly us sales returns also considers factors could impact sales returns nutritionals consumer medicines pharmaceuticals businesses addi factors include levels inventory distribution channel esti tion number countries outside us including major european coun mated shelf life product recalls product discontinuances price changes tries company provides rebates government entities company competitive products introductions generic products introductions generally accounts grosstonet adjustments establishing competitive new products company considers factors accrual amount equal companys estimate adjustments attribut adjusts accrual periodically throughout quarter reflect actual able sale company generally determines estimates accruals experience grosstonet sales adjustments primarily based historical experience company considers level inventory distribution channel performance commitments government entities relevant factors determines whether believes adjustment sales return accrual including levels inventory distribution channel cases adjusts appropriate example levels inventory distribution channel accruals periodically throughout quarter reflect actual experience increase company analyzes reasons increase rea sons indicate sales returns larger expected company bristolmyers squibb company annual reportuse information external sources company provides comprehensive medical group life benefits company uses information external sources estimate signifi substantially us retirees elect participate companys compre cant grosstonet sales adjustments companys estimates inventory hensive medical group life plans asset allocation postretire wholesalers deferred revenue consigned inventory based ment plans identical asset allocation described us projected prescription demandbased sales products historical inven defined benefit pension plans tory experience well companys analysis thirdparty information including written oral information obtained certain wholesalers accrual accounting significant assumptions respect inventory levels sellthrough customers thirdparty consistent requirements sfas employers accounting market research data companys internal information inventory pensionsthe company accounts pension benefits using accrual information received wholesalers product recordkeeping method recognizing pension expense payment benefits process excludes inventory held intermediaries sell retirees accrual method accounting pension benefits necessarily retailers hospitals company receives information ims requires actuarial assumptions concerning future events determine health supplier market research pharmaceutical industry amount timing benefit payments uses project prescription demandbased sales many us companys key assumptions used calculating cost pension ben pharmaceutical products company also uses information external efits discount rate rate compensation increase expected sources identify prescription trends patient demand average selling longterm rate return plan assets company consultation prices companys estimates subject inherent limitations estimates actuaries evaluates key actuarial assumptions assumptions used rely thirdparty information certain thirdparty information calculating cost pension benefits retirement turnover mor form estimates reflect limitations including lags tality rates based expectations actual experience appropriate date thirdparty information generated date determines assumptions december year calculate liabil company receives thirdparty information ity information date pension expense following year depending assumptions used pension expense could vary within retirement benefits range outcomes material effect reported earnings addition companys pension plans postretirement benefit plans assumptions materially affect accumulated benefit obligations accounted using actuarial valuations required sfas employers future cash funding actual results given year may differ esti accounting pensionsand sfas employers accounting mated economic factors postretirement benefits pensionsthe company considers assumed discount rate used company determining future accounting retirement plans critical management required pension obligations us plans based indices aarated corpo make significant subjective judgments number actuarial assump rate bonds indices high quality corporate bonds selected reflect tions including discount rates salary growth longterm return plan assets weightedaverage remaining period benefit payments assumed rate retirement turnover health care cost trend rates mortality rates depending compensation increase used company determining future pension assumptions estimates used pension postretirement bene obligations reflects estimate change actual future compensation lev fit expense could vary within range outcomes material effect els due general price levels productivity seniority factors reported earnings addition assumptions materially affect accumu net pension expense companys defined benefit pension lated benefit obligations future cash funding plans included earnings minority interest income taxes million compared million plan description us plans pension expense determined using company certain subsidiaries defined benefit pension assumed discount rate assumed rate compensation increase plans defined contribution plans regular fulltime employees princi present value benefit obligations december us pal defined benefit pension plan bristolmyers squibb retirement income plans determined using assumed discount rate plan principal defined contribution plan bristolmyers squibb salary increase rate assumed discount rate used determining us savings investment program plans pension expense reduced expense approximately total company defined benefit pension plan assets would increased approximately million assumed rate liabilities held us plans assets us plans held compensation increase used determining us plans pension expense single trust common asset allocation unless specified otherwise reduced expense would decreased references section total company plans ie us plans together approximately million assumed discount rate used determining international plans accumulated benefit obligation december reduced benefits companys defined benefit pension plans based pri accumulated benefit obligation would increased marily years credited service participants compensation assets million companys defined benefit plans consist primarily equity fixed us plans pension expense determined using income securities december fair market value plan assets expected longterm rate return plan assets expected longterm rate companys defined benefit plans increased million return plan assets used determining us plans pension expense million december us plans assets allocated reduced expense would increased equity securities compared end fixed million income securities compared end private equity investments compared end bristol myers squibb common stock represented less assets us plans end bristolmyers squibb company annual reportactual rates return earned us plan assets last ten years tions due changes assumed discount rate differences follows actual expected returns plan assets assumption changes year return year return sfas requires unrecognized net actuarial gain loss determined based marketrelated value plan assets differs fair market value calculated value recognizes changes fair value system atic rational manner five years amortized pension income expense year extent unrecognized net actuar ial loss gain exceeds greater projected benefit obligation marketrelated value plan assets beginning year net discussed gaap provides differences expected gains losses recognized pension income expense prospectively actual returns recognized average future service employees period approximates average remaining service period active december company lowered assumed discount rate employees expected receive benefits plans approximately years us plans maintained assumed rate compensa extent offset losses gains subsequent years tion increase compensation assumed increase scale december unrecognized net actuarial loss determined different rates different ages rate disclosed december based marketrelated value plan assets million single rate used age would produce amount exceeded greater projected benefit obligation present value benefit obligations reduction discount rate market related value plan assets million unless offset future effect increasing present value benefit obligations accordingly unrecognized gains higher discount rates higher expected returns effect increasing pension expense addition plan assets amortization unrecognized loss expected increase company revised based upon review experience assumption lump pension expense following ten years approximately mil sum utilization revision effect increasing present value lion per year amount reflected higher expense expected benefit obligations accordingly effect increasing pension december unrecognized net actuarial loss determined based expense marketrelated value plan assets million amount following many years strong performance global equity market fell exceeded greater projected benefit obligation market sharply eg sp declined cumulative related value plan assets million reversed eg sp rose cumulative event fair market value pension plan assets particular plan company reduced expected rate return us plan assets less accumulated benefit obligation plan yearend gaap revision effect increas may require additional minimum liability circumstances ing pension expense reduction stockholders equity establishment intangible asset company expects net pension expense defined benefit december fair market value companys defined benefit pension plans included earnings minority interest income taxes pension plan assets million related accumulated benefit approximately million higher million obligation million company recognized additional mini reflecting among things decrease assumed discount rate mum liability million cumulatively million december company used assumed discount rates expected offset million charge comprehensive income longterm rates return plan assets calculating cost pension bene included stockholders equity million reduction intangible fits cost postretirement benefits us plans except case asset december fair market value companys defined discount rates december rates benefit pension plan assets million related accumulated used pension benefits versus respectively benefit obligation million company recognized additional postretirement benefits reflect shorter duration minimum liability million cumulatively million december postretirement liabilities offset million charge comprehensive income us health care costs retiree population assumed increase included stockholders equity trend expected increase per year actual costs higher assumed likely put signifi plan funding cant upward pressure companys expense retiree health care companys funding policy defined benefit plans contribute december president bush signed law medicare amounts provide current service fund past service liability prescription drug improvement modernization act effects company contributed million million defined benefit medicare act reflected net periodic postretirement benefit cost plans respectively reduction million accumulated postretirement benefit obligation discussions retirement benefits see note pension december reduction million postretirement benefit plans delayed recognition actuarial gains losses acquired inprocess research development december unrecognized net actuarial losses fair value inprocess research development acquired busi companys defined benefit plans million million ness combination determined independent appraisal based pres respectively based fair market value plan assets unrecognized ent value research projects projected cash flows income approach net actuarial losses reflect large part steady reduction weighted utilized consistent guidance practice aid issued average discount rate years american institute certified public accountants entitled assets acquired sfas provides delayed recognition actuarial gains losses business combination used research development activities including amounts arising changes estimated plan benefit obliga focus software electronic devices pharmaceutical industries future bristolmyers squibb company annual reportcash flows predominately based net income forecast project discussions equity investments see note accounting policies consistent historical pricing margins expense levels similar prod investments note alliances investments ucts revenues estimated based relevant market size growth factors expected industry trends individual project life cycles life restructuring research projects underlying patent determining fair value downsize streamline operations rationalize manufacturing facili research project expected revenues first adjusted technical risk com ties company periodically recorded restructuring charges result pletion resulting cash flows discounted rate approximating company made estimates judgments regarding future plans companys weighted average cost capital including future termination benefits exit costs incurred discussions acquired inprocess research development see restructuring actions take place actual results could vary esti note accounting policies acquired inprocess research development mates resulting adjustment earnings discussions restructuring see note accounting policies impairment longlived assets restructuring note restructuring items accordance sfas accounting impairment disposal longlived assets company periodically evaluates whether current facts contingencies circumstances indicate carrying value depreciable longlived normal course business company subject contingencies assets held used may recoverable circumstances legal proceedings claims arising business cover determined exist estimate undiscounted future cash flows produced wide range matters including government investigations shareholder law longlived asset appropriate grouping assets compared suits product environmental liability accordance sfas carrying value determine whether impairment exists asset deter accounting contingenciesthe company records accruals contin mined impaired loss measured based difference gencies probable liability incurred amount assets fair value carrying value estimate assets fair value loss reasonably estimated based quoted market prices active markets available quoted mar discussions contingencies see note accounting policies ket prices available estimate fair value based various valua income taxes contingencies note income taxes note legal tion techniques including discounted value estimated future cash flows proceedings contingencies company reports asset disposed lower carrying value estimated net realizable value income taxes goodwill evaluated least annually impairment accordance december company approximately billion sfas goodwill intangible assetssfas requires undistributed earnings foreign subsidiaries company accrued provi goodwill tested impairment using twostep process first step sion million estimated deferred taxes fourth quarter identify potential impairment second step measures amount anticipation repatriating approximately billion earnings impairment loss goodwill deemed impaired carrying pursuant ajca taxes provided balance undistributed amount reporting units goodwill exceeds estimated fair value sfas earnings approximately billion company invested expects requires indefinitelived intangible assets tested impairment invest undistributed earnings permanently offshore future using onestep process consists comparison fair value earnings repatriated united states company deter carrying value intangible asset intangible assets deemed mines earnings remitted foreseeable future additional tax impaired net book value exceeds estimated fair value provisions would required due complexities tax laws estimates future cash flows based reasonable supportable assumptions would made practicable estimate assumptions projections require managements judgment changes amounts income taxes would provided key assumptions companys businesses prospects company evaluates need deferred tax asset valuation changes market conditions could result impairment charge allowance assessing whether likely realize discussions impairment longlived assets see note accounting deferred tax assets future assessment whether valuation policies impairment longlived assets goodwill allowance required often requires significant judgment including forecast intangible assets future taxable income evaluation tax planning initiatives adjustments deferred tax valuation allowances made earnings equity investments period assessments made december company reviews equity investments impairment based company net deferred tax assets million net valuation determination whether decline market value investment allowance million companys carrying value temporary making determi addition company conducts business various countries throughout nation company considers apb opinion equity method world subject tax numerous jurisdictions result busi accounting investments common stockand related interpretations ness activities company files significant number tax returns set forth factors evaluated determining whether loss value subject audit various tax authorities tax audits often complex tax recognized including companys ability hold investment authorities may disagree treatment items reported company market price market price fluctuations investments publicly may require several years resolve company recorded accruals traded shares inability investee sustain earnings capacity tax contingencies related potential audit exposures including lim would justify carrying amount investment companys ited transfer pricing certain tax credits various state foreign tax mat investment imclone subject accounting see note alliances ters accruals based managements judgment best estimate investments discussion companys investment ultimate outcome tax audits actual audit results could vary imclone estimates bristolmyers squibb company annual reportfor discussions income taxes see note accounting policiesincome composition matter patent plavix expires currently taxes note income taxes subject litigation united states similar proceedings involving plavix instituted outside united states company continues believe patent valid infringed alliance part outlook ner patentholder sanofi vigorously pursuing cases possi previously disclosed although anticipated sales declines due contin ble time reasonably assess outcome litigations ued exclusivity losses expected less adverse determination litigations timing potential offset growth sales companys inline recently launched poten generic competition plavix however generic competition occur tial new products period changes product mix adversely company believes unlikely occur second half impact gross margins products lost expected company subsidiaries subject number significant lose exclusivity generally higher margins addition earnings pending lawsuits claims proceedings investigations possible adversely affected companys investments support introduction time reasonably assess final outcome investigations litiga new products development launch additional new compounds tions management continues believe previously disclosed based managements current estimates growth companys next years aggregate impact beyond current reserves inline recently launched products riskadjusted assessment legal matters affecting company reasonably likely material potential new product launches company expects earnings growth companys results operations cash flows may material resume company continue rationalize cost base line financial condition liquidity companys expectations next sev strategy increase sales marketing emphasis specialists eral years described reflect potential impact litigation high value primary care physicians companys results operations previously disclosed company experienced substantial revenue losses last years due expiration market exclusivity protection cautionary factors may affect future results certain products company expects substantial incremental rev annual report written oral statements company enue losses representing continuing declines makes time time contain certain forwardlooking statements within revenues products well declines revenues certain addi meaning section securities act section e tional products lose market exclusivity primarily securities exchange act identify forwardlooking state company estimates reductions net sales range billion ments fact use words expect anticipate esti billion levels products lost lose mate target may project guidance intend plan believe exclusivity protection specifically monoprilin united words terms similar meaning expression connection states canada europe glucophage xr glucovance united discussion future operating financial performance one also states cefzilin united states paraplatinin united states videx ec identify forwardlooking statements fact relate strictly united states taxolin europe pravacholin europe company historical current facts forwardlooking statements based cur also expects substantial incremental revenue losses rent expectations involve inherent risks uncertainties including factors representing continuing declines net sales products lost exclusivity could delay divert change could cause actual protection additional declines attributable prod comes differ materially current expectations statements likely ucts lose exclusivity protection primarily prod relate among things companys goals plans projections ucts years lose exclusivity protection include regarding financial position results operations cash flows market posi glucophageglucovanceglucophage xr united states tion product development product approvals sales efforts expenses perform taxolin europe japan pravacholin united states ance results current anticipated products outcome europe paraplatinin united states monopril contingencies legal proceedings financial results based united states canada europe zeritin current expectations involve inherent risks uncertainties including united states europe cefzilin united internal external factors could delay divert change states europe videxvidex ec next several years timing amounts sales reductions exclusivity losses although possible predict identify factors may include realization particular periods eventual levels remaining sales rev limited following enues uncertain dependent levels sales time exclusivity new government laws regulations health care reform initia protection ends timing degree development generic competition tives united states state federal level countries speed approvals market entry impact factors ii changes fda foreign regulatory approval processes may pravachol hmg coa reductase inhibitor statin net sales bil cause delays approving preventing approval new products iii lion company experienced increased competition tax changes phasing tax benefits heretofore available pravacholfrom established brands new entrants us prescriptions united states certain foreign countries iv new laws regulations pravacholdeclined compared product judicial decisions affecting pricing marketing within across jurisdictions begun lose exclusivity markets anticipated loss v changes intellectual property law us exclusivity april expected rate decline sales mar ket share could accelerated increased competition established competitive factors new products developed competitors brands new entrants lower prices superior performance features otherwise companys expectations future sales growth include substantial competitive companys current products ii generic competition expected increases sales plavix net sales billion companys products mature patents expire products iii techno currently companys largest product ranked net sales logical advances patents attained competitors iv problems bristolmyers squibb company annual reportlicensors suppliers distributors v business combinations among changes product mix may affect margins companys competitors major customers changes companys structure operations revenues costs staffing difficulties delays inherent product development manufacturing efficiency resulting acquisitions divestitures mergers alliances restruc sale products may appear promising development fail turings strategic initiatives reach market approved additional indications number reasons including efficacy safety concerns inability obtain neces economic factors company control changes sary regulatory approvals difficulty excessive cost manufacture business economic conditions including limited changes ii failure products achieve maintain commercial viability interest rates fluctuation foreign currency exchange rates iii seizure recalls pharmaceutical products forced closings manu facturing plants iv failure obtain imposition limitations changes business political economic conditions due political use loss patent intellectual property rights v failure social instability military armed conflict nationalization assets debt company vendors suppliers comply current good payment moratoriums restrictions commerce actual threat manufacturing practices application regulations quality assur ened terrorist attacks united states parts world ance guidelines could lead temporary manufacturing shutdowns related military action product shortages delays product manufacturing vi man ufacturing distribution problems including changes manufacturing pro changes accounting standards promulgated fasb sec duction sites manufacturing capacity due regulatory requirements aicpa may require adjustments financial statements changes types products produced biologics physical limita tions could impact continuous supply capacity efficiency reliability security potential breakdown invasion destruction interruption information systems legal difficulties including lawsuits claims proceedings investigations preclude delay commercialization products reliance company vendors partners third parties adversely affect operations profitability liquidity financial condition meet contractual regulatory obligations relation including intellectual property disputes ii adverse decisions litigation arrangements company including product liability commercial cases iii inability obtain adequate insurance respect type liability iv recalls pharma results clinical studies relating companys competitors products ceutical products forced closings manufacturing plants v failure fulfill obligations supply contracts government although company believes prudent plans assump customers may result liability vi government investigations includ tions assurance given goal plan set forth forwardlook ing relating wholesaler inventory financial restatement product ing statements achieved readers cautioned place undue pricing promotion vii claims asserting violations securities antitrust reliance statements speak date made federal state pricing laws viii environmental health company undertakes obligation release publicly revisions forward safety matters ix tax liabilities assurance looking statements result new information future events otherwise increase scope matters future lawsuits claims proceedings investigations material quantitative qualitative disclosures market risk increasing pricing pressures worldwide including rules practices managed care groups institutional governmental purchasers judi company exposed market risk due changes currency cial decisions governmental laws regulations related medicare exchange rates interest rates reduce risk company enters medicaid health care reform potential impact importation legisla certain derivative financial instruments available costeffective basis tive otherwise pharmaceutical reimbursement pricing general hedge underlying economic exposure instruments managed consolidated basis efficiently net exposures thus take advantage fluctuations buying patterns inventory levels major distributors natural offsets derivative financial instruments used speculative retail chains trade buyers may result seasonality pric purposes gains losses hedging transactions offset gains ing wholesaler buying decisions including effect incentives offered losses underlying exposures hedged ineffective portion companys wholesaler inventory management policies including hedges reported earnings occurs workdown changes wholesaler inventory levels factors foreign exchange option contracts forward contracts used hedge anticipated transactions companys primary foreign currency exposures greater expected costs difficulties including unanticipated relation us dollar euro japanese yen canadian dollar effects difficulties acquisitions dispositions events includ mexican peso ing obtaining regulatory approvals connection evolving business table summarizes companys outstanding foreign exchange strategies legal defense costs insurance expense settlement costs contracts december fair value foreign exchange con risk adverse decision related litigation tracts based yearend currency rates blackscholes model case option contracts fair value option contracts forward con changes advertising promotional spending categories tracts viewed relation fair value underlying hedged spending may affect sales transactions overall reduction exposure adverse fluctuations foreign currency exchange rates bristolmyers squibb company annual reportas hedges marked market incomeexpense notional weighted fair value amount foreign exchange forward contracts december dollars millions average notional fair million million respectively except currency rates strike price amount value maturity company uses derivative instruments part interest rate risk man agement policy derivative instruments used include interest rate swaps foreign exchange forwards australian dollar subject fairvalue hedge accounting treatment british pound company executed several fixedtofloating interest rate swaps canadian dollar convert billion companys fixed rate debt paid euro variable rate debt year ended december polish zloty company recognized net reduction interest expense swedish krona million reflects benefit lower floating rate obtained swap swiss franc agreement sfas requires revaluation fair value swap others contracts well underlying debt hedged swap con option contracts tracts underlying debt revalued resulting increase japanese yen noncurrent assets million shortterm liabilities million long total contracts term debt million increase noncurrent assets longterm december company held option forward exchange debt million december respectively swap con contracts maturity dates notional amounts fair tracts generally held maturity used speculative purposes values maturity dates expressed table following table summarizes interest rate swaps outstanding december notional notional amount variable amount fair value underlying rate year maturity millions millions dollars millions debt received maturity fair value interest rate contracts swaps associated month us notes due libor swaps associated month us december company held option contracts aggre notes due libor gate notional amount fair value million million respectively options give company right buy japanese yen specified swaps associated month us rates company also held forward contracts aggregate notional notes due libor amount million fair value forward contracts mil lion recorded current liability contracts primarily related swaps associated month us exposures euro canadian dollar australian dollar company obli notes due libor gated settle forward contracts based specified contract rates swaps associated month us december balance deferred net aftertax losses option notes due libor forward contracts included accumulated comprehensive income million million estimated reclassified earnings swaps associated month us within next months notes due libor year ended december impact hedge ineffectiveness earnings loss million additionally company uses forward contracts offset exposure certain currency assets liabilities december company held interest rate swap contracts forward contracts designated hedges therefore changes notional value million fair value million fair value derivatives recognized earnings occur estimated change interest rate structure would december company recorded loss million related material impact companys consolidated financial position results ward exchange contracts qualify hedge accounting treatment operations cash flows december company held option forward exchange company million million longterm debt contracts aggregate notional amount fair value million standing december respectively see note short million respectively contracts primarily related exposures term borrowings longterm debt note financial instruments euro japanese yen canadian dollar australian dollar additional information addition foreign exchange hedge contracts noted company maintains cash cash equivalents marketable securities company also uses foreign exchange forward contracts hedge foreign currency various financial institutions order limit exposure one financial denominated monetary assets liabilities primary objective institution financial institutions headquartered primarily north eign exchange forward contracts protect us dollar value foreign america europe currency denominated monetary assets liabilities effects volatility foreign exchange might occur prior receipt settlement us dollars foreign currency denominated monetary assets liabilities primarily denominated japanese yen euro forward contracts designated bristolmyers squibb company annual reportconsolidated statement earnings year ended december dollars millions except per share data earnings net sales cost products sold marketing selling administrative advertising product promotion research development acquired inprocess research development provision restructuring items net litigation charges net gain sales businessesproduct lines asset impairment charge investment imclone equity net income affiliates expense net total expenses earnings continuing operations minority interest income taxes provision income taxes minority interest net taxes earnings continuing operations discontinued operations net earnings net gain disposal net earnings earnings per common share basic earnings continuing operations discontinued operations net earnings net gain disposal net earnings diluted earnings continuing operations discontinued operations net earnings net gain disposal net earnings average common shares outstanding basic diluted dividends declared per common share accompanying notes integral part financial statements bristolmyers squibb company annual reportconsolidated statement comprehensive income retained earnings dollars millions comprehensive income net earnings comprehensive income foreign currency translation net tax benefit deferred losses derivatives qualifying hedges net tax liability tax benefit minimum pension liability adjustment net tax benefit available sale securities net tax liability total comprehensive income comprehensive income retained earnings retained earnings january net earnings cash dividends declared zimmer common stock dividend retained earnings december accompanying notes integral part financial statements bristolmyers squibb company annual reportconsolidated balance sheet december dollars millions assets current assets cash cash equivalents marketable securities receivables net allowances inventories including consignment inventory deferred income taxes net valuation allowances prepaid expenses total current assets property plant equipment net goodwill intangible assets net deferred income taxes net valuation allowances assets total assets liabilities current liabilities shortterm borrowings accounts payable accrued expenses accrued rebates returns us foreign income taxes payable dividends payable accrued litigation liabilities deferred revenue consigned inventory total current liabilities liabilities longterm debt total liabilities commitments contingencies stockholders equity preferred stock convertible series authorized million shares issued outstanding liquidation value per share common stock par value per share authorized billion shares million issued million issued capital excess par value stock restricted stock accumulated comprehensive loss retained earnings less cost treasury stock million common shares million total stockholders equity total liabilities stockholders equity accompanying notes integral part financial statements bristolmyers squibb company annual reportconsolidated statement cash flows year ended december dollars millions cash flows operating activities net earnings adjustments reconcile net earnings net cash provided operating activities depreciation amortization deferred income tax benefitexpense litigation settlement expense provision restructuring items gain sales businessesproduct lines including discontinued operations acquired inprocess research development loss gain disposal property plant equipment investment companies undistributed earningslosses affiliates net unfunded pension expense impairment charges asset writeoffs changes operating assets liabilities receivables inventories prepaid expenses assets deferred revenue consigned inventory litigation settlement payments accounts payable accrued expenses product liability us foreign income taxes payable liabilities net cash provided operating activities cash flows investing activities purchases net sales maturities marketable securities additions property plant equipment capitalized software proceeds disposal property plant equipment investment companies proceeds sales businessesproduct lines imclone milestone payment purchase acordis specialty fibres purchases trademarks patents licenses businesses investments companies divestiture acquisition costs net cash used investing activities cash flows financing activities shortterm borrowings net repayments longterm debt borrowings longterm debt repayments issuances common stock stock plans purchases treasury stock dividends paid net cash used financing activities effect exchange rates cash increase decrease cash cash equivalents cash cash equivalents beginning year cash cash equivalents end year accompanying notes integral part financial statements bristolmyers squibb company annual reportnote accounting policies million december respectively basis consolidation rebate accruals established period related revenue consolidated financial statements include accounts bristolmyers recognized resulting reduction sales establishment liability squibb company bms company bristolmyers squibb included accrued liabilities accrual recorded based esti controlled majority owned subsidiaries intercompany balances transac mate proportion recorded revenue result rebate return tions eliminated certain prior year amounts reclassified prime vendor chargeback accruals established similar manner conform current year presentation recorded reduction accounts receivable million million december respectively use estimates preparation financial statements conformity us generally income taxes accepted accounting principles gaap requires use estimates provision income taxes determined using asset lia assumptions affect reported amounts assets liabilities dis bility approach accounting income taxes approach deferred closure contingent assets contingent liabilities date financial taxes represent future tax consequences expected occur statements reported amounts revenues expenses reported amounts assets liabilities recovered paid provision reporting period significant assumptions employed estimates income taxes represents income taxes paid payable current year used determining values intangible assets restructuring charges plus change deferred taxes year deferred taxes result accruals sales rebate return accruals legal contingencies tax assets differences financial tax bases companys assets tax liabilities well estimates used applying revenue recogni liabilities adjusted changes tax rates tax laws changes tion policy accounting retirement postretirement benefits including enacted valuation allowances recorded reduce deferred tax assets actuarial assumptions actual results could differ estimated results likely tax benefit realized december company approximately billion revenue recognition undistributed earnings foreign subsidiaries company accrued provi company recognizes revenue substantially risks sion million estimated deferred taxes fourth quarter rewards ownership transferred customer case certain anticipation repatriating approximately billion earnings sales made nutritionals healthcare segments certain pursuant american jobs creation act ajca taxes nonus businesses within pharmaceuticals segment revenue recognized provided balance undistributed earnings approximately billion date receipt purchaser revenues reduced time company invested expects invest undistributed earnings sale reflect expected returns estimated based historical experience permanently offshore future earnings repatriated additionally provisions made time sale discounts rebates united states company determines earnings remitted estimated sales allowances based historical experience updated foreseeable future additional tax provisions would required due com changes facts circumstances appropriate provisions plexities tax laws assumptions would made recorded reduction revenue practicable estimate amounts income taxes would case sales made wholesalers result incentives provided excess wholesalers ordinary course business inventory level ajca provides temporary percent dividends received deduction time understanding agreement course dealing con certain cash distributions earnings foreign subsidiaries deduc sistent business practice company would extend incentives based tion would result federal tax rate approximately repatriated levels excess inventory connection future purchases time earnings assuming marginal federal tax rate earnings incentives would cover substantially vary directly qualify deduction repatriated earnings must reinvested wholesalers cost carrying inventory excess wholesalers ordinary united states pursuant domestic reinvestment plan approved com course business inventory level substantially risks rewards panys chief executive officer board directors january ership transfer upon shipment accordingly sales department treasury issued guidelines permitted investments accounted using consignment model determination plan company expects meet requirements criteria qualify sales wholesaler meet foregoing criteria involves evaluation vari deduction however several provisions ajca require clarifica ety factors number complex judgments consignment tion may addressed coming months treasury model company recognize revenue upon shipment product congress companys estimate tax cost related repatriation rather upon shipment product company invoices wholesaler december based tax laws effect extent tax records deferred revenue gross invoice sales price classifies inven laws guidance changes estimate revised companys esti tory held wholesalers consignment inventory companys cost mate may also revised result changes companys factual inventory company recognizes revenue consignment assumptions may occur inventory longer subject incentive arrangements later guidance financial accounting standards board fasb inventory sold wholesalers customers firstin first staff position fsp application fasb statement fifo basis accounting income taxes tax deduction qualified production activities provided american jobs creation act deduction sales rebate return accruals treated special deduction described statement financial medicaid rebate accruals million million december accounting standards sfas special deduction respectively women infants children wic rebate affect deferred tax assets liabilities existing enactment date rather accruals million million respectively managed health impact deduction reported period deduc care rebate contractual discount accruals million tion claimed companys tax return bristolmyers squibb company annual reportthe company establishes liabilities possible assessments tax authori capitalized software ties resulting known tax exposures amounts represent reasonable certain costs obtain internal use software significant systems projects provision taxes ultimately expected paid may need adjusted capitalized amortized estimated useful life software time information becomes known ranges three ten years costs obtain software projects significant expensed incurred capitalized software net accu cash cash equivalents mulated amortization included assets million mil cash equivalents primarily highly liquid investments original maturi lion december respectively amortization expense ties three months less time purchase recorded cost million million million years ended december approximates fair value respectively marketable securities investments company accounts marketable securities accordance sfas january company adopted fasb interpretation fin accounting certain investments debt equity securities interpretation consolidation variable interest entities interpretation company determined appropriate classification marketable securities arb fin clarifies application accounting research bulletin availableforsale time purchase december arb consolidated financial statements certain entities companys investments marketable securities equity investors characteristics controlling financial interest reported fair value unrealized gains losses reported component sufficient equity risk entity finance activities accumulated comprehensive income loss stockholders equity additional subordinated financial support parties entities amortized cost debt securities adjusted amortization premiums known variable interest entities vies fasb issued revision fin accretion discounts date purchase maturity amortization fin r december fin r effective interim period included interest income addition deduction coupon ending march new existing vies adoption fin interest earned investments company follows investment man effect companys financial statements agers method determining cost basis computing realized gains entity meet definition vie fin company losses sale availableforsale securities average cost accounts entity provisions arb consolidated method realized gains losses included income expense financial statements amended sfas consolidation majorityowned subsidiarieswhich requires company consolidates inventory valuation majority owned subsidiaries ability exercise inventories generally stated average cost excess market control company accounts less owned companies ability exercise significant influence using equity method capital assets depreciation accounting companys share net income losses equity invest expenditures additions renewals improvements capitalized ments included equity net income affiliates consolidated state cost depreciation generally computed straightline method based ment earnings company periodically reviews equity investments estimated useful lives related assets estimated useful lives impairment adjusts investments fair value decline major classes depreciable assets years buildings years market value deemed temporary machinery equipment fixtures company periodically evaluates company recorded asset impairment charge million whether current events circumstances indicate carrying value thantemporary decline market value imclone systems incorporated depreciable assets may recoverable imclone longterm investments securities comprise marketable equity impairment longlived assets securities securities investments market values read effective january company adopted provisions sfas ily available included assets marketable equity securities classi accounting impairment longlived assetsthe adoption fied availableforsale reported fair value fair value based quoted sfas material effect consolidated financial state market prices end reporting period securities investments ments company sfas establishes accounting impair market values readily available carried cost unrealized ment longlived tangible intangible assets goodwill gains losses reported net related tax effects component disposal segment business pursuant sfas company accumulated comprehensive income loss stockholders equity periodically evaluates whether current facts circumstances indicate sold time sale gains losses calculated specific identi carrying value depreciable assets held used may fication method recognized incomeexpense losses also recoverable circumstances determined exist estimate recognized income decline market value deemed undiscounted future cash flows produced longlived asset appro temporary priate grouping assets compared carrying value determine whether impairment exists asset determined impaired loss goodwill intangible assets measured based difference assets fair value car company adopted sfas goodwill intangible assets rying value estimate assets fair value based quoted market january certain provisions adopted july prices active markets available quoted market prices available respect amortization goodwill arising acquisitions made june estimate fair value based various valuation techniques including sfas addresses initial recognition measurement discounted value estimated future cash flows company reports intangible assets acquired outside business combination recognition asset disposed lower carrying value estimated net measurement goodwill intangible assets subsequent realizable value bristolmyers squibb company annual reportacquisition sfas goodwill longer amortized subject tions changes fair value derivative recorded compre annual impairment tests hensive income loss subsequently recognized consolidated accordance sfas goodwill tested impairment upon statement earnings hedged item affects earnings cash flows adoption new standard annually thereafter sfas requires classified consistent underlying hedged item purchased foreign goodwill tested impairment using twostep process first step currency options entire change fair value included measurement identify potential impairment second step measures amount hedge effectiveness cash flow hedges ineffective portions changes impairment loss goodwill deemed impaired carrying fair value cash flow hedges recognized charge credit amount reporting units goodwill exceeds estimated fair value earnings company completed goodwill impairment assessment indicated company designates assigns derivatives hedges forecasted impairment goodwill transactions specific assets specific liabilities hedged assets liabili intangible assets consisting patents trademarks technology ties sold extinguished forecasted transactions hedged licenses amortized straightline basis useful lives ranging longer expected occur company immediately recognizes gain years sfas requires indefinitelived intangible assets loss designated hedging financial instruments consolidated state tested impairment using onestep process consists compari ment earnings son fair value carrying value intangible asset intangible assets deemed impaired net book value exceeds esti shipping handling costs mated fair value intangible assets evaluated impairment company typically charge customers shipping accordance sfas described impairment longlived handling costs shipping handling costs charged included assets marketing selling administrative expenses million million million respectively restructuring downsize streamline operations rationalize manufacturing facili advertising costs ties company periodically recorded restructuring charges result advertising costs expensed incurred advertising expense company made estimates judgments regarding future plans million million million respectively including future termination benefits exit costs approved incurred actual results could vary estimates resulting adjust milestone payments ment earnings company time time enter strategic alliances third parties give company rights develop manufacture market andor product liability sell pharmaceutical products rights owned third par accruals product liability recorded undiscounted basis ties result alliances company may obligated make pay probable liability incurred amount liability ments alliance partners contingent upon achievement certain reasonably estimated based existing information accruals predetermined criteria milestones achieved prior marketing approval adjusted periodically assessment efforts progress additional informa product payments expensed research development tion becomes available receivables related insurance thirdparty product approval additional milestones capitalized amortized recoveries product liabilities recorded undiscounted basis cost products sold remaining useful life asset capitalized probable recovery realized classified reduction liti milestone payments tested recoverability whenever events changes gation charges consolidated statement earnings circumstances indicate carrying amounts may recoverable contingencies acquired inprocess research development normal course business company subject contingencies fair value inprocess research development acquired busi legal proceedings claims arising business cover ness combination determined independent appraisal based wide range matters including among others product liability environmental present value research projects projected cash flows income liability tax matters accordance sfas accounting approach utilized consistent guidance practice aid assets contingencies company records accruals contingencies acquired business combinations used research development probable liability incurred amount loss reason activities focus software electronic devices pharmaceutical ably estimated discussion contingencies reference made note industries issued american institute certified public accountants income taxes note legal proceedings contingencies future cash flows predominately based net income forecast project consistent historical pricing margins expense levels similar derivative financial instruments products revenues estimated based relevant market size growth derivative financial instruments used company principally factors expected industry trends individual project life cycles life management interest rate foreign currency exposures company research projects underlying patent determining fair value hold issue derivative financial instruments speculative purposes research project expected revenues first adjusted technical risk com company records derivative instruments balance sheet fair pletion resulting cash flows discounted rate approximating value changes derivatives fair value recognized earnings unless companys weighted average cost capital acquired inprocess specific hedge criteria met derivative designated fair value research development expensed incurred underlying prod hedge changes fair value derivative hedged item uct received regulatory approval future alterna attributable hedged risk recognized consolidated statement tive use addition costs nonrefundable related acquisition earnings derivative designated cash flow hedge effective por licensing products yet received regulatory approval bristolmyers squibb company annual reportmarketed alternative future use charged earnings recently issued accounting standards incurred december fasb issued revised sfas sfas r sharebased paymentthis standard eliminates ability account share earnings per share based compensation transactions using intrinsic valuebased method basic earnings per common share computed using weightedaver apb opinion accounting stock issued employeesand age number shares outstanding year diluted earnings per com requires instead transactions accounted using fairvalue mon share computed using weightedaverage number shares based method sfas r effective financial statements issued outstanding year plus incremental shares outstanding assuming first interim period beginning june currently company exercise dilutive stock options restricted stock convertible instruments discloses pro forma net income related pro forma income per share information accordance sfas accounting stockbased foreign currency translation compensation sfas accounting stockbased compensation net assets companys foreign subsidiaries translated us costs transition disclosurethe company evaluating impact dollars using current exchange rates us dollar effects arise statement could material impact results operations translating net assets subsidiaries changing rates recorded december fasb issued fsp application sfas foreign currency translation adjustment account included accounting income taxesto tax deduction qualified comprehensive income production activities provided american jobs creation act effect adoption fsp material companys consol stock compensation plans idated financial statements see income taxes currently company applies accounting principles board apb opinion december fasb issued fas exchanges nonmonetary accounting stockissued employees related interpretations assets provisions statement effective nonmonetary asset accounting stockbased compensation plans discloses pro forma exchanges occurring fiscal periods beginning june provi net income related pro forma income per share information accordance sions statement applied prospectively eliminates sfas accounting stockbased compensationand sfas exception fair value measurement nonmonetary exchanges similar accounting stockbased compensation costs transition productive assets paragraph b apb opinion accounting disclosure company recognize compensation expense stock nonmonetary transactions replaces exception exchanges options granted plans exercise price option date commercial substance adoption accounting pro grant equal fair market value date grants restricted nouncement expected material effect consolidated finan stock company recognizes compensation expense straightline basis cial statements period restrictions expire november fasb issued sfas inventory costsan following table summarizes companys results pro forma basis amendment arb chapter standard requires abnormal recorded compensation expense based upon fair value amounts idle facility related expenses recognized current period grant date awards plans consistent methodology pre charges also requires allocation fixed production overheads scribed sfas costs conversion based normal capacity production facilities sfas effective inventory costs incurred fiscal years begin dollars millions except per share data ning june company evaluating impact state ment financial position results operations net earnings june fasb issued fsp accounting disclosure reported requirements related medicare prescription drug improvement total stockbased employee compensation modernization act medicare act medicare act introduces expense included reported net income prescription drug benefit medicare well federal subsidy spon net related tax effects sors retiree health care benefit plans provide benefit least total stockbased employee compensation actuarially equivalent medicare part fsp requires expense determined fair value based effects new law accounted sfas employers method awards net related accounting postretirement benefits pensionsthe company tax effects adopted fsp third quarter retroactive january pro forma reduction net periodic benefit cost benefits basic earnings per share million based remeasurement accumulated postre reported tirement benefit obligation january effect adoption pro forma fsp material companys consolidated financial state diluted earnings per share ments see note pension postretirement benefit plans reported march emerging issues task force eitf reached consensus pro forma issue participating securities twoclass method fas requires use twoclass method computing earn options related discontinued operations impact basic ings per share enterprises participating securities multiple diluted earnings per share see note stockholders equity additional classes common stock consensus effective fiscal periods begin information ning march adoption eitf affect companys consolidated financial statements bristolmyers squibb company annual reportin december fasb revised fin consolidation variable idated balance sheet million million december interest entities fin requires variable interest entity consolidated respectively company company subject majority risk loss vari able interest entitys activities entitled receive majority entitys resid otsuka ual returns fin also requires disclosures variable interest company worldwide commercialization agreement otsuka entities company required consolidate signif pharmaceutical co ltd otsuka codevelop copromote abilify arip icant variable interest consolidation requirements fin revised iprazole treatment schizophrenia related psychotic disorders apply immediately variable interest entities created january except japan china taiwan north korea south korea philippines existing entities first fiscal year interim period ending march thailand indonesia pakistan egypt company began copromoting certain disclosure requirements apply financial state product otsuka us puerto rico november june ments issued january regardless variable interest company received marketing approval european entity established accounting pronouncement material commission product currently copromoted otsuka united effect consolidated financial statements kingdom germany also copromoted france spain company records alliance revenue contractual share net sales note alliances investments copromotion countries excluding united kingdom records sanofiaventis expenses related product alliance revenue recorded company company agreements sanofiaventis sanofi codevel net sales based upon otsukas net sales copromotion coun opment cocommercialization avaproavalide angiotensin ii receptor tries company recognizes alliance revenue abilify shipped antagonist indicated treatment hypertension plavix platelet risks rewards ownership transferred otsukas customers inhibitor worldwide alliance operates framework two geo uk company records net sales related cost prod graphic territories one americas principally united states canada ucts sold puerto rico latin american countries australia company also exclusive right sell abilify number europe asia accordingly two territory partnerships formed manage countries europe americas asia countries sales com central expenses marketing research development royalties mence company record net sales related cost prod supply finished product individual countries general ucts sold terms agreement company purchases country level agreements either copromote whereby partnership product otsuka performs finish manufacturing sale formed parties sell brand comarket whereby company customers agreement expires november parties operate sell brands independently place us puerto rico countries european union agreements expire later respect plavix company exclusive right sell abilify agreement expires respect avaproavalide americas australia tenth anniversary first commercial sale country europe asia ii expiration patents exclusivity rights company exclusive right sell abilify agreement expires applicable territory later tenth anniversary first commercial sale country expi company acts operating partner territory covering ration applicable patent country americas australia owns majority controlling interest company recorded revenue abilify million mil territory sanofis ownership interest territory lion million total milestone payments made otsuka company consolidates country partnership results territory agreement december million records sanofis share results minority interest net taxes million expensed acquired inprocess research development million million million remaining million capitalized intangible assets company recorded sales territory comarketing countries amortized cost products sold remaining life agreement germany italy spain greece million million us ranging eight eleven years included million capi million talized payments million payment made july attainment sanofi acts operating partner territory covering europe marketing approval european union company amortized cost asia owns majority financial controlling interest territory products sold million million million companys ownership interest territory company unamortized capitalized payment balance million million accounts investment partnership entities territory december respectively equity method records share results equity net income affiliates consolidated statement earnings companys share net imclone income partnership entities taxes million company commercialization agreement expiring september million million imclone biopharmaceutical company focused developing tar company sanofi formed alliance copromotion geted cancer treatments codevelopment copromotion erbitux irbesartan part company contributed irbesartan distribu united states february us food drug administration tion rights united states sanofi paid company total fda approved biologics license application bla erbitux use million company accounted transaction sale combination irinotecan treatment patients epidermal growth interest license deferred amortized million factor receptor egfrexpressing metastatic colorectal cancer income expected useful life license approximately refractory irinotecanbased chemotherapy use single agent eleven years company recognized income million mil treatment patients egfrexpressing metastatic colorectal cancer lion million respectively unamortized intolerant irinotecanbased chemotherapy accordance portion deferred income recorded liabilities section consol terms agreement company paid imclone million bristolmyers squibb company annual report million paid march million paid march ment approximately sixteen years company recognized company paid million march milestone payment million payments income million milestone pay initial approval erbitux additional million payable upon fda ment deferred recorded receivable december approval use treating additional tumor type agreement amortized income beginning january remaining imclone receives distribution fee based flat rate product rev useful life agreement addition company records mercks share enues north america addition company also codevelopment codevelopment costs reduction research development expense copromotion rights canada japan extent product commer mercks share copromotion costs reduction advertising prod cialized countries uct promotion expense respect million milestone payments company paid imclone million expensed first quarter summary financial information acquired inprocess research development million following summarized financial information companys equity recorded additional equity investment eliminate income statement investments imclone joint venture sanofi europe asia effect portion milestone payment company economic claim ownership interest imclone company accounts million approval milestone paid march unaudited dollars millions license acquisition amortizes payment cost products sold expected useful life license approximately fourteen years revenues amortization expense million unamortized portion gross profit approval payment recorded intangibles net mil net income lion december current assets company accounts investment imclone equity noncurrent assets method records share results equity net income affiliates current liabilities consolidated statement earnings company recorded pre noncurrent liabilities tax charge million temporary decline market value imclone based decline value imclones share note restructuring items companys recorded investment imclone common stock activities december million million respectively company recorded pretax restructuring charges representing approximately imclone shares outstanding million relating downsizing streamlining worldwide operations respectively per share basis carrying value imclone investment rationalization worldwide manufacturing operations charge closing market price imclone shares december million relates primarily employee termination benefits approxi respectively compared respec mately employees including manufacturing administrative sales tively december personnel europe north america asia latin america exit costs company determines equity share imclones net income loss million relate primarily lease termination costs items mil eliminating imclones results milestone revenue imclone recognizes lion relate primarily relocation expenses result consolidation preapproval milestone payments recorded company research facilities charges partially offset adjustment due additional equity investment share imclones results operations changes estimates prior period reserves million principally company recorded net income million net losses mil due reduced separation costs also million gain sale lion million respectively company recorded research facility previously written restructuring company expects net sales erbitux million complete restructuring activities following table presents detail provision restructuring merck items operating segment type company allocate restruc april company entered collaboration agreement turing charges business segments merck co inc merck worldwide codevelopment copromotion muraglitazar companys dual ppar peroxisome proliferator activated employee employee termination exit receptor agonist currently phase iii clinical development use treating dollars millions terminations benefits costs items total type diabetes december company submitted new drug pharmaceuticals application nda fda regulatory approval murgalitazar healthcare terms agreement company received million upfront payment may entitled receive additional million milestone reduction reserves changes estimates payment december subsequently received january gain sale research property company entitled receive million additional payments provision restructuring items upon achievement certain regulatory milestones company merck jointly develop clinical marketing strategy muraglitazar share addition company recorded million asset impairments equally future development commercialization costs copromote accelerated depreciation relating rationalization manufacturing product physicians global basis merck receive payments based operations primarily cost products sold million research net sales levels upfront payment million received may deferred amortized income expected remaining useful life agree bristolmyers squibb company annual reportemployee development related upfront payments licensing agreements employee termination exit allocated business segments dollars millions terminations benefits costs items total pharmaceuticals activities nutritionals company recorded pretax restructuring charges healthcare million relating downsizing streamlining worldwide operations corporateother rationalization worldwide manufacturing operations charge subtotal reduction reserves changes estimates million relates primarily termination benefits approximately employ provisions restructuring items ees including manufacturing administrative sales personnel europe north america asia latin america items million relate prima addition million accelerated depreciation relating planned rily relocation expenses result consolidation research facilities shutdown research facilities united states included charges partially offset adjustment due changes esti research development expense million inventory writeoffs asso mates prior period reserves million principally due higher ciated projects included cost products sold anticipated proceeds disposal assets reduced separation third quarter company recorded pretax restructuring charge costs company expects complete restructuring activities million severance exit costs associated consolidation following table presents detail provision restructuring research development efforts closure two leased facilities items operating segment type company allocate restruc result action impairment assessment performed long lived turing charges business segments assets used sites accordance sfas company con cluded although million assets recoverable remaining employee useful life assets mainly laboratory equipment leasehold improve employee termination exit dollars millions terminations benefits costs items total ments alternate use residual value accelerated four years three months reflect date abandonment facili pharmaceuticals ties fourth quarter healthcare subtotal reduction reserves changes estimates rollforward provision restructuring items restructuring charges spending liabilities associated prior current actions follows addition company recorded million asset impairments employee termination exit cost accelerated depreciation relating rationalization manufacturing opera dollars millions liability liability total tions cost products sold million research development related upfront payments four licensing agreements balance december allocated business segments charges spending activities changes estimate company recorded pretax restructuring charges balance december million relating reduction elimination nonstrategic research charges efforts well consolidation research facilities workforce reductions spending downsizing streamlining worldwide operations charge changes estimate million relates employee termination benefits approximately employ balance december ees including research manufacturing sales administrative personnel charges million represents asset writedowns including million impairment spending charge companys investment deltagen million exit changes estimate costs closure facilities related expenses charges balance december offset adjustment prior period restructuring reserves mil lion million due lower expected separation costs liabilities included accrued expenses consolidated bal million due higher anticipated proceeds disposal assets previ ance sheet ously written restructuring million projects cancelled addition million adjustment cost products sold note acquisitions divestitures made reflect reversal inventory reserves associated canceled february company completed divestiture adult projects company completed restructuring activities nutritionals business novartis ag novartis million included following table presents detail provision restructuring million contingent achievement contractual requirements items operating segment type company allocate restruc satisfied million upfront payment supply agreement turing charges business segments company recorded pretax gain million million net tax included million contingent payment million reduction company goodwill associated mead johnson product lines adult nutritionals products recorded sales million bristolmyers squibb company annual reportin april company completed acquisition acordis specialty net earnings discontinued operations also includes million fibres acordis headquartered united kingdom supplies statement earnings primarily related reduction tax contin materials convatec wound therapeutics line acquisition gency reserve related spinoff zimmer holdings inc expected strengthen companys leadership position wound therapies following summary assets liabilities discontinued oper company purchased stock acordis million incurred ations expected sold amounts presented derived million acquisition costs connection transaction additional historical financial information otn adjusted exclude cash million payment contingent achievement future sales volumes intercompany receivables payables otn company purchase price acquisition allocated tangible identifi excluded divestiture addition goodwill related otn able intangible assets acquired liabilities assumed based esti december million excluded following mated fair values acquisition date million million summary net assets disposed considered determining allocated inprocess research development represents esti gain sale date transaction consummated mated fair value acquired inprocess projects consisting primarily medicel wound therapeutics product yet reached technological feasi dollars millions bility alternative future use therefore expensed esti mated fair value projects determined employment assets discounted cash flow model million assigned identifiable intan receivables net gible assets predominantly patents excess purchase price current assets estimated fair values net assets acquired approximately million total current assets recorded goodwill acquisition accounted purchase property plant equipment method accordingly results operations included noncurrent assets accompanying consolidated financial statements date acquisition total assets company completed sale two branded products moisturel duricef resulted pretax gain million liabilities accounts payable note discontinued operations accrued expenses december company committed plan sell otn total liabilities entered definitive sale agreement one equity partners llc otn net assets sold leading specialty distributor pharmaceutical products officebased oncolo gists united states formerly reported distinct operating seg accounts payable balance primarily includes payables mckesson ment transaction expected completed first half corporation mckesson december usually paid within sale price equal million plus sale price adjustment sale first five days month goods shipped preceding month price adjustment based excess current assets current liabilities result timing accounts payable balances otn net liability working capital closing date sale price shall increased balance december decreased amount working capital exceeds less consolidated statement cash flows includes otn business million closing date sale result pretax gain approximately periods presented company uses centralized approach cash million subject sale price adjustment postclosing management financing operations accordingly debt allo matters gain sale otn recognized closing date cated business cash inflows operating investing activities following amounts related otn business segregated discontinued operations million million years ended continuing operations reported discontinued operations december respectively cash outflows reflect costs certain services provided otn company million year ended december costs allocated company otn services include legal counsel insurance external audit fees payroll processing note earnings per share certain human resource services information technology systems support numerator basic earnings per share net earnings available com mon stockholders numerator diluted earnings per share net earnings year ended december available common stockholders interest expense added back assumed conversion convertible debt common shares denomi dollars millions nator basic earnings per share weighted average number common net sales shares outstanding period denominator diluted earnings per cost products sold share weighted average shares outstanding adjusted effect dilutive gross profit total operating expenses earnings income taxes provision income taxes net earnings discontinued operations bristolmyers squibb company annual reportstock options computations basic earnings per common share note income taxes diluted earnings per common share follows components earnings loss continuing operations minority year ended december interest income taxes year ended december dollars millions except per share amount dollars millions earnings continuing operations discontinued operations us net earnings nonus net gain disposal net earnings amounts categorized based location taxing basic authorities average common shares outstanding provisionbenefit income taxes attributable continuing operations earnings continuing operations consisted discontinued operations year ended december net earnings dollars millions net gain disposal current net earnings us diluted nonus average common shares outstanding conversion convertible debt bonds deferred incremental shares outstanding assuming us exercise dilutive stock options nonus earnings continuing operations discontinued operations companys provision income taxes dif net earnings ferent amount computed applying statutory us federal income net gain disposal tax rate earnings continuing operations minority interest income taxes result following net earnings earnings minority interest income taxes weightedaverage shares issuable upon exercise stock options dollars millions included diluted earnings per share calculation earnings continuing operations dilutive million million million minority interest income taxes us statutory rate net earnings include interest expense million million respectively added back assumed conversion convertible debt common effect operations shares ireland puerto rico switzerland note expense net state local taxes components expense net net valuation year ended december allowance changes estimate dollars millions contingent tax matters interest expense nondeductible reserves interest income anticipated dividend foreign exchange transaction loss net repatriation ajca net federal foreign expense net valuation allowance foreign interest expense reduced net interest swap gains million million million respectively interest income relates primarily cash cash equivalents investments marketable secu effective income tax rate earnings continuing operations rities income includes income thirdparty contract manufacturing minority interest income taxes compared royalty income gains losses disposal property plant equip higher effective tax rate attributable pri ment marily million charge estimated deferred taxes taken fourth bristolmyers squibb company annual reportquarter anticipation repatriating approximately billion special repatriation may revised result additional guidance clarifying lan dividends companys nonus subsidiaries pursuant ajca guage may issued congress andor department treasury increase estimates contingent tax matters compared changes companys factual assumptions may occur taxes charge related establishment valuation allowance certain provided balance undistributed earnings approximately charitable contribution carryforwards partially offset favorable resolution billion company invested expects invest undistrib certain tax refund claims increased foreign tax credits uted earnings permanently offshore future earnings repatri effect certain litigation reserves nondeductible increase ated united states company determines earnings effective tax rate effective tax rate primarily due decrease remitted foreseeable future additional tax provisions would required effective tax rate benefit operations ireland puerto rico due complexities tax laws assumptions would switzerland treatment provisions certain litigation reserves non made practicable estimate amounts income taxes would deductible increase estimates contingent tax matters provided compared company settled us federal income tax returns internal components current noncurrent deferred income tax assets revenue service irs liabilities company establishes liabilities possible assessments taxing december authorities resulting known tax exposures including limited transfer pricing certain tax credits various state foreign tax matters dollars millions amounts represent reasonable provision taxes ultimately expected acquired inprocess research development paid may need adjusted time information becomes intercompany profit inventory items known december certain tax contingencies foreign tax credit carryforward liabilities established although company reasonably deferred income estimate possible amount contingency possible alternative minimum tax research contingencies could material effect changes estimates related development credit carryforward contingent tax matters included rate reconciliation charitable contribution carryforward year ended december company recognized income tax bene state tax net operating loss carryforward fit million due settlement certain prior year tax matters foreign net operating loss credit determination company expected settlement tax litigation carryforward company reorganized structure ownership many postretirement pension benefits nonus subsidiaries principal purpose reorganization depreciation facilitate companys ability efficiently deploy financial resources deferred foreign currency gainloss side united states company believes reorganization transac anticipated dividend repatriation ajca tions generally taxfree inside outside united states net possible however taxing authorities particular jurisdictions could assert tax liabilities arising reorganization transactions operations valuation allowance reorganized subsidiaries reasonably possible predict whether deferred tax assets net taxing authority assert tax liability reasonably estimate possible loss range loss respect asserted tax liability recognized company would vigorously challenge assertion believes deferred income taxes current would prevail assurance result company deferred income taxes noncurrent prevail final nonappealable determinations possible us foreign income taxes payable impact could material liabilities noncurrent total note receivables major categories receivables follow valuation allowance million december relates december million foreign state net deferred tax assets million foreign dollars millions state net operating loss tax credit carryforwards million charitable contribution carryforwards company currently believes trade receivables likely realized miscellaneous receivables income taxes paid year million million million respectively less allowances current tax benefit realized upon exercise stock options charged receivables net capital excess par value stock amounted million mil lion million respectively december company approximately billion undistributed earnings foreign subsidiaries company accrued provi sion million estimated deferred taxes fourth quarter anticipation repatriating approximately billion earnings pursuant ajca companys estimate tax cost related bristolmyers squibb company annual reportnote inventories note goodwill major categories inventories follow changes carrying amount goodwill years ended december december follows dollars millions pharmaceuticals nutritionals healthcare discontinued dollars millions segment segment segment operations total finished goods work process balance raw packaging materials december inventories net purchase accounting adjustments note consignment reduction due company experienced substantial buildup whole sale adult saler inventories us pharmaceuticals business resulting sales incen nutritionals tives offered company wholesalers october company business determined required restate sales earnings correct errors purchase price timing revenue recognition certain sales made two largest allocation wholesalers us pharmaceuticals business company determined adjustments sales accounted consignment model balance described note accounting policiesrevenue recognition based december part relationship amount nature incentives offered wholesalers amount inventory held wholesalers note intangible assets consignment model transactions resulted deferred revenue intangible assets major asset class follows million december deferred revenue december december inventory accounted using consignment model dollars millions fully worked company recognized approximately million patentstrademarks million million deferred revenue net sales licenses respectively net rebates returns adjustments technology note property plant equipment less accumulated amortization major categories property plant equipment follow net carrying amount december dollars millions amortization expense intangible assets majority land included costs products sold years ended december buildings million million million respectively machinery equipment fixtures expected amortization expense related current net carrying amount construction progress intangible assets follows less accumulated depreciation years ending december dollars millions property plant equipment net capitalized interest included categories property plant equip ment shown company capitalized interest million mil lion million years ended december respectively later years bristolmyers squibb company annual reportnote shortterm borrowings company entered fixed floating interest rate swaps longterm debt billion longterm debt cash payments interest million included shortterm borrowings amounts due foreign banks million million respectively million million current installments longterm debt mil lion million december respectively us short payments due period term borrowings primarily consist commercial paper later million december average interest rate dollars millions total years us commercial paper outstanding december proceeds longterm debt commercial paper issuance used general corporate purposes average interest rates international shortterm borrowings obligations included shortterm borrowings companys consolidated current installments longterm debt outstanding december balance sheet balances represent outstanding nominal longterm debt values respectively compared respec companys convertible debenture included due payment con tains put call feature described tively december december company replaced prior billion revolving credit facilities new billion five year revolving credit facility syndicate december company provided financial guarantees lenders extendable anniversary date consent form standby letters credit performance bonds majority lenders facility contains financial covenant whereby ratio consoli standby letters credit insurance companies support third dated debt consolidated capital exceed company party liability programs performance bonds relate sale company compliance covenant since inception new facility products various foreign ministries health middle east borrowings outstanding revolving credit facilities company believes significant majority guarantees expire december company unused shortterm lines funded amounts obligations presented follow credit foreign banks million million december ing table respectively components longterm debt follows expiration period december less dollars millions total year years dollars millions notes due standby letters credit notes due performance bonds guarantees floating rate convertible debentures due notes due total commercial commitments notes due debentures due debentures due debentures due yen notes due yen notes due euro interest yen principal term loan due industrial revenue bonds due yen notes due yen notes due variable rate industrial revenue bonds due companys outstanding billion convertible debentures pay interest quarterly annual rate equal month libor reset quarterly minus yield never less zero final maturity september debentures callable par time september issuer holders also redeem debentures par september fundamental change ownership company occurs bond initial con version price conversion rate shares adjustable depending average closing prices applicable period maximum conver sion rate shares bristolmyers squibb company annual reportnote stockholders equity accumulated balances related component comprehen changes common shares treasury stock capital excess par value sive income loss follows stock restricted stock deferred minimum accumulated loss pension available capital foreign currency effective liability sale comprehensive cost excess dollars millions translation securities adjustment securities incomeloss dollars common treasury treasury par value restricted shares millions shares issued shares stock stock stock balance balance december december comprehensive issued pursuant stock income loss plans options balance amortization december restricted stock comprehensive lapses forfeitures income loss restricted stock balance purchases december balance december comprehensive income loss issued pursuant balance stock plans options december amortization restricted stock stock compensation plans lapses forfeitures companys stock incentive plan executive officers key restricted stock employees may granted options purchase companys common stock balance december less market price date option granted options generally become exercisable installments per year issued pursuant stock first fourth anniversaries grant date maxi plans options mum term years additionally plan provides granting stock amortization appreciation rights whereby grantee may surrender exercisable rights restricted stock receive common stock andor cash measured excess market lapses forfeitures price common stock option exercise price restricted stock terms stock incentive plan authorized shares include balance outstanding shares per year well number december shares tendered prior year pay purchase price options number shares previously utilized satisfy withholding tax obligations upon exercise shares available grant prior year share companys preferred stock convertible shares granted year shares canceled forfeited expired common stock callable companys option reductions also available future grant number issued shares preferred stock stock incentive plan provides granting common stock due conversions shares common stock key employees subject restrictions continuous employment dividends declared per common share restrictions generally expire fiveyear period date grant compensation expense recognized restricted period december million million shares restricted stock outstanding plan respectively million shares restricted stock granted fair value bristolmyers squibb company annual reportthe stock incentive plan also incorporates companys longterm following tables summarize information concerning companys performance awards awards delivered form target stock compensation plans currently outstanding exercisable options number performance shares threeyear cycle awards based eps growth sales growth ulti number number securities remaining securities issued weighted average available future issuance mate payout modified companys total stockholder return versus upon exercise exercise price equity compensation eleven companies proxy peer group threshold targets met outstanding options outstanding options plans excluding securities performance period payment made longterm perform rights rights reflected column plan category b c ance award plan maximum performance three measures result shares millions shares millions maximum payout target december million million performance shares outstanding equity compensation plan respectively million performance shares granted plans approved fair value security holders teamshare stock option plan fulltime employees excluding key equity compensation executives granted options purchase companys common stock plans approved market price date options granted company author security holders ized million shares issuance plan individual grants generally become exercisable evenly third fourth fifth anniversary grant date maximum term years options million shares options outstanding options exercisable exercised plan december weighted fair value options granted esti average weighted weighted range remaining average average mated per common share per common share per exercise number contractual exercise number exercise common share respectively date grant using blackscholes prices outstanding life price exercisable price shares millions years shares millions optionpricing model following assumptions dividend yield volatility riskfree interest rate expected life years stock option transactions december million shares common stock reserved issuance pursuant stock plans options conversions preferred weighted stock options related discontinued operations included shares common stock average available issued exercise price amounts material shares millions option award plan shares balance december authorized granted exercised lapsed balance december authorized granted exercised lapsed balance december authorized granted exercised lapsed balance december bristolmyers squibb company annual reportnote financial instruments company uses derivative instruments part interest rate risk man company exposed market risk due changes currency agement policy derivative instruments used comprised principally fixed exchange rates interest rates accordingly company utilizes foreign floating rate interest rate swaps subject fairvalue hedge account exchange option forward contracts offset effect exchange rate ing treatment company entered several fixed fluctuations anticipated foreign currency transactions primarily intercom floating interest rate swap contracts several financial institutions pany inventory purchases expected occur within next two years notional amounts swaps billion billion company exposures net foreign currency denominated assets december respectively accordance sfas liabilities approximated million million accounting derivative instruments hedging activitiesthe company rec december respectively primarily europe japan ognized net reduction interest expense million million mexico canada million respectively reflects benefit lower foreign exchange option contracts forward contracts used hedge floating rate obtained swap compared fixed rate underlying anticipated transactions companys primary foreign currency exposures debt swap contracts well underlying debt hedged relation us dollar euro canadian dollar australian dollar recorded fair value resulted increase noncurrent assets japanese yen notional amounts companys foreign exchange deriv million shortterm liabilities million longterm debt million ative contracts december million increase noncurrent assets longterm debt million million respectively derivatives majority qualify december respectively swap contracts generally held hedges future anticipated cash flows effective portion changes maturity company use derivative financial instruments fair value temporarily deferred comprehensive income oci speculative purposes recognized earnings hedged item affects earnings company reclassified deferred losses sfas requires company perform periodic assessments million million million respectively compre hedge effectiveness assessments determine whether derivatives desig hensive income earnings majority classified cost nated qualifying hedges continue highly effective offsetting changes products sold cash flows hedged items ineffective portion fair value carrying amount companys financial instruments longer deferred oci included current period earnings includes cash cash equivalents marketable securities accounts receivable year ended december company recognized loss due ineffec accounts payable approximates fair value december tive contracts million fair value option forward contracts longterm debt noted difference liabilities million million december fair value carrying value material respectively recorded assets accrued liabilities december fair value foreign exchange contracts note segment information based yearend currency rates blackscholes model case company organized pharmaceutical company related health option contracts care businesses three reportable segmentspharmaceuticals addition foreign exchange hedge contracts noted nutritionals healthcare pharmaceuticals segment comprised company also uses foreign exchange forward contracts hedge foreign cur global pharmaceutical international excluding japan consumer rency denominated monetary assets liabilities primary objective medicines businesses nutritionals segment consists mead johnson pri foreign exchange forward contracts protect us dollar value marily infant formula business healthcare segment consists foreign currency denominated monetary assets liabilities effects convatec medical imaging consumer medicines united states volatility foreign exchange might occur prior receipt settlement japan businesses us dollars foreign currency denominated monetary assets companys products sold principally wholesale retail liabilities primarily denominated japanese yen euro forward trade nationally internationally certain products also sold contracts designated hedges marked market drug manufacturers hospitals clinics government agencies medical incomeexpense notional fair value amount foreign profession three wholesalers accounted approximately exchange forward contracts december million respectively companys total net sales sales million respectively wholesalers accounted respectively companys total net sales three wholesalers accounted approxi mately respectively companys total net sales sales concentrated pharmaceuticals segment bristolmyers squibb company annual reportbusiness segments earnings minority interest net sales income taxes yearend assets dollars millions pharmaceuticals nutritionals healthcare total segments corporateother total corporateother consists principally interest income interest expense certain administrative expenses allocations business segments certain corporate programs corporateother also includes gain sales businessesproduct lines million million respectively accelerated depreciation million termination benefits exit costs million million million respectively asset writedown impairment charges million million respectively upfront milestone payments licensing agreements million million respectively litigation charges net million million million respectively acquired inprocess research development charge million also includes million asset impairment charge imclone pharmaceuticals segment includes accelerated depreciation million certain manufacturing facilities north america expected closed relocation million retention million pharmaceuticals includes litigation settlement income million upfront pay ment licensing agreement million million accelerated depreciation assets manufacturing facilities north america expected closed end million charge asset impairment million charge relocation expenses million charge retention bonus benefits additionally pharmaceuticals segment includes charge acquired inprocess research development million corporateother assets include cash cash equivalents marketable securities goodwill assets otn held available sale certain assets capital expenditures depreciation dollars millions pharmaceuticals nutritionals healthcare total segments corporateother total geographic areas net sales yearend assets dollars millions united states europe middle east africa western hemisphere pacific total bristolmyers squibb company annual reportnote leases minimum rental commitments noncancelable operating leases primarily real estate motor vehicles effect december years ending december dollars millions later years total minimum payments less total minimum sublease rentals net minimum rental commitments operating lease rental expense net sublease rental income million million million million million million note pension postretirement benefit plans company certain subsidiaries defined benefit pension plans defined contribution plans regular fulltime employees principal pen sion plan bristolmyers squibb retirement income plan funding policy contribute amounts provide current service fund past service lia bility plan benefits based primarily years credited service participants compensation plan assets consist principally equity fixedincome securities company also provides comprehensive medical group life benefits substantially us retirees elect participate comprehensive medical group life plans medical plan contributory contributions adjusted periodically vary date retirement original retiring company life insurance plan noncontributory plan assets consist principally equity fixedincome securities similar plans exist employees certain countries side united states cost companys deferred benefits postretirement benefit plans included following components pension benefits benefits dollars millions service costbenefits earned year interest cost projected benefit obligation expected return plan assets net amortization deferral net periodic benefit cost curtailments settlements total net periodic benefit cost company recognized impact medicare prescription drug improvement modernization act accordance fsp recorded million reduction net periodic benefit cost bristolmyers squibb company annual reportchanges benefit obligations plan assets december several plans underfunded accrued benefit obligations exceeded companys defined benefit postretirement benefit accrued benefit liabilities december additional mini plans mum liabilities established increase accrued benefit liabilities pension benefits benefits values underfunded accrued benefit obligations liabilities totaled dollars millions million million december respectively us unfunded benefit equalization plan several international plans benefit obligation additional minimum liability offset intangible assets million beginning year million charges comprehensive income included stock service costbenefits holders equity million million december earned year respectively interest cost projected accumulated benefit obligation defined benefit pension plans benefit obligation million million december respectively plan participants contributions information pension plans accumulated benefit obligations excess curtailments settlements plan assets actuarial gainloss december plan amendments dollars millions benefits paid exchange rate losses projected benefit obligation benefit obligation accumulated benefit obligation end year fair value plan assets fair value plan assets attributable primarily unfunded us benefit equalization plan beginning year several plans international markets unfunded us benefit equal actual return plan assets ization plan provides pension benefits employees compensation employer contribution irs limits funded taxadvantaged manner plan participants contributions settlements transfer inout benefits paid exchange rate gains fair value plan assets end year funded status unamortized net obligation adoption unrecognized prior service cost unrecognized net actuarial loss net amount recognized amounts recognized balance sheet consist prepaid benefit cost accrued benefit cost intangible assets accumulated comprehensive income net amount recognized bristolmyers squibb company annual reportadditional information pertaining companys pension postretirement plans pension benefits benefits dollars millions increase minimum liability including impact foreign currency fluctuations included comprehensive income weightedaverage assumptions used determine benefit obligations december pension benefits benefits discount rate rate compensation increase weightedaverage actuarial assumptions used determine net periodic benefit cost years ended december pension benefits benefits discount rate expected longterm return plan assets rate compensation increase december companys expected longterm rate return assumed health care cost trend rates effect amounts us pension plan assets target asset allocation public equity reported health care plans onepercentagepoint change assumed us international private equity fixed income health care cost trend rates would following effects approximated applying expected returns public equity private equity fixed income target allocation actual histor percentage percentage ical returns also relevant annualized returns periods ended december dollars millions point increase point decrease years years years us pension plan assets represented approximately total company effect total service interest cost pension plan assets december disclosed effect postretirement benefit obligation total company expected return assets us pension plans due impact international pension plans typically companys asset allocation pension postretirement benefits employ less aggressive asset allocation december expected return disclosed benefits relevant assets invested manner us pension plan assets pension benefits benefits international plan assets assumed health care cost trend rates december public equity securities debt securities including cash private equity health care cost trend rate assumed next year total rate cost trend rate assumed decline ultimate trend rate companys investment strategy emphasizes equities order achieve year rate reaches high expected returns long run low expense low required cash ultimate trend rate contributions us pension plans target asset allocation public equity us international private equity fixed income maintained cash flow ie cash contributions benefit payments used rebalance back targets necessary investments well diversi fied within three major asset categories us equity passively managed otherwise investments actively managed investment strategies international pension plans typically similar although asset allocations usually conservative bristolmyers squibb company annual reportbristolmyers squibb company common stock represents less insurance outweighs benefits coverage protection losses plan assets december selfinsured product liabilities effective july company assets postretirement benefits commingled us pension plan continue evaluate risks benefits determine insurance assets therefore investment strategy identical described needs future us pension plans plavix litigation contributions united states although minimum contributions required company plans companys us territory partnership alliance sanofi make cash contributions us pension plans plaintiff three pending patent infringement lawsuits instituted us contributions made us pension plans company may district court southern district new york entitled sanofisynthelabo make taxdeductible contributions h account retiree medical sanofisynthelabo inc bristolmyers squibb sanofi pharmaceuticals benefits equal portion pension normal cost holding partnership v apotex inc apotex corp cv shs contributions international pension plans expected sanofisynthelabo sanofisynthelabo inc bristolmyers squibb sanofi million range pharmaceuticals holding partnership v dr reddys laboratories ltd dr reddys laboratories inc cv shs sanofisynthelabo sanofi estimated future benefit payments synthelabo inc bristolmyers squibb sanofi pharmaceuticals holding following benefit payments reflect expected future service partnership vs teva pharmaceuticals usa inc teva pharmaceuticals appropriate expected paid industries ltd cv teva pharmaceuticals industries ltd since benefits dismissed case proceedings involving plavix also pension medicare instituted outside united states significant proceedings dollars millions benefits gross subsidy net pending canada described us suits filed march may september respectively based us patent compo sition matter patent discloses claims among things hydrogen sulfate salt clopidogrel marketed plavix first two suits also based us patent discloses years claims among things use clopidogrel prevent secondary ischemic event plaintiffs later withdrew patent two savings plan lawsuits plaintiffs infringement position based defendants filing principal defined contribution plan bristolmyers squibb savings abbreviated new drug applications anda fda seeking approval investment program companys contribution based employee sell generic clopidogrel bisulfate prior expiration composition contributions level company match companys contributions matter patent defendants responded alleging patent plan million million million invalid andor unenforceable apotex added antitrust counterclaims first two cases consolidated discovery fact discovery closed note legal proceedings october expert discovery completed november contingencies trial could occur early second quarter although may occur legal proceedings contingencies later discovery yet commenced third action various lawsuits claims proceedings investigations pending companys us territory partnership alliance sanofi company certain subsidiaries accordance sfas plaintiff another pending patent infringement lawsuit instituted us accounting contingencies company records accruals district court district new jersey entitled sanofisynthelabo sanofi contingencies probable liability incurred amount synthelabo inc bristolmyers squibb sanofi pharmaceuticals holding loss reasonably estimated matters involve antitrust securities partnership v watson pharmaceuticals inc watson laboratories inc patent infringement employee retirement income security act cv suit filed october based us patent amended erisa pricing sales marketing practices environmental discloses claims particular crystalline polymorph health safety matters product liability insurance coverage form hydrogen sulfate salt clopidogrel marketed plavix significant matters described assurance case early stages discovery yet begun increase scope matters plavixis currently companys largest product ranked net sales net future lawsuits claims proceedings investigations material sales plavix approximately billion billion years management continues believe previously disclosed next ended december respectively years aggregate impact beyond current reserves currently company expects plavix market exclusivity legal matters affecting company reasonably likely material united states composition matter patent plavix found companys results operations cash flows may material infringed invalid andor unenforceable district court level fda financial condition liquidity could approve defendants andas sell generic clopidogrel companys decision obtain insurance coverage dependent generic competition plavix could begin company exhausted market conditions including cost availability existing time appeals generic competition would likely result substantial decisions made result external factors availability insurance decreases sales plavix united states become restrictive cost increased significantly although plaintiffs intend vigorously pursue enforcement company evaluated risks determined cost obtaining patent rights plavix possible time reasonably assess bristolmyers squibb company annual reportcome lawsuits company prevail lawsuits tevas generic product june unless court decision adverse timing potential generic competition plavix however generic com company kyorin date petition us occur company believes unlikely erbitux october complaint filed yeda research occur second half also possible reasonably esti development company ltd yeda imclone aventis mate impact lawsuits company pharmaceuticals inc us district court southern district new however loss market exclusivity plavix subsequent develop york action alleges seeks three individuals associated yeda ment generic competition would material companys sales plavix also named coinventors us patent cov results operations cash flows could material financial ers therapeutic combination egfrspecific monoclonal antibody condition liquidity antineoplastic agents chemotherapeutic agents use treatment cancer yedas action successful yeda could posi canada tion practice license others practice invention could result sanofisynthelabo sanofisynthelabo canada inc instituted pro product competition erbitux might otherwise occur hibition action federal court canada apotex inc apotex company party action unable predict outcome minister health response notice allegation apotex directed stage proceedings canadian patent covering clopidogrel bisulfate apotexs may repligen corporation repligen massachusetts notice allegation noa indicated filed abbreviated new drug institute technology mit filed lawsuit united states district court submission ands clopidogrel bisulfate tablets sought approval district massachusetts imclone claiming imclones manu notice compliance ands expiration canadian patent facture sale erbitux infringes patent generally covers expires august apotexs noa alleged process protein production mammalian cells repligen mit seek patent invalid infringed hearing held february damages based sales erbitux commenced february february decision expected april patent expired may although repligen mit seeking date statutory month stay imposed approval apotexs extension patent company party action ands expires unable predict outcome stage proceedings decision favorable apotex could result generic product abilifyon august otsuka filed united states patent market canada second quarter company believes trademark office uspto request reexamination us composition outcome canada predictive outcome us matter patent covering abilify antipsychotic agent used treatment light different procedural substantive rules two jurisdictions schizophrenia us patent number patent sanofiaventis sanofisynthelabo canada inc also instituted expires may extended pending supplemental prohibition action federal court canada novopharm limited protection extensions granted otsuka determined original novopharm minister health response notice allegation patent application contained error description prior art refer novopharm directed canadian patent covering clopido ence identified wrong patent number addition otsuka taken grel bisulfate novopharms noa indicated filed ands clopidogrel opportunity bring citations attention uspto bisulfate tablets sought approval notice compliance uspto granted request reexaminationand reexamination ands expiration canadian patent expires proceeding ongoing reexamination proceeding allow uspto august novopharms noa alleged patent consider patentability patent claims light corrected patent invalid action early stages hearing date set number newly cited documents uspto expected make final decision reexamination within next ten fifteen months united kingdom company otsuka believe invention claimed december aircoat limited aircoat filed nullity petition patent patentable prior art expect uspto reconfirm court session glasgow scotland nullity petition aircoat seeks revo reexamination however guarantee cation european patent registered united come patentability patent reconfirmed following kingdom european patent covers inter alia clopidogrel bisulfate reexamination may sooner expected loss market exclusivity active ingredient plavix aircoat specifically alleges claims abilify subsequent development generic competition would european patent invalid revoked grounds material company lack novelty andor lack inventive step avalideranbaxy laboratories limited ranbaxy served notice filed anda piv certification directed us patent patent litigation formulation patent expires june ranbaxys piv notice tequinthe company kyorin pharmaceuticals co ltd kyorin com asserts proposed generic formulation infringe patent menced patent infringement action march teva usa ranbaxys piv notice include challenge composi teva industries united states district court southern district tion matter patent currently expires september company new york relating antibiotic gatifloxacin kyorin holds partner sanofi currently evaluating ranbaxys piv notice composition matter patent company sells tequin teva avaproranbaxy served notice filed anda piv certifi industries since dismissed case action relates tevas cation directed us patent formulation patent filing anda generic version gatifloxacin tablets certification expires june ranbaxys piv notice asserts proposed generic composition matter patent expires december formulation infringe patent ranbaxys piv notice invalid infringed filing suit places stay approval include challenge composition matter patent currently expires september company partner sanofi currently evaluating ranbaxys piv notice bristolmyers squibb company annual reporttequin injectable form apotex corp apotex sicor pharmaceuticals possible time reasonably assess final outcome inc sicor american pharmaceutical partners inc app served litigation reasonably estimate possible loss range loss notice filed abbreviated ndas piv certifications directed respect litigation company prevail final nonappeal us patent apotex sicor also submitted piv certifications able determinations litigation impact could material us patent patent composition matter patent expires december patent term extension securities matters applied december us patent covers spe period march may company number cific form gatifloxacin used tequin apotex sicor allege piv current former officers named defendants number securi notices us patent invalid apotex sicor app allege ties class action suits suits variously alleged violations federal securities proposed generic formulations would infringe us patent laws regulations connection three different matters vanlev company currently evaluating piv notices discussed sales incentives wholesaler inventory levels imclone imclones product erbitux discussed allega vanlev litigation tions concerning vanlev transferred us district court april may june company former chairman district new jersey consolidated action pending board chief executive officer charles heimbold jr former remaining actions consolidated pending us district chief scientific officer peter ringrose phd named defendants court southern district new york plaintiffs filed consolidated class number class action lawsuits alleging violations federal securities laws action complaint april company certain current regulations actions consolidated one action former officers alleging class period october march us district court district new jersey plaintiff claims consolidated class action complaint alleges violations federal defendants disseminated materially false misleading statements andor securities laws connection among things companys invest failed disclose material information concerning safety efficacy com ment relationship imclone imclones product erbitux mercial viability product vanlev period november certain accounting issues including issues related wholesaler inventory april sales incentives establishment reserves accounting certain asset may plaintiff submitted amended complaint adding allega sales plaintiffs seek compensatory damages costs tions company present chairman board chief executive expenses march us district court granted companys officer peter r dolan former chairman board chief executive motion dismiss consolidated class action complaint dismissed officer charles heimbold jr former chief scientific officer peter case prejudice plaintiffs appealed dismissal second circuit ringrose phd disseminated materially false misleading statements court appeals court appeals appeal pending par andor failed disclose material information concerning safety efficacy ties reached agreement principle settle action july commercial viability vanlev period april court appeals stayed appeal remanded action district march number related class actions making essentially court district court could consider settlement july allegations also filed us district court southern district court vacated clerks judgment order consider settle district new york actions transferred us district ment also day district court entered order preliminarily approv court district new jersey ing settlement certifying class settlement purposes pursuant company filed motion partial judgment favor based upon terms proposed settlement claims action dis pleadings plaintiff opposed motion part seeking amend missed litigation terminated defendants receive releases complaint court granted part denied part companys company pay million fund class members motion ruled plaintiff may amend complaint challenge certain november fairness hearing district court approved set alleged misstatements tlement judgment dismissing case prejudice settlement court certified two separate classes class relating period become final company discussing recovering insurance poli november april class relating period cies reflected financial statements portion million march march class certification proposed class settlement approximately million shares excluded set certification without prejudice defendants rights fully contest mer tlement pursuant requests exclusion approximately million plaintiffs claims plaintiff purports seek compensatory damages shares held plaintiffs four pending actions discussed costs expense behalf shareholders respect class period company established reserves liabilities possible time proposed class period reasonably assess final outcome lawsuits accordance december company defendants made gaap company determined amounts represent mini motion summary judgment plaintiffs claims final pretrial mum expected probable losses respect lawsuits eventual losses conference matter commenced december sched related lawsuits may exceed reserves impact uled completed may trial date set could material company believe topend range january plaintiff moved leave file third amended complaint losses estimated seeking combine two class periods one expanded class period addition action filed early october new york state october march add allegations supreme court making similar factual allegations asserting variety company peter r dolan charles heimbold jr peter ringrose claims including among others common law fraud negligent misrepresen phd disseminated materially false misleading statements failed tation discovery taken matter january disclose material information concerning safety efficacy commercial company moved dismiss complaint plaintiffs filed amended viability vanlev defendants opposed plaintiff 's motion complaint december making similar allegations also adding court scheduled hear oral argument motion april allegations sec complaint issued august company filed bristolmyers squibb company annual reporta motion dismiss amended complaint february plaintiffs consolidated amended complaint alleges among things violations opposition motion dismiss due march companys federal securities laws breaches fiduciary duty certain individual reply due april three related actions filed one september defendants connection companys conduct concerning among one november one december making similar things safety efficacy commercial viability vanlev discussed factual allegations asserting claims similar made amended companys sales incentives certain wholesalers inventory complaint new york state supreme court action filed october levels wholesalers companys investment relations company intends file motion dismiss related actions imclone imclones product erbitux alleged anticompetitive behav briefing schedule identical action filed october ior connection busparand taxol lawsuit also alleges malprac possible time reasonably assess final outcome litigation tice negligent misrepresentation negligence pwc plaintiffs seek reasonably estimate possible loss range loss respect restitution rescission certain officers directors compensation litigation company prevail final nonappealable determina alleged improper insider trading proceeds injunctive relief fees costs tions litigation impact could material expenses contribution certain officers alleged liability consoli company number companys current former officers dated securities class action pending us district court southern named defendants purported class action filed october district new york discussed contribution indemnification state court cook county illinois complaint makes factual allega pwc discovery taken matter december tions similar made settled federal class action southern company moved dismiss consolidated amended complaint district new york asserts common law fraud breach fiduciary motion dismiss administratively withdrawn without prejudice duty claims complaint purports assert claims behalf stock party right reinstated upon request two similar actions holders purchased companys stock october pending new york state court plaintiffs seek equitable relief damages held onto stock march company removed costs attorneys fees parties currently engaged discussions action northern district illinois february plaintiffs ' motion regarding potential settlement action remand due march company 's opposition due april previously disclosed august company entered plaintiffs ' reply due may possible time rea final settlement sec concluding investigation concerning certain sonably assess final outcome litigation reasonably estimate wholesaler inventory accounting matters settlement reached possible loss range loss respect litigation company consent copy attached exhibit prevail final nonappealable determinations litigation companys quarterly report form q period ended september impact could material consent company agreed without admitting denying november class action complaint filed united states liability violate certain provisions securities laws company district court eastern district missouri company k also agreed establish million fund class shareholders healthcare resources inc k several current former k directors distributed courts supervision million fund officers behalf purchasers k stock august included million civil penalty distributed certain company september class action complaint alleges company shareholders plan distribution established sec participated fraudulently inflating value k stock allegedly engag settlement resolve ongoing investigation sec ing improper channelstuffing agreements k company filed activities certain current former members companys manage motion dismiss case january plaintiffs opposition ment connection wholesaler inventory issues accounting motion dismiss due march companys reply due matters investigation ongoing addition investigation us april private securities litigation reform act discovery attorneys office district new jersey concerning inventory automatically stayed pending outcome motion dismiss plain accounting matters covered companys settlement sec con tiff filed motion partially lift automatic discovery stay february tinuing company continuing cooperate investigations company 's opposition motion due march plaintiff 's reply due march impact expected material erisa litigation beginning october number companys current former december first quarter company others officers directors named defendants three shareholder deriva named defendants five class actions brought erisa tive suits pending us district court southern district new york us district courts southern district new york district new number companys current former officers directors jersey actions consolidated southern district new named defendants three shareholder derivative suits filed york caption bristolmyers squibb co erisa litigation cv period march may us district court district lap amended consolidated complaint alleging class period new jersey july us district court district new jersey january march served august ordered three shareholder derivative lawsuits filed court amended consolidated complaint brought behalf four named plain transferred us district court southern district new york tiffs putative class consisting participants bristolmyers subsequently us district court southern district new york squibb company savings investment program savings plan ordered six federal shareholder derivative suits consolidated plaintiffs beneficiaries whose benefit savings plan held andor acquired company filed consolidated amended verified shareholder complaint stock time class period excluding defendants heirs certain members board directors current former officers predecessors successors assigns named defendants pricewaterhousecoopers pwc independent registered public accounting company bristolmyers squibb company savings plan committee firm customary derivative suits company named committee thirteen individuals presently serve committee defendant action nominal defendant company liable served committee recent past charles heimbold jr peter r damages suit specific relief sought company dolan past present chief executive officers respectively bristolmyers squibb company annual reportcompany amended consolidated complaint generally alleges amended master complaint asserts claims federal rico defendants breached fiduciary duties erisa class period antitrust statutes state consumer protection fair trade statutes among things continuing offer company stock fund amended master complaint brought behalf two main proposed company stock investment alternatives savings plan continuing classes whose definitions subject amendment case invest company matching contributions company stock fund progressed december proposed classes may sum company stock failing disclose investments company stock marized persons entities forward paid reimbursed allegedly imprudent savings plans purchases company stock part listed drug medicare part b private contract january alleged transactions prohibited expressly used awp pricing standard persons entities erisa finally defendants heimbold dolan alleged breached forward paid reimbursed portion purchase price fiduciary duties erisa failing monitor actions drug covered together rx card program based whole part committee erisa claims predicated upon factual allegations awp first class divided several proposed subclasses similar raised securities matters concerning among depending whether listed drug question physicianadministered things safety efficacy commercial viability vanlev companys selfadministered sold pharmacy benefits manager specialty phar sales incentives certain wholesalers inventory levels whole macy brandname generic drug september plaintiffs salers companys investment relations imclone imclones awp multidistrict litigation moved certification proposed plaintiff class product erbitux alleged anticompetitive behavior connection parties briefed motion related amended proposed definition busparand taxol first main class subclasses discussed motion heard significant discovery date discovery currently court february stayed october company defendants moved company defendants moved dismiss amended master dismiss amended consolidated complaint plaintiffs opposed complaint grounds fails state claims applicable statutes motion dismiss defendants replied motions dismiss february court denied motion large part although administratively withdrawn without prejudice plaintiffs court dismissed one plaintiffs claims failure plead cognizable rico requested premotion conference intend ask court leave file enterprise accordingly court required company second amendment complaint second quarter company defendants answer amended master complaint court subsequently established reserves liabilities litigation million possi ordered five defendants including company engage accelerated ble time reasonably assess final outcome litigation accor discovery respect remaining allegations amended master dance gaap company determined reserves established complaint allegations related together rx represent minimum expected probable losses respect litigation extended discovery schedule accelerated discovery closed five eventual losses related litigation may exceed reserves defendants january addition company defen impact could material company believe topend dants obtained discovery named plaintiffs several nonparties range losses estimated company prevail benefits consultants federal government health insurers final nonappealable determination matter impact could material current schedule calls expert reports expert depositions summary judg results operations ment briefing liability issues first half cases commenced nevada montana pennsylvania wisconsin pricing sales promotional practices litigation investigations illinois alabama kentucky attorneys general attorneys general company together number pharmaceutical manufactur awp cases cases commenced new york city four new york ers defendant several private class actions actions brought counties new york city county awp cases include fraud consumer nevada montana pennsylvania wisconsin kentucky illinois alabama protection claims similar amended master complaint certain attorneys general city new york four new york counties states city counties also made additional allegations defen pending federal state courts relating pricing certain company dants including company violated state medicaid statutes among products federal cases related state court cases things failing provide states adequate rebates required removed federal courts consolidated pretrial purposes federal law attorneys general awp cases montana action caption pharmaceutical industry average wholesale price litigation proceeding respective state courts mdl civ action cvpbs united states district series decisions june september october affecting court judge patti b saris united states district court district montana attorney generals case new york city county awp cases massachusetts awp multidistrict litigation june private proceeding awp multidistrict litigation coordination plaintiffs awp multidistrict litigation filed amended master private class actions court declined find medicaid rebate claims consolidated complaint amended master complaint amended master preempted federal law nevertheless dismissed many claims complaint contains two sets allegations company first alleges relating rebate payments made several drug manufacturers including companys many pharmaceutical manufacturers reporting claims relating company insufficiently pled court allowed prices certain drug products listed drugs companys case proceed state law claims allege company misreported effect falsely overstating average wholesale price awp published awps company filed answer claims remaining industry compendia turn improperly inflated reimbursement paid montana attorney generals complaint medical providers pharmacists others prescribed administered company also joined defendants motion dismiss sold products consumers second alleges company pennsylvania attorney generals action decision filed february certain defendant pharmaceutical manufacturers conspired one pennsylvania commonwealth court granted motion dismiss another program called together rx card program fix awps ground plaintiff failed plead complaint requisite par certain drugs made available consumers program ticularity court gave attorney general days replead july bristolmyers squibb company annual report nevada court denied companys defendants motions previously disclosed mid company initiated internal dismiss complaint except state rico claim granted review certain sales marketing practices focusing whether attorney general leave replead opinion based prior rul practices comply applicable antikickback laws analyzing ings awp multidistrict litigation court company defen practices respect compliance best price reporting rebate dants also made may soon make motions dismiss requirements medicaid program certain us governmental attorneys general awp cases programs reference medicaid rebate program applicable company also one number defendants private class action fda requirements company met representatives us making awpbased claims remanded awp multidistrict attorneys office district massachusetts discuss review litigation arizona state court individual robert j swanston asserts received related subpoenas us attorneys office companys claims arizona state law behalf alleged class per internal review expected continue resolution pending governmental sons entities arizona paid prescription drugs based awp investigations related matters swanston action claims generally allege defendant drug manu company producing documents actively cooperating inves facturers conspired inflate awps order dated august tigations could result assertion civil andor criminal claims arizona court denied defendants motions dismiss stay proceedings second quarter company increased reserves liabilities parties currently briefing plaintiffs motion class certification relation pharmaceutical pricing sales marketing practices described defendants papers due february court swanston section million bringing total reserves liabilities action ordered discovery matter coordinated dis matters million possible time reasonably assess covery awp multidistrict litigation final outcome matters accordance gaap company october company added defendant determined amount represents minimum expected probable putative class action previously commenced drug manufacturers losses respect matters losses could include imposition federal court alabama case brought two health care providers fines penalties administrative remedies andor liability additional rebate allegedly entitled federal statute section b public amounts eventual losses related matters may exceed reserves health service act discounted prices prescription drugs dispensed impact could material company believe poor providers local areas plaintiff health care providers contend topend range losses estimated company alleged class providers authorized obtain discounted prevail final nonappealable determinations litigations prices statute may fact received level discounts investigations impact could material entitled amended complaint company previously disclosed company undertook analysis manufacturers asserts claims directly federal statute well methods processes calculating prices reporting governmental state law unjust enrichment accounting company rebate pricing programs related us pharmaceuticals business joined motion dismiss complaint filed original manu analysis completed early based analysis company facturer defendants courts approval made applica identified need revisions methodology processes used cal ble amended complaint culating reported pricing related rebate amounts expects implement finally company defendant related state court proceedings com revised methodologies processes beginning reporting menced new york new jersey california tennessee proceed federal government agency primary responsibility rebate ings transferred awp multidistrict litigation pretrial purposes price reporting obligations centers medicare medicaid services plaintiffs california new jersey actions sought remand cms first quarter addition using revised methodologies cases state courts california remand motions denied processes company also recalculated best price new jersey remand motion remains pending average manufacturers price required reported companys cases preliminary stage company unable federal medicaid rebate agreement certain state agreements cor assess outcome possible effects business profitability responding revised rebate liability amounts programs three reasonably estimate possible loss range loss respect cases year period third quarter based results company prevail final nonappealable determinations companys analysis time company recorded additional litigations investigations impact could material liability equal estimated additional rebate liability resulting company together number pharmaceutical manufactur proposed revisions material upon completion analysis ers also received subpoenas document requests various early company finally determined estimated rebate liabil government agencies seeking records relating pricing sales market ity programs threeyear period actually less ing practices best price reporting drugs covered medicare andor rebates paid company period medicaid requests records come us attorneys offices accordingly fourth quarter company reversed additional district massachusetts eastern district pennsylvania rebate liability recorded third quarter recorded northern district texas civil division department justice additional reduction rebate liability amount estimated offices inspector general department health human payment companys proposed revisions updated estimate services office personnel management conjunction submitted review cms company anticipates submission civil division department justice several states addition cms also likely reviewed department justice doj conjunc requests information come house committee energy tion previously disclosed subpoena received company commerce senate finance committee connection investiga doj relating among things best price reporting drugs covered tions committees currently conducting medicaid best medicaid discussed detail agencies may take price issues position revisions companys methodologies calcula tions required upon completion governmental review company bristolmyers squibb company annual reportdetermine whether recalculation liability company ppain may yale university published results hemorrhagic identified programs period similar pro stroke project concluded evidence suggestion grams necessary appropriate company believes based current ppa may increase risk hemorrhagic stroke limited population information recalculation likely result material rebate november fda issued public health advisory requested liability however due uncertainty surrounding recoverability manufacturers ppacontaining products voluntarily cease manufacturing companys estimated overpayment arising review process described marketing time ppacontaining products manufac company also recorded reserve amount equal esti tured sold company comtrexliquigel formulations mated overpayment company remediated internal controls naldeconon november company well man processes procedures company believes resulted proposed ufacturers ppa containing products discontinued manufacture mar revisions continue strengthen internal controls keting ppacontaining products allowed customers return unused company received civil investigative demand attorney product possession general state missouri relating directtoconsumer advertising january company served first ppa lawsuit pravacholfor period company received written confir company currently defendant approximately personal injury lawsuits mation attorney general july concluding investigation filed behalf approximately plaintiffs federal state courts action taken company company also received notice united states many lawsuits involve multiple defendants putative class action lawsuit involving issues related directto consumer among claims plaintiffs allege ppa causes hemorrhagic advertising filed february circuit court jackson county ischemic strokes defendants aware risk failed warn con missouri kansas city caption richard summers v bristolmyers squibb sumers failed remove ppa products plaintiffs seek compen company company served complaint march satory punitive damages federal cases transferred removed action federal court action remanded us district court western district washington state court impact expected material phenylpropanolamine ppa products liability litigation mdl company together number pharmaceutical manufactur district court denied motions class certification ers named defendant action filed california state class action lawsuits pending company litigation superior court oaklandjames clayworth et al v bristolmyers squibb june district court issued ruling effectively limiting company et al alleging defendants conspired fix prices plaintiffs claims hemorrhagic ischemic strokes rulings favorable pharmaceuticals preventing importation foreign drugs united defendants included inadmissibility expert testimony cases alleging states asserting claims californias cartwright act unfair compe injuries occurring three days ingestion ppacontaining tition law plaintiffs seek treble damages damages sus product cases involving psychoses seizures cardiac injuries tained restitution profit obtained defendants charging company expects dismissed additional cases products artificially higher prices plaintiffs injunction barring defendants never used plaintiffs plaintiffs alleged injury occurred charging plaintiffs higher prices offered customers award rea three days ingestion ppacontaining product sonable attorneys fees costs relief court deems proper plaintiff suffered cardiac injuries psychoses plaintiffs propounded interrogatories defendants served serzone serzonenefazodone hydrochloride antidepressant objections responses january parties process launched company may canada march meeting conferring resolve disputes defendants responses united states december company added black box warning objections plaintiffs also propounded form interrogatories itsserzonelabel warning potential risk severe hepatic events including requests admission request production documents possible liver failure need transplantation risk death within company preparing responses objections discovery several months black box warning added package insert requests november company filed demurrer action serzone number lawsuits including several class actions filed plaintiffs filed opposition brief december company plaintiffs allege company knew company filed reply brief january oral argument demur known hepatic risks posed byserzoneand failed adequately warn rer held february order dated february physicians users risks seek compensatory punitive dam court sustained demurrer court also granted plaintiffs leave file ages medical monitoring refunds costs purchasingserzone second amended complaint already done defendants may company announced following evaluation com response second amended complaint filed march mercial potential product generic entry marketplace case preliminary stage company unable assess rapidly declining brand sales decided discontinue manufacture outcome possible effect business profitability reason sale product effective june ably estimate possible loss range loss respect case present company approximately lawsuits behalf company prevail final nonappealable determination liti approximately plaintiffs pending federal state courts gation impact could material throughout united states twentyseven cases pending new york state court consolidated pretrial discovery addition product liability litigation approximately alleged unfiled claims injury associated company party product liability lawsuits involving allegations withserzone august federal cases transferred us injury caused companys pharmaceutical overthecounter medica district court southern district west virginia serzoneproducts tions majority lawsuits involve certain overthecounter medica liability litigation mdl although discovery still early stage tions containing phenylpropanolamine ppa companysserzoneand appears cases involve liver failure june stadol ns prescription drugs addition lawsuits company also faces district court dismissed class claims two class action com unfiled claims involving products plaints purported class action also filed illinois although num bristolmyers squibb company annual reportber class action complaints filed company sought breast implant litigation company together subsidiary certification one personal injury classes remaining class action medical engineering corporation mec certain companies remains complaints seek certification personal injury classes addition defendant number claims lawsuits alleging damages personal cases filed united states four national class actions filed injuries various types resulting polyurethanecovered breast implants canada smoothwalled breast implants formerly manufactured mec related without admitting wrongdoing liability around october company vast majority claims company direct lawsuits company entered settlement agreement respect resolved settlements trial claims united states territories regardingserzone settlement likewise claims potential claims company registered agreement embodies schedule payments dependent upon whether nationwide class action settlement approved federal district court class member developed qualifying medical condition whether birmingham alabama revised settlement resolved demonstrate purchased tookserzone whether certain revised settlement company established accruals criteria apply settlement subject final approval district court respect breast implant product liability litigation company believes appeals therefrom pursuant settlement agreement plaintiffs class possible loss addition amounts accrued material counsel filed class action complaint seeing relief settlement class november district court conditionally certified temporary settle hormone replacement therapy hrt litigationin national ment class preliminarily approved settlement optout period ends institute health began clinical trials involving prempro estrogen april fairness hearing scheduled june pursuant progestin premarin estrogen manufactured wyeth terms proposed settlement claims dismissed litigation july jama article reported among prempro subjects terminated defendants receive releases company com increased risks breast cancer heart attacks blood clots strokes mits paying least million funds class members class counsel prempro phase study stopped july july right petition court award reasonable attorneys fees company served first hrt lawsuit company products involved expenses fees paid company reduce amount litigation estrace estrogenonly tablet estradiol generic estro money paid class members part settlement company may termi genonly tablet delestrogenan injectable estrogen ovcon oral con nate settlement based upon number claims submitted number traceptive containing estrogen progestin products purported class members opt participate settlement sold companies january august instead pursue individual claims company maintains estrace anda second quarter company established reserves liabili company currently defendant approximately lawsuits involving ties lawsuits million possible time reasonably mentioned products filed behalf approximately plaintiffs assess final outcome lawsuits accordance gaap federal state courts throughout united states majority law company determined amounts represent minimum suits involve multiple defendants company expects dismissed expected probable losses respect lawsuits eventual losses related many cases products never used plaintiffs allege among lawsuits may exceed reserves impact could things products cause breast cancer stroke blood clots car material company believe topend range diac injuries women defendants aware risks losses estimated failed warn consumers federal cases transferred stadol ns stadol ns approved fda unscheduled us district court eastern district arkansas prempro wyeth opioid analgesic nasal spray february company asked fda products liability litigation mdl schedule stadol ns schedule iv low potential abuse drug due post company vigorously defending product liability lawsuits marketing reports suggestive inappropriate use product october believes majority cases claims without merit became schedule iv drug since company received possible time reasonably assess final outcome number lawsuits involving stadol late number filed suits companys pending product liability lawsuits unfiled claims cer increased due newly passed tort reform legislation became effective tainty management opinion ultimate disposition january plaintiffs new suits previ matters material adverse effect companys financial ously asserted claims company alleged injuries may position except otherwise indicated company believes company announced following evaluation commercial adequate selfinsurance reserves commercially available excess potential product generic entry marketplace rapidly insurance cover potential material losses related product liability declining brand sales decided discontinue manufacture sale cases claims product effective june company party approximately cases pending behalf environmental proceedings total approximately plaintiffs federal state courts throughout following discussion describes environmental proceedings united states plaintiffs claim company committed fraud fda governmental authority may involve potential monetary sanctions wrongfully promoted stadol ns nonaddictive plaintiffs allege threshold prescribed specific sec rule civil company failed adequately warn addiction dependency action environmental claim could result significant liabilities risk associated use stadol ns company reached agree updates ongoing matters resolution matters disclosed ment principle settle lawsuits involving approximately plain recent public filings summary environmental remediation costs tiffs addition lawsuits approximately active alleged results internal audit performed companys facility unfiled claims majority cases claims pending mississippi hopewell nj indicate operations sites wastewater treatment plant second quarter company recovered insurance proceeds related discharges always compliance new jersey million respect stadol ns case water pollution control act implementing regulations terms bristolmyers squibb company annual reportcompanys discharge permits company reported findings new finance portion study epa estimates study cost mil jersey department environmental protection njdep february lion roughly half financed private party group study entered settlement agreement njdep november paid may also lead cleanup actions directed epa army corps penalty none results audit suggests engineers company working cooperatively group parties adverse impact public health company taken received njdep directive andor epa notice explore potential continue take corrective actions address identified deficiencies resolutions directive address risk collateral claims although prevent future occurrences company believe caused contributed contamina us environmental protection agency epa investigating industrial tion lower passaic river watershed company informed commercial facilities throughout us use refrigeration equipment njdep willing discuss allegations company containing ozonedepleting substances ods enforcing compliance directive recent communications cooperating group njdep regulations governing prevention service repair leaks ods require stated responsible parties cooperate njdep may per ments recently company performed voluntary corporatewide audit form damage assessment restoration take civil action recover facilities us puerto rico use odscontaining refrigeration remedial costs treble damages administrative costs penalties equipment company submitted audit report epa november late group federal agencies designated trustees natural identifying potential violations ods requirements several resources affected contamination passaic river watershed facilities currently discussions epa resolve matters approached cooperating group solicit interest funding cooperative addition matters covered companys audit report letter epa study possible natural resources damages nrd area study pre epa previously sent companys wholly owned subsidiary mead sumably would dovetail ongoing epa study ideally would johnson request information regarding compliance ods require joined njdep coordinate actions njdep may seek ments facility evansville indiana company responded directive discussions federal trustees ongoing extent request june epa currently process reviewing liability company may face either directive epas notice let information company provided epa determines ter respect future nrd actions claims federal trustees evansville facility facilities violation applicable ods contribution responsible parties yet determined requirements company could subject penalties andor required october michigan department environmental quality convert replace refrigeration equipment use nonods approved substitutes mdeq sent company letter violation lov alleging january njdep sent company approximately five unspecified period time emissions certain digestion tanks mead companies information request letter relating site north brunswick johnsons zeeland michigan facility exceeded applicable limit facil township nj waste materials er squibb sons squibb itys renewable operating air permit lov requires company take cor wholly owned subsidiary company may disposed rective action submit compliance program report although mdeq fill material containing industrial waste heavy demanded fines penalties enforcement action could result metals excess residential standards discovered fall penalties injunctive relief company contesting allegations expansion project north brunswick township high school well lov company mdeq also working revisions number neighboring residential properties adjacent public park areas companys air use permit although predict ultimate outcome school board township current owners site certainty permit revisions may resolve matter without additional conducting jointly financing soil remediation work work plan enforcement action need continue contesting lov approved njdep asked company contribute cost december company njdep entered remediation company discussions njdep site owners administrative consent order aco concerning alleged violations potentially responsible parties regarding scope costs work new jersey air pollution control act implementing regulations required address known conditions concern recently offered companys new brunswick facility pursuant aco company agreed negotiate school board township terms cooperative submit permit application creating facilitywide emissions cap pay funding agreement allocation process company also actively inves administrative fine approximately obligations tigating historic use site including companys possible connec satisfied early subsequently february aco tion date claims asserted company amended provide company would install new cogeneration turbine september njdep issued administrative enforcement new brunswick facility december would obtain air per directive notice new jersey spill compensation control act mits including required cogeneration turbine december requiring company approximately companies perform estimated cost new cogeneration turbine approximately assessment natural resource damages implement unspecified interim million remedial measures restore conditions lower passaic river company one several defendants class action suit filed supe directive alleges company liable historically sent bulk rior court puerto rico february residents three wards waste former inland chemical company facility newark nj repro municipality barceloneta alleging air emissions government cessing releases hazardous substances facility owned operated wastewater treatment facility said municipality migrated newark bay continue adverse impact caused respiratory ailments violated local air rules lower passaic river watershed subsequently epa also issued notice company believes wastewater discharges treatment facility letter comprehensive environmental response compensation material compliance terms companys permit company liability act cercla numerous parties including company believes litigation resolved immaterial amount however seeking cooperation study conditions substantially although suit five years old still initial stage even stretch passaic river subject njdeps directive group issue class certification still pending event adverse judgment parties entered consent agreement epa companys ultimate financial liability could greater anticipated bristolmyers squibb company annual reportthe company also responsible various state federal foreign aforementioned indemnity applicable certain prior period insur laws including cercla certain costs investigating remediating con ance policies however certain indemnification payments may covered tamination resulting past industrial activity companys current companys directors officers insurance coverage company mer sites waste disposal reprocessing facilities operated third predict certainty extent company recover parties company typically estimates costs based information insurers indemnification payments made connection litigation obtained epa counterpart state agency andor studies prepared matters regulatory actions described independent consultants including total estimated costs site july one companys insurers federal insurance expected costsharing potentially responsible parties company federal filed lawsuit new york supreme court prp company accrues liabilities probable reasonably company several current former officers members board estimable december company estimated directors seeking rescission alternative declarations allowing federal share total future costs sites approximately million avoid payment certain directors officers insurance policies million respectively recorded liabilities represents sum certain fiduciary liability insurance policies respect potential liability best estimates simple estimate reasonably made estimates arising connection matters described vanlev litigation minimal probable amount among range costs without taking securities matters erisa litigation sections discovery account potential recoveries parties currently taken matter parties currently engaged discussions expected company paid less million excluding legal fees regarding potential settlement action last five years investigation remediation matters october another companys insurers sr international including liabilities cercla onsite remedial obligations business insurance co ltd sri informed company intended try although possible predict certainty outcome envi avoid certain insurance policies issued company grounds ronmental proceedings ultimate costs remediation company alleged material misrepresentation nondisclosure initiated believe reasonably possible expenditures company may arbitration proceedings london england sri indicated intends incur excess existing reserves material adverse effect rely upon allegations similar described securities matters business financial position results operations section support avoidance action matters october sec notified company conducting note subsequent events informal inquiry activities certain companys german pharma january company announced plans divest us ceutical subsidiaries employees andor agents company believes canadian consumer medicines business year ended december secs informal inquiry may encompass matters currently investiga sales consumer medicines brands us canada totaled tion staatsanwaltin prosecutor munich germany although uncertain approximately million companys consumer medicines businesses time company believes inquiry investigation may concern japan asia pacific latin america europe middle east africa potential violations foreign corrupt practices act andor german law included planned divestiture company cooperating sec german authorities november company medarex inc medarex entered possible time reasonably assess final outcome mat worldwide collaboration develop commercialize mdx fully human ters reasonably estimate possible loss range loss antibody investigational product targeting ctla receptor mdx company conducting internal review pharmaceutical opera developed medarex currently phase iii clinical development tions mexico total sales million twelve months treatment metastatic melanoma collaboration agreement became effec ended december broad review includes areas compliance tive january time company made cash payment legal financial regulatory requirements companys standards million medarex expensed research development business conduct ethics reviews ongoing time additional million equity investment medarex company unable assess impact results investiga tions may company indemnification officers directors companys corporate bylaws require extent permitted law company shall indemnify officers directors judgments fines penalties amounts paid settlement including legal fees appeals incurred connection civil criminal actions proceedings relates services company subsidiaries bylaws provide limit amount indemnification indemnification permitted case willful misconduct knowing violation criminal law improper per sonal benefit permitted laws state delaware company many years purchased directors officers insurance cover age cover claims made directors officers amounts types coverage varied period period dictated market con ditions various excess policies provide additional coverage litigation matters regulatory actions described involve certain companys current former directors officers covered bristolmyers squibb company annual reportnote selected quarterly financial data unaudited dollars millions except per share data first quarter second quarter third quarter fourth quarter year net sales gross margin earnings continuing operations discontinued operations net net earnings earnings per common share basic earnings continuing operations discontinued operations net net earnings diluted earnings continuing operations discontinued operations net net earnings dividends declared per common share cash cash equivalents marketable securities dollars millions except per share data net sales gross margin earnings continuing operations discontinued operations net net earnings earnings per common share basic earnings continuing operations discontinued operations net net earnings diluted earnings continuing operations discontinued operations net net earnings dividends declared per common share cash cash equivalents marketable securities note earnings per share quarters may add amounts year period computed discrete basis includes litigation charges million million million second third fourth quarters respectively second quarter includes litigation settlement income million first second third fourth quarters include gain sale mead johnson adult nutritionals business million million million million respectively first second third fourth quarters include provisions restructuring items million million million million respectively first sec ond third fourth quarters include upfront payments licensing agreements million million million million respectively second third quarters include writeoffs acquired inprocess research development million million respectively includes litigation settlement charges million million second fourth quarters respectively first second third quarters include litigation settlement income million million million respectively first second third fourth quarters include provisions restructuring items million million million million respectively second third fourth quarters include reversals prior period restructuring items million million million respectively third fourth quarters include upfront payments licensing agreements million million respectively common equivalent shares excluded computation diluted earnings per share effect would antidilutive follows millions first second third fourth quarter quarter quarter quarter year bristolmyers squibb company annual reportreports management managements responsibility financial statements management responsible preparation presentation integrity financial information presented annual report accompanying consolidated financial statements prepared conformity accounting principles generally accepted united states america gaap applying certain estimates judgments required managements opinion consolidated financial state ments present fairly companys financial position results operations cash flows audit committee board directors meets regularly internal auditors pricewaterhousecoopers llp pwc companys independent registered public accounting firm management review accounting internal control structure financial reporting mat ters internal auditors pwc full free access audit committee set forth companys standards business conduct ethics company firmly committed adhering highest standards moral ethical behavior business activities managements report internal control financial reporting management also responsible establishing maintaining adequate internal control financial reporting supervision participation management including chief executive officer chief financial officer management assessed effectiveness internal control financial reporting december based framework internal controlintegrated frameworkissued committee sponsoring organizations treadway commission based assessment management concluded companys internal control financial reporting effective december provide reasonable assurance regarding reliabili ty financial reporting preparation financial statements external purposes accordance gaap due inherent limitations internal control financial reporting may prevent detect misstatements also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree com pliance policies procedures may deteriorate pricewaterhousecoopers llp pwc independent registered public accounting firm audited companys consolidated financial statements included annual report issued report managements assessment effectiveness companys internal control financial reporting appears annual report peter r dolan chairman board chief executive officer andrew rj bonfield senior vice president chief financial officer march bristolmyers squibb company annual reportreport independent registered public accounting firm board directors stockholders bristolmyers squibb company completed integrated audit bristolmyers squibb companys company consolidated financial statements internal control financial reporting december audits consolidated financial statements accordance standards public company accounting oversight board united states opinions based audits presented consolidated financial statements opinion consolidated financial statements present fairly material respects financial position company subsidiaries december results operations cash flows three years period ended december con formity accounting principles generally accepted united states america financial statements responsibility companys manage ment responsibility express opinion financial statements based audits conducted audits statements accordance standards public company accounting oversight board united states standards require plan perform audit obtain rea sonable assurance whether financial statements free material misstatement audit financial statements includes examining test basis evidence supporting amounts disclosures financial statements assessing accounting principles used significant estimates made manage ment evaluating overall financial statement presentation believe audits provide reasonable basis opinion internal control financial reporting also opinion managements assessment included managements report internal control financial reporting appearing annual report company maintained effective internal control financial reporting december based criteria established internal controlintegrated frameworkissued committee sponsoring organizations treadway commission coso fairly stated material respects based criteria furthermore opinion company maintained material respects effective internal control financial reporting december based criteria established internal controlintegrated frameworkissued coso companys management responsible maintaining effective internal control financial reporting assessment effectiveness internal control financial reporting responsibility express opinions managements assessment effectiveness companys internal control financial reporting based audit conducted audit internal control financial reporting accordance standards public company accounting oversight board united states standards require plan perform audit obtain reasonable assurance whether effective internal control financial reporting maintained material respects audit internal control financial reporting includes obtaining understanding internal control financial reporting evaluating managements assessment testing evaluating design operating effectiveness internal control performing pro cedures consider necessary circumstances believe audit provides reasonable basis opinions companys internal control financial reporting process designed provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles companys internal control finan cial reporting includes policies procedures pertain maintenance records reasonable detail accurately fairly reflect transac tions dispositions assets company ii provide reasonable assurance transactions recorded necessary permit preparation financial statements accordance generally accepted accounting principles receipts expenditures company made accordance authorizations management directors company iii provide reasonable assurance regarding prevention timely detection unauthorized acquisition use disposition companys assets could material effect financial statements inherent limitations internal control financial reporting may prevent detect misstatements also projections evaluation effec tiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate pricewaterhousecoopers llp philadelphia pa march bristolmyers squibb company annual reportcontrols procedures evaluation disclosure controls procedures december management carried evaluation supervision participation chief executive officer chief finan cial officer effectiveness design operation disclosure controls procedures term defined exchange act rule ae based evaluation management concluded december disclosure controls procedures effective provide reason able assurance company records processes summarizes reports information company must disclose reports company files submits securities exchange act amended within time periods specified sec 's rules forms management 's report internal control financial reporting management responsible establishing maintaining adequate internal control financial reporting supervision participation management including chief executive officer chief financial officer management assessed effectiveness internal control financial reporting december based framework internal controlintegrated frameworkissued committee sponsoring organizations treadway commission based assessment management concluded company 's internal control financial reporting effective december provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance united states generally accepted accounting principles due inherent limitations internal control financial reporting may prevent detect misstatements also projections evaluation effectiveness future periods subject risk controls may become inade quate changes conditions degree compliance policies procedures may deteriorate pricewaterhousecoopers llp pwc independent registered public accounting firm audited company 's financial statements included annual report issued report management 's assessment effectiveness company 's internal control financial reporting december appears annual report status previously disclosed internal control items making evaluation effectiveness design operation disclosure controls procedures management considered signifi cant resources devoted substantial actions taken company past two years remediate reportable condition defined standards established american institute certified public accountants relating internal control financial reporting income taxes initially identified communicated company audit committee pwc connection audit company 's consolidated financial statements year ended december repeated year ended december reportable condition identified pwc need enhance income tax accounting function provide timely analysis reconciliation income tax provision related income tax assets liabilities actions taken company included engaging outside consultant assist company 's personnel conduct comprehensive detailed review certain company 's income tax reporting accounting throughout company continued strengthen internal control financial reporting income taxes efforts included continuing work outside consultants making significant personnel changes including hiring new vice president taxes increasing number tax department key personnel well implementing policies procedures enhance communication business unit tax department financial reporting personnel ensure comprehensive appropriate timely review matters implementing new updating existing tax accounting policies providing training policies based evaluation chief executive officer chief financial officer concluded december internal control financial reporting income taxes issues sufficiently remediated discussed note legal proceedings contingencies management identified need remediate deficiencies internal con trol methodology processes calculate prices reporting governmental rebate pricing programs related us pharmaceuticals busi ness conducting evaluation chief executive officer chief financial officer also considered substantial efforts undertaken company remediate internal control deficiencies included retaining several outside consultants subject matter expertise conducting exhaustive review existing methodologies processes training employees implementation revised methodologies processes based review chief executive officer chief financial officer concluded company 's internal control methodology processes calculate prices described sufficiently remediated changes internal control financial reporting changes company 's internal control financial reporting quarter ended december materially affected reasonably likely materially affect company 's internal control financial reporting bristolmyers squibb company annual reportfiveyear financial summary dollars millions except per share data income statement data net sales earnings continuing operations minority interest income taxes earnings continuing operations earnings continuing operations per common share basic diluted average common shares outstanding basic diluted dividends paid common preferred stock dividends declared per common share financial position data december total assets cash cash equivalents marketable securities longterm debt stockholders equity company recorded items affected comparability results set forth table managements discussion analysis financial condition results operations expenses years discussion items see managements discussion analysis financial condition results operationsexpenses note alliances investments note restructuring items note acquisitions divestitures note discontinued operations excludes discontinued operations otn years clairol zimmer includes discontinued operations years bristolmyers squibb company annual reportboard directors management executive committee board directors management executive committee robert e allen peter r dolan retired chairman chairman chief executive officer chief executive officer att corporation abd lamberto andreotti lewis b campbell senior vice president president international chairman president chief executive officer stephen e bear textron inc abc senior vice president human resources vance coffman andrew g bodnar md chairman retired chief executive officer senior vice president strategy lockheed martin corporation ac medical external affairs james cornelius andrew r j bonfield nonexecutive chairman senior vice president chief financial officer guidant corporation cirm carlo de notaristefani peter r dolan president technical operations chairman chief executive officer bristolmyers squibb company wendy l dixon phd president global marketing ellen v futter chief marketing officer president american museum natural history b donald j hayden jr executive vice president president americas louis v gerstner jr retired chairman chief executive officer anthony c hooper ibm corporation bd president us pharmaceuticals laurie h glimcher md tamar howson irene heinz given professor immunology senior vice president corporate harvard school public health business development professor medicine harvard medical school ab john l mcgoldrick leif johansson executive vice president general counsel president ab volvo chief executive officer volvo group ab elliott sigal md phd chief scientific officer president james robinson iii pharmaceutical research institute cofounder general partner robert zito rre ventures bcd senior vice president corporate affairs louis w sullivan md president emeritus morehouse school medicine ac audit committee b committee directors corporate governance c compensation management development committee executive committee bristolmyers squibb company annual reportstockholder information product namesand company common stock programs appearing throughout ticker symbol bmy free copy companys annual italics trademarks bristolmyers new york stock exchange report fiscal year squibb company one sub pacific stock exchange ended december contact sidiary companies global products secretary referred herein registered annual meeting bristolmyers squibb company approved us trademarks unless stockholders park avenue specifically noted otherwise tuesday may new york ny hotel dupont abilifyis trademark otsuka th market streets also available pharmaceutical company ltd wilmington de wwwbmscominvestors avapro avalide plavixand iscover trademarks sanofiaventis stockholder services recent certifications delestrogenis trademark programs companys chief executive officer king pharmaceuticals inc inquiries concerning stockholder chief financial officer pursuant section accounts stock transfer matters sarbanesoxley act estraceis trademark galen including address changes elimination filed exhibits companys chemicals ltd duplicate mailings dividend reinvest company also filed emsamis trademark somerset ment see direct deposit new york stock exchange pharmaceuticals inc dividends directed recent annual ceocertification companys transfer agent registrar required section aa erbituxis trademark imclone new york stock exchange listed systems incorporated mellon investor services company manual gleevec trademark novartis ag challenger road glucophage ir glucophage xrand ridgefield park nj following reports glucovanceare trademarks merck wwwmelloninvestorcom available writing sant sas associate merck within us corporate affairs kgaa darmstadt germany outside us bristolmyers squibb company tdd telephone service park avenue javloris trademark pierre fabre hearing impaired new york ny mdicament sa within us kaletrais trademark outside us bristolmyers squibb foundation abbott laboratories inc sustainabilityenvironmental programs dividend reinvestment plan political contributions ovconis trademark registered stockholders stock must eeo report warner chilcott inc held name hold premarinand premproare trademarks shares companys stock may partic wyeth ipate stockholderpaid dividend shapedowndeveloped reinvestment plan drip back cover university california includes safekeeping saleofstock feature hold fewer shares truvadais trademark gilead still eligible participate october team sciences inc safekeeping saleofstock features cyclists composed cancer well direct registration option survivors physicians nurses care givers researchers began eightday transcontinental odyssey los angeles washington dc joined points along copyright way cancer survivor sixtime bristolmyers squibb company tour de france champion lance rights reserved armstrong bristolmyers squibb tour hopeteam helped educate designed photographed written americans nationwide bristolmyers squibb promise cancer clinical trials corporate affairs department importance cancer research printed recycled paper help speed search curelopqr hopetriumph miracle medicine park avenue new york ny telephone wwwbmscom